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An estimated 1158 nuclear encoded proteins function within mammalian mitochondria. 
Over the past ten years the increased implementation of next generation sequencing-
driven diagnostics, particularly whole exome sequencing (WES), has resulted in the 
identification of over 150 nuclear genes not previously implicated in mitochondrial 
disease, necessitating extensive functional studies to determine and confirm 
pathogenicity. Over one third of reported mitochondrial disease-causing nuclear 
genetic variants reside in genes encoding proteins with a role in mtDNA gene 
expression. The overarching aim of my research project was to functionally validate 
novel candidate mitochondrial disease variants, focusing on those identified in genes 
encoding proteins with roles in mitochondrial translation, in order to achieve genetic 
diagnoses for affected patients.
WES of two unrelated patients with early-onset neurological disease presentations 
identified different and previously unreported variants in the GFM2 gene encoding 
ribosome recycling factor mtEFG2. Differential and tissue-specific patterns of 
combined OXPHOS defects were identified in each patient. Novel compound 
heterozygous variants in the TSFM gene, encoding the elongation factor mtEF-Ts, 
were identified in a single patient presenting with adult-onset hypertrophic 
cardiomyopathy. The abundance of mtEF-Ts was significantly decreased in patient 
fibroblasts and cardiac tissue. The resulting OXPHOS deficiency was most severe in 
cardiac tissue, accompanied by decreased levels of elongation factor mtEF-Tu.
A homozygous nonsense mutation in the MRPL47 gene, encoding a mitoribosomal 
large subunit (LSU) protein, was identified in three unrelated paediatric patients 
presenting with metabolic acidosis, epilepsy and liver involvement. Patient fibroblasts 
exhibited disorders of translation and combined OXPHOS defects. Some truncated 
MRPL47 protein was visualised within the destabilised LSU. Variants in MRPL65, a 
second LSU gene, were identified in five paediatric patients presenting with 
overlapping clinical features including developmental delay, ataxia and nystagmus. 
Attempts to generate a CRISPR/Cas9 MRPL65 knock-out cell line were unsuccessful 




karyotyping in gene editing studies. MRPL65 cDNA analysis in a single patient 
identified retention of intronic sequence due to a +5 splice variant. Patient fibroblasts 
displayed normal levels of MRPL65 and OXPHOS proteins, but appeared to exhibit a 
defect in mitochondrial translation alongside some abnormal assembly of the LSU.
This work expands upon our current knowledge of Mendelian mitochondrial disorders, 
adding to a growing list of nuclear genes implicated in disorders of translation and 
achieving genetic diagnosis in the presented families. Tissue-specific defects illustrate 
the complexity of the pathomechanisms underlying these disorders and highlight the 
gaps in our understanding of adaptive compensatory mechanisms employed in 
different tissues. This research also emphasises the importance of identifying and 
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Chapter 1 : Introduction
1.1 Mitochondria: The organelle
Mitochondria are dynamic double membrane bound organelles present in, and 
essential to, all nucleated human cells. Mitochondria are the product of an 
endosymbiotic event some 1.5 billion years ago, in which the common cellular ancestor 
of all eukaryotes endocytosed an α-proteobacterium with anaerobic respiratory 
capability (Gray, Burger and Lang, 1999). As such, mitochondria possess a genome 
containing retained genes of bacterial origin. However, the evolution of this genome 
varied vastly between both animal and non-animal species (Gray, 2012). From this 
point forward this thesis will focus on human mitochondria, unless otherwise specified. 
A primary function of mitochondria is the generation of chemical cellular energy, in the 
form of adenosine triphosphate (ATP), through a process known as oxidative 
phosphorylation (OXPHOS). Several other vital cellular processes are mediated by the 
mitochondria, including iron sulphur cluster and haem biosynthesis, calcium 
homeostasis and apoptosis (Osellame, Blacker and Duchen, 2012). Many features of 
human mitochondrial biology that are seen today, such as the unique circular genome, 
distinct translation machinery, double membrane bound structure and dynamic fission 
and fusion capabilities are reminiscent of their ancestry as a once independent 
bacterium (Roger, Munoz-Gomez and Kamikawa, 2017). 
1.1.1 Mitochondrial structure
The composition of the outer mitochondrial membrane (OMM) and the inner 
mitochondrial membrane (IMM) differ from each other to reflect their roles within 
mitochondrial structure and function. The OMM forms a smooth lipid bilayer, most 
similar to the plasma membranes of eukaryotes, containing voltage dependent anion 
channels (VDAC) and translocase of the outer membrane (TOM) complexes to 
mediate the movement of small molecules and ions between the cytosol and the 
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intermembrane space (IMS) (Ponnalagu and Singh, 2017). The IMM is less permeable 
and more selective than the OMM, a property which is of significant importance in the 
maintenance of the proton gradient that drives ATP synthesis during oxidative 
phosphorylation. The architecture of the IMM is highly convoluted with many 
invaginations, termed cristae (Figure 1.1) (Gohil and Greenberg, 2009). The cristae 
provide a large surface area, allowing mitochondria to house and abundance of 
membrane proteins (Kondadi, Anand and Reichert, 2019). The central cavity of 
mitochondria, named the matrix, sits within the IMM.
Figure 1.1 Mitochondrial ultrastructure and network organisation. A schematic (A) and an electron micrograph 
(B) image of a single mitochondrion, highlighting the key structural features and compartments formed by the outer 
mitochondrial membrane (OMM), the inner mitochondrial membrane (IMM), the intermembrane space (IMS), cristae 





Though commonly depicted diagrammatically as static organelles around 2μm in 
length, the mitochondria of healthy cells are typically part of a dynamic reticular 
network, allowing mitochondria to travel between different cellular regions in response 
to energy requirements (Chan, 2012) (Figure 1.1). These changes in network shape 
and mitochondrial morphology are primarily driven by fission and fusion events.
Mitochondrial fission is the process by which both the OMM and IMM divide, to produce 
two separate daughter mitochondria. For this to occur, the protein dynamin-related 
protein 1 (DRP1), a large GTPase, is recruited from the cytosol to the OMM by four 
key proteins; mitochondrial fission protein 1 (Fis1), mitochondrial fission factor (Mff), 
and mitochondrial dynamics proteins 49 and 51 (Mid49 and Mid51) (Loson et al., 
2013). Once positioned at the OMM, DRP1 forms oligomeric ring-like structures at ER-
mitochondria contact sites, where GTP-driven hydrolysis drives constriction of 
mitochondria. The final stage of mitochondrial fission is the scission of the constricted 
area, carried out by the Dynamin-2 (Dnm2) protein, to produce two daughter 
mitochondria (Kraus and Ryan, 2017).
Fusion of mitochondria is initiated upon the docking of mitofusin GTPases Mfn1 and 
Mfn2 at adjacent outer mitochondrial membranes of two proximal mitochondria. 
Conformational changes in mitofusins cause an increase in membrane contact sites, 
followed by GTPase dependent fusion of the OMM (Song et al., 2009). Mitochondrial 
dynamin-like protein OPA1, a large GTPase, interacts with IMM phospholipid content 
to drive subsequent fusion of the IMM (Ban et al., 2017).
1.1.3 The mitochondrial genome
In the matrix of mitochondria there are approximately 1-15 mtDNA molecules, however 
this number is dynamic and responsive to cell-type specific mechanisms of copy 
number control (Clay Montier, Deng and Bai, 2009; Satoh and Kuroiwa, 1991). At 
16,569bp in size, the circular double stranded mitochondrial genome encodes 37 
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genes (Figure 1.2) (Anderson et al., 1981). Of these genes, 13 encode polypeptides, 
all of which are core subunits of one of the OXPHOS complexes I, III, IV and V. The 
remaining genes encode 22 transfer RNAs (tRNAs) and two ribosomal RNAs (rRNAs), 
16S and 12S, that are integral parts of the large and small mitoribosomal subunits 
respectively.
Figure 1.2 The human mitochondrial genome. Diagram of the 16,569 bp human mtDNA molecule with protein 
coding regions in turquoise (complex I), blue (complex III), pink (complex IV) and yellow (complex V). Ribosomal 
RNAs are orange and tRNAs are in black. OH and OL depict the origins of replication for the heavy and light strand 
respectively, with arrows pointing in the direction of replication. Mitochondrial tRNA genes in black are labelled with 
their single letter abbreviations in red.
The two strands of mtDNA are termed the heavy strand (H strand) and light strand (L 
strand) and differ in their guanine content. The H strand is particularly guanine rich and 
encodes the majority of mitochondrial transcripts, whilst the L strand generates the MT-
ND6 transcript and eight of the tRNAs (Figure 1.2). The amount of non-coding DNA 
within mtDNA is very low in comparison to the nuclear genome, with no intronic regions 
and just one main non-coding region (NCR) within which the displacement loop (D-
loop) is found. The D-loop region is a section of the mitochondrial genome 
approximately 1.1 kb in length, in which the H strand has been displaced by the binding 
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of an additional linear DNA strand, termed 7S DNA, to the L strand. The NCR contains 
both heavy (HSP) and light (LSP) strand promoters and other regulatory elements 





Unlike the mendelian pattern of inheritance displayed by genes of diploid nuclear DNA, 
mtDNA is widely accepted to be inherited solely through the maternal lineage (Giles et 
al., 1980). An unfertilised egg contains up to 600,000 copies of mtDNA which vastly 
outnumbers the ~100 copies carried within each sperm cell (Shoubridge and Wai, 
2007; Wai et al., 2010). In mice, during the early stages of fertilisation, the mitochondria 
of sperm cells were demonstrated to be ubiquitinated within the oocyte cytoplasm, 
marking them for subsequent autophagic proteolytic degradation (Sutovsky et al., 
2004). However, in later studies the role of autophagy in the degradation of sperm 
mitochondria was questioned when it was shown that the association of autophagic 
proteins occurring only transiently and significantly earlier than the elimination of 
paternal mitochondria (Luo et al., 2013). A single case of paternal inheritance of a rare 
mtDNA disease variant isolated to patient muscle has been previously reported 
(Schwartz and Vissing, 2002), igniting debate surrounding the possibility and 
prevalence of paternal mtDNA ‘leakage’. A subsequent study of a cohort of 35 
mitochondrial myopathy patients detected no evidence of paternal mtDNA inheritance, 
suggesting that the phenomenon does not frequently occur (Taylor et al., 2003). More 
recently the publication of data indicating the existence of high heteroplasmy and two 
individual haplotypes resulting from biparental mtDNA inheritance within three 
unrelated families (Luo et al., 2018) has renewed academic interest and debate around 
this topic, though whether paternal mtDNA inheritance exists remains a contentious 
question (Lutz-Bonengel and Parson, 2019; McWilliams and Suomalainen, 2019).  
In 2019, it was hypothesised that the second mtDNA haplotypes detected by Luo et 
al., could be assigned to multi-copy mtDNA concatemers within the nuclear genome, 
rather than circular mtDNA inherited paternally (Balciuniene and Balciunas, 2019). It 
has since been demonstrated experimentally, through the application of WGS in a 
cohort of 11,03 trios, rare instances of heteroplasmic haplotypes can be attributed to 
nuclear-encoded mitochondrial segments (NUMTs) that create the impression of 
paternally inherited mtDNA (Wei et al., 2020).
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1.1.4 Bi-genomic control of mitochondria 
An estimated 1,158 proteins are present within mitochondria to maintain regular 
function, of which only 13 are encoded by mtDNA (Calvo, Clauser and Mootha, 2016). 
During mitochondrial evolution there was vast gene transfer from ancestral 
endosymbiont genome to the nuclear genome (Adams and Palmer, 2003) These 
proteins are synthesised in the cytosol, prior their import into mitochondria. A complex 
system of protein import machinery is required for the appropriate transport of nuclear 
encoded mitochondrial proteins across the OMM and IMM, essential to the 
maintenance of mitochondrial function.
1.1.5 Mitochondrial protein import
Transport of proteins into mitochondria is facilitated by dedicated protein translocases. 
The exact route taken for translocation and assembly is dependent on the type of 
precursor protein being imported and the targeting sequence it carries. Five distinct 
mitochondrial protein import pathways have been described to date (Wiedemann and 
Pfanner, 2017) (Figure 1.3). 
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Figure 1.3 Mitochondrial protein import pathways. Schematic overview of the five major mitochondrial protein 
import pathways. Cysteine rich proteins cross the OMM through translocase of the outer membrane (TOM) and are 
then undergo folding and assembly directed by the mitochondrial import and assembly (MIA) pathway. Proteins 
with an N-terminal pre-sequence are imported through TOM and then translocase of the inner membrane 23 
(TIM23) driven by the presequence translocase associated motor (PAM). IMM carrier proteins cross the OMM 
through TOM and are then directed to translocase of the inner membrane 22 (TIM22) by Tim chaperone proteins. 
Mitochondrial β-barrel proteins also cross the OMM through TOM and interact with Tim chaperone proteins as they 
are directed to the OMM sorting and assembling machinery (SAM). OMM α- helical proteins are imported and 
inserted into the membrane by the mitochondrial import complex MIM.
1.1.5.1 Import pathway for N-terminal presequence proteins
The first import pathway to be described, often termed the ‘classical import pathway’, 
is responsible for the translocation of mitochondrial precursor proteins that carry N-
terminal presequences as mitochondrial targeting signals. Translocase of the outer 
membrane (TOM) and translocase of the inner membrane (TIM23) transport these 
precursor proteins through the outer and inner mitochondrial membranes respectively 
 
9 
(Abe et al., 2000; Dayan et al., 2019). Presequence translocase-associated motor 
(PAM) is the driving force behind import through TIM23 and into the matrix (Schiller, 
2009). N-terminal presequences are subsequently cleaved off by the mitochondrial 
processing peptidase (MPP) (Hawlitschek et al., 1988).
1.1.5.2 Import pathway for cysteine rich proteins
The TOM complex also acts as the common OMM entry gate for proteins that do not 
possess cleavable mitochondrial targeting sequences (MTS). These proteins are 
imported according to a range of different internal targeting sequences (Backes et al., 
2018). Proteins targeted to the IMS commonly have mitochondrial IMS sorting signals 
(MISS) residing next to a number of cysteine residues that, once in the IMS, direct 
them into the mitochondrial import and assembly (MIA) pathway (Sideris et al., 2009). 
Components of the MIA machinery interact with imported precursor IMS proteins 
through transiently formed disulphide bonds using specific cysteine residues to 
facilitate proper folding and assembly (Banci et al., 2009).
1.1.5.3 Import pathway for metabolite carrier proteins
The translocation and assembly of IMM metabolite carrier protein precursors represent 
a third unique import mechanism, known as the carrier pathway. Following their TOM 
mediated import into the IMS, carrier precursors are bound by a complex of small Tim 
chaperones Tim9-Tim10 and Tim12 (Ivanova, Jowitt and Lu, 2008; Gebert et al., 
2008). These chaperone proteins direct the carrier precursors to the carrier translocase 
of the inner membrane (TIM22) for insertion and assembly within the IMM (Koehler et 
al., 1998). 
1.1.5.4 Import pathways for OMM proteins
Mitochondrial β-barrel proteins of the OMM also rely on the small Tim chaperone 
complexes of the IMS, through which they are directed to the sorting and assembly 
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machinery (SAM), embedded within the OMM (Wiedemann et al., 2003). 
Conformational changes within the SAM complex mediate the folding of β-barrel 
substrates and their release into the lipid bilayer of the OMM (Becker et al., 2008). 
Another group of OMM proteins, containing α- helical transmembrane segments, are 
thought to be the only class of mitochondrial proteins not to rely on TOM for import. 
Instead, the mitochondrial import (MIM) complex promotes the insertion of these 




1.2 Mitochondrial DNA replication
A faithful system of mtDNA replication is essential to the maintenance of the 
mitochondrial genome and the expression of its 13 encoded genes. Two main origins 
of replication have been described: the origin of H-strand replication (OH), which lies 
within the NCR, and the origin of L-strand replication (OL), which lies within a cluster of 
tRNAs downstream from OH. The RNA primers necessary for mtDNA replication are 
synthesised by the mitochondrial RNA polymerase (POLRMT) (Fusté et al., 2010; Kuhl 
et al., 2016). DNA synthesis is driven by the mitochondria-specific DNA polymerase γ 
(Pol γ), a heterotrimer composed of one catalytic subunit encoded by POLG and a 
homodimeric accessory subunit, encoded by POLG2, which confers processivity to Pol 
γ by increasing its affinity to DNA (Lee, Kennedy and Yin, 2009). 
In order for Pol γ to proceed the two mtDNA strands must be unwound at the replication 
fork, a role carried out by a hexamer of the mtDNA helicase Twinkle (TWNK) through 
disruption of the hydrogen bonds between strands (Milenkovic et al., 2013). The 
mitochondrial single strand binding protein (mtSSB) additionally enhances the activity 
of both Pol γ and Twinkle (Oliveira and Kaguni, 2010). In addition to these 
mitochondria-specific proteins, several other proteins with dual nuclear and 
mitochondrial functions are involved in mtDNA replication,  including DNA ligase III, 
ribonuclease H1 (RNase H1) (Cerritelli et al., 2003), flap structure-specific 
endonuclease 1 (FEN1) and topoisomerase 3 alpha (TOP3) (Ruhanen, Ushakov and 
Yasukawa, 2011; Nicholls et al., 2018). The termination of replication requires several 
factors with nuclease activity for primer removal, processing and re-ligation. The 
processing of RNA primers can take place in a number of ways, usually involving the 
partial degradation of annealed primers by RNase H1 and subsequent displacement 
of remaining nucleotides by Pol γ to generate a ‘flap’ of varying length. This flap can 
then be cleaved and cleared by FEN1, DNA2 or MGME1 (Uhler and Falkenberg, 2015). 
To complete each replication event, separation of the two newly synthesised mtDNA 
molecules must take place. It has been demonstrated recently that the protein 
topoisomerase 3α (TOP3) carries out decatenation of interlinked mtDNA, releasing 
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each mtDNA molecule to form their final compact nucleoid structure (Nicholls et al., 
2018).
Mitochondria maintain continuous cycles of DNA replication, running independently of 
the broader cell cycle in both actively proliferating and post-mitotic cells (Korr et al., 
1998; Magnusson et al., 2003). Different models for mtDNA replication have been 
proposed, with the main points of contention being whether replication proceeds in a 
strand-synchronous or strand-asynchronous manner and whether the lagging-strand 
template is coated with protein or RNA (Robberson, Kasamatsu and Vinograd, 1972; 
Clayton, 1982; Falkenberg, 2018) (Figure 1.4).
Figure 1.4 The three models of mtDNA replication. Left to right: The strand displacement model (asynchronous), 




1.2.1 ‘Strand displacement’ model of mtDNA replication
The model of asynchronous strand-displacement, first described in 1972, suggests that 
replication begins at the OH within the NCR (Robberson, Kasamatsu and Vinograd, 
1972). Unidirectional replication of the H-strand alone then proceeds, either stalling at 
a termination associated sequence (TAS) ~700 nucleotides after the OH, or continuing 
fully around the genome. The displaced lagging-strand template is coated and 
protected by mtSSB until L-strand synthesis is initiated (Miralles Fusté et al., 2014). 
Once the replisome has passed OL, a stem-loop structure becomes exposed, allowing 
POLRMT to form a primer for L-strand replication to begin in the opposite 
direction(Shadel and Clayton, 1997; Clayton, 1982).
1.2.2 ‘Synchronous’ model of mtDNA replication
An alternative model of mtDNA replication postulates that conventional strand-coupled 
DNA synthesis, resulting from bidirectional replication initiation, occurs in mitochondria. 
This theory is predominantly based upon the observation of fully duplex replication 
intermediates using 2-dimensional agarose gel electrophoresis (Holt, Lorimer and 
Jacobs, 2000), and implies the presence of multiple short Okazaki fragments during 
lagging-strand synthesis. However, their role within the mtDNA replication system has 
yet to be demonstrated experimentally (Holt, 2009; Wanrooij and Falkenberg, 2010). 
1.2.3 ‘Ribonucleotide Incorporation Throughout Lagging Strand (RITOLS)’ 
model of mtDNA replication
The third, most recently proposed model of mtDNA replication is RITOLS. The model 
postulates that RNA (rather than mtSSB) is hybridised to the displaced H strand during 
leading-strand replication, providing stability and protection to the exposed ssDNA as 
replication advances. This RNA was more recently suggested to derive from processed 
RNA transcripts, and is referred to as the ‘bootlace model’ due to its emphasis on RNA 
‘threading’ (Reyes et al., 2013). An enzymatic machinery responsible for this process 
has not been identified.
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1.2.4 Maintenance of the dNTP pool
The replication and repair of both the nuclear and mitochondrial genomes requires a 
steadily available pool of deoxyribonucleoside triphosphates (dNTPs). The two major 
pathways that regulate dNTP supply to mitochondria are the salvage and the de novo 
synthesis pathways. The latter operates in the cytosol where the key regulatory 
enzymes involved in dNTP synthesis are ribonucleotide reductase (RNR) and 
thymidylate synthase (TS). RNR is responsible for the reduction of ribonucleotides to 
deoxyribonucleotides (Penque et al., 2018; Pontarin et al., 2008). Specific 
mitochondrial carriers, such as MPV17, then facilitate the transport of cytosolic dNTPs 
into the matrix, as mitochondria do not possess de novo nucleotide synthesis 
pathways, nor can such molecules permeate the inner mitochondrial membrane (IMM) 
due to their charge (Dahout-Gonzalez, 2006). 
The unique mitochondrial dNTP salvage pathway constantly converts former 
deoxynucleosides, already within the mitochondrial matrix as a result of DNA turnover, 
into dNTPs (D’Souza and Minczuk, 2018). Mitochondrial thymidine kinase 2 (TK2) is a 
key driver of the pyrimidine nucleotide salvage pathway as it carries out the initial 
phosphorylation of pyrimidine precursors (Johansson and Karlsson, 1997). Similarly, 
the primary phosphorylation step in purine nucleotide salvage is carried out by 
mitochondrial deoxyguanosine kinase (DGK) (Johansson and Karlsson, 1996). Two 
additional phosphorylation steps follow, performed sequentially by nucleotide 
monophosphate kinase (NMPK) and nucleotide diphosphate kinase (NDPK), resulting 
in the conversion of each of the deoxyribonucleoside monophosphates (dNMPs) into 
dNTPs (Wang, 2016). For NMPK to execute the final phosphorylation of each 
nucleotide it must form a complex with succinyl CoA ligase (SUCL) and 4-





Within the D-loop of the mitochondrial genome are the sites of transcription initiation 
for both the H and L strands. Early studies of mitochondrial transcription identified two 
heavy-strand promoters, named HSP1 and HSP2, while the initiation of light strand 
transcription was attributed to a single LSP site. Transcription originating from HSP1 
was proposed to run from the 5’ end of the  mitochondrial (mt)-tRNAPhe  gene through 
to the 3’ end of the 16S gene, thus transcribing two mt-tRNA genes (encoding mt-
tRNAPhe and mt-tRNAVal) and the two mt-rRNA genes (12S and 16S). Transcription 
originating from HSP2, 100bp downstream of HSP1, begins at the boundary between 
the gene encoding mt-tRNAPhe and the 12S gene and proceeds along the entirety of 
the H strand to produce a long polycistronic transcript containing all of the mt-tRNAs, 
mt-rRNAs and mt-mRNAs encoded within the H strand (Montoya et al., 1982). 
Similarly, transcription originating at the LSP continues along the full strand to produce 
a polycistronic transcript of all genes encoded within the L strand. However, difficulties 
in faithfully reconstituting transcription initiation from HSP2 in vitro (Litonin et al., 2010), 
as well as the finding that the proposed HSP transcription termination protein MTERF1 
appears to terminate transcription from LSP rather than HSP (Terzioglu et al., 2013), 
have led many to question the existence of HSP2 as a functional promoter, and there 
is currently little consensus.
The mitochondrial transcription machinery is entirely nuclear encoded and it is well 
demonstrated that mitochondrial transcription can be reconstituted in vitro in the 
presence of just three proteins: mitochondrial RNA polymerase (POLRMT), 
mitochondrial transcription factor A (TFAM) and mitochondrial transcription factor B2 
(TFB2M) (Posse et al., 2015; Falkenberg et al., 2002). POLRMT, a single subunit RNA 
polymerase that is related to the bacteriophage T7 RNA polymerase (T7 RNAP) is the 
driver of mitochondrial transcription. The transcription activity of POLRMT is exclusive 
to the mitochondrial genome. POLRMT requires the two additional cofactors TFAM 
and TFB2M for promoter recognition and melting  during transcription initiation (Hillen, 




TFAM has the ability to bind to high affinity binding sites ~10-15bp upstream of the 
promoter sites and introduce a 180° bend in the bound mtDNA. TFAM binding and the 
subsequent conformational change allows for the recruitment of POLRMT to promoter 
DNA to form the pre-initiation complex (Hillen, Temiakov and Cramer, 2018). Finally, 
the recruitment of TFB2M to the pre-initiation complex introduces structural changes 
in POLRMT that drive promoter melting and allow the entry of the initiating nucleotide 
into the catalytic site of POLRMT; thus completing initiation and allowing elongation to 
commence (Figure 1.5).
 
Figure 1.5 Mitochondrial transcription initiation. A four-step model of transcription initiation. 1. TFAM binds 
mtDNA upstream of the transcription start site, introducing a 180° bend. 2.  TFAM recruits POLRMT, which interacts 
with a DNA region upstream of the TFAM binding site. 3. POLRMT undergoes a conformational change. 4. This 
conformational change allows the binding of TFB2M, the final step in the formation of a complete transcription 
initiation complex. Figure adopted from (Gustafsson, Falkenberg and Larsson, 2016). 
1.3.2 Transcription elongation
During the transition from initiation to elongation, TFB2M dissociates and a new 
combination of proteins, the elongation complex, assembles. The mitochondrial 
transcription elongation factor TEFM forms a dimer, binding the POLRMT site 
previously occupied by TFB2M, thus promoting the formation of  a sliding clamp 
structure (Hillen et al., 2017). TEFM drives elongation by increasing POLRMT-DNA 
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interactions, greatly enhancing POLRMT processivity along the mtDNA strand and 
preventing premature termination or stalling (Posse et al., 2015; Posse et al., 2014). 
1.3.3 Transcription termination
The exact mechanism by which mitochondrial transcription is terminated remains 
somewhat unresolved. One protein known to play a key role in the termination of 
transcription is MTERF1 (Terzioglu et al., 2013). As a member of a family of proteins 
with nucleic acid binding properties, MTERF1 binds along the major groove of mtDNA 
at the 3’ end of the 16S rRNA gene and induces a bend, partial unwinding of the double 
helix and the eversion of three nucleotides to stabilise this interaction (Asin-Cayuela et 
al., 2005). MTERF1 exhibits polar transcription termination activity consistent with a 
role in terminating transcription originating only from LSP (Terzioglu et al., 2013). 
Equivalent proteins involved in the termination of transcription originating from HSP 
are yet to be identified. As previously described, mitochondrial transcription, from either 
HSP or LSP, produces long polycistronic messages that must undergo essential post-
transcriptional processing and modification steps prior to mitochondrial translation.
1.3.4 Transcript processing
The majority of protein coding mtDNA genes, along with both mt-rRNA genes, are 
separated by individual mt-tRNA genes. The mt-tRNAs act as guides for 
endonucleolytic excision and thus the release of each flanking mRNA and rRNA 
transcript in a system termed the ‘tRNA punctuation model’ (Ojala, Montoya and 
Attardi, 1981). Cleavage of each tRNA is carried out by ribonuclease P (RNaseP) and 
ribonuclease Z (RNase Z) at the 5’ and 3’ ends respectively. In human mitochondria 
the RNAseP is a complex of 3 proteins, MRPP1, MRPP2 and MRPP3 whereas the 
RNaseZ activity is carried out by a single protein, ElaC ribonuclease Z (ELAC2). 
Though this model can account for the release of the majority of individual transcripts, 
there are some protein-coding genes not flanked by tRNAs on either side. It has been 
suggested that the remaining 3 precursors that are not flanked by tRNAs require one 
of two proteins for their processing, GRSF1 or PTCD2. GRSF1 is crucial for the 
 
18 
processing of the MTND6-ncRNA and RNA14-MT-CO3 precursors (Jourdain et al., 
2013; Antonicka et al., 2013) while PTCD2, a pentatricopeptide repeat (PPR) RNA-
binding protein that is involved in the processing of the MT-ND5-MT-CYB transcript 
(Xu et al., 2008). 
1.3.5 mt-mRNA maturation
Following the nucleolytic processing of each polycistronic message, all but one of the 
mt-mRNA transcripts undergo adenylation on their 3’ ends. The majority of mt-mRNAs 
are polyadenylated with poly(A) tails (~45-55 nucleotides in length) with the exception 
of the MT-ND6 transcript. In addition, the poly(A) tails detected on the MT-ND5 
transcript are much shorter in length (between 0-10 nucleotides) than the majority of 
other mt-mRNAs (Temperley et al., 2010). Poly(A) tail synthesis is carried out by the 
poly(A) polymerase (mtPAP) that is localised to the mitochondrial RNA granules and 
is capable of using each of the four NTPs in its polymerase activity, despite showing 
an ATP substrate preference (Bai et al., 2011). An essential function of poly(A) tails is 
to provide mt-mRNA transcripts with a complete ‘stop’ codon. Seven of the thirteen 
mitochondrial open reading frames have incomplete stop codons (‘U’ or ‘UA’) that, 
without poly- or oligo-adenylation to form ‘UAA’, would not cause termination of 
mitochondrial translation (Temperley et al., 2010). The impact of polyadenylation upon 
mt-mRNA stability varies between transcripts. Some mt-mRNAs, such as MT-ATP6/8, 
MT-CO1, MT-CO2 and MT-CO3 appear to be destabilised upon addition of poly(A) 
tails, whereas MT-CYTB, MT-ND3, MT-ND4/4L and MT-ND5 all show increased 
stability in their polyadenylated state (Temperley et al., 2010). The mechanism and 
function behind this transcript-specific response to polyadenylation remains unclear
1.3.6 mt-mRNA turnover
An important regulator of mtDNA gene expression is the ‘mitochondrial degradosome’ 
dedicated to the turnover of RNAs within the matrix. The RNA degradosome apparatus 
consists of a mitochondria-specific helicase hSuv3p that can unwind double stranded 
DNA (dsDNA), double stranded RNA (dsRNA) and DNA-RNA hybrids (Minczuk et al., 
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2002) and polynucleotide phosphorylase (PNPase), encoded by the PNPT1 gene, that 
has poly(A) polymerase (PAP) and 3’-5’ exoribonuclease activities. It has been 
demonstrated that hSuv3p and PNPase form a stable complex that is believed to play 
a role in the removal of RNA transcripts that are antisense, aberrant or have undergone 
damage as well as normally processed mature transcripts in the mitochondrial matrix 
(Borowski et al., 2013; Szczesny et al., 2010). A third protein with a proposed role in 
mitochondrial RNA degradation is RNA exonuclease 2 (REXO2). Showing localisation 
to the matrix and the IMS, as well as the cytosol, REXO2 is an exonuclease that 
degrades oligonucleotides in the 3’ to 5’ direction. The substrates of REXO2 are likely 
to be short ribonucleotides generated during the degradation of RNA transcripts by 
hSuv3p-PNPase or by other nucleases (Bruni et al., 2013). 
The leucine rich PPR (pentatricopeptide repeat)-containing protein (LRPPRC) and 
stem-loop interacting RNA binding protein (SLIRP) are both mitochondrial RNA binding 
proteins involved in the regulation of mt-mRNA stability.  It has been demonstrated that 
the LRPPRC-SLIRP complex conveys stability to mt-mRNAs by blocking PNPase 
access and aiding in the polyadenylation of the 3’ terminus of bound mRNAs (Chujo et 
al., 2012).
1.3.7 mt-tRNA maturation
Following their release from primary polycistronic transcripts, mt-tRNAs are subject to 
a broad range of different post-transcriptional maturation and modification steps, 
necessary for the formation of stable and fully functioning tRNA structures (Salinas-
Giege, Giege and Giege, 2015; Suzuki and Suzuki, 2014). A number of different 
nuclear encoded tRNA modifying enzymes are responsible for the chemical 
modifications of different sites of each mitochondrial tRNAs, some of which also modify 
nuclear tRNAs (Suzuki, Nagao and Suzuki, 2011). The final maturation step that 
involves the addition of CCA nucleotides to the 3’ terminus of mt-tRNAs is followed by 
aminoacylation by the correct mitochondrial aminoacyl-tRNA synthetase (aa-RS). 
Nineteen unique aa-RSs are required for mitochondrial translation (Sissler, Gonzalez-
Serrano and Westhof, 2017). The aa-RSs that produce aminoacyl-tRNA conjugates in 
the cytosol and in mitochondria are generally encoded by two distinct genes. However, 
two aa-RSs, glycyl-ARS aa-RS (GARS) and lysyl-ARS aa-RS (LARS), act within both 
 
20 
the cytosolic and mitochondrial systems, which is achieved via the inclusion or 
exclusion of a mitochondrial targeting sequence as a result of alternative initiation sites 
or splicing (Tolkunova et al., 2000; Echevarria et al., 2014).
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Figure 1.6 Schematic of mtDNA gene expression. Replication and transcription of the mitochondrial genome 
depends on a pool of available nucleotides. Following transcription and processing, mt-rRNAs (beige and 
turquoise), mt- mRNAs (light green) and mt-tRNAs (pink) undergo a number of post-transcriptional modification 
steps facilitated by numerous maturation and modification enzymes. The mitoribosomal LSU (turquoise) and SSU 
(beige) assemble to synthesise each of the 13 mitochondrial-encoded OXPHOS polypeptides, followed by their 




Like mt-tRNAs, both the 12S and 16S mt-rRNAs undergo a number of nucleotide 
modifications believed to convey stability and promote mitoribosome biogenesis. The 
12S mt-rRNA is subject to methylation of a cytidine at position 841 and dimethylation 
of neighbouring adenines at positions 936 and 937 by the methyltransferase NSUN4 
and dimethyltransferase TFB1M proteins respectively (Metodiev et al., 2014; Metodiev 
et al., 2009). The recently identified METTL15 protein introduces an N-4 
methylcytedine at position 839 of the 12S mt-rRNA believed to stabilise folding (Haute 
et al., 2019).
The 16S mt-rRNA undergoes one pseudouridinylation, carried out by the 
pseudouridine synthase RPUSD4 at position 1397 (Zaganelli et al., 2017). There are 
also several methylation sites on the 16S mt-rRNA. The protein TRMT61B, a known 
tRNA modifying enzyme, has been shown to introduce a methyladenosine at position 
947 of the 16S mt-rRNA. Structurally this modification sits at the interface of the 
mitochondrial large (mt-LSU) and small subunit (mt-SSU) and may be required to 
maintain mitoribosomal structure and function (Bar-Yaacov et al., 2016). The three 
proteins MRM1, MRM2 and MRM3 are a group of 2’-O-ribose methyltransferases, 
each believed to modify specific bases (Gm1145, Um1369, and Gm1370) within the 
peptidyl transferase centre of the 16S mt-rRNA (Rorbach et al., 2014; Lee and 




Reflective of their alphaproteobacterial ancestral origins, the mechanism of translation 
employed by mitochondria is more akin to prokaryotic protein synthesis systems than 
to the cytosolic translation of eukaryotes (Smits, Smeitink and van den Heuvel, 2010). 
Unlike transcription, mitochondrial translation is yet to be successfully reconstituted in 
vitro and as such is not as well characterised as eubacterial or eukaryotic cytosolic 
translation.
1.4.1 The mammalian mitoribosome
The core driver of mitochondrial translation is the mitoribosome. Consisting of a small 
(28S) subunit (SSU) and large (39S) subunit (LSU), the human mitoribosome contains 
~80 nuclear encoded proteins, two mt-rRNAs (12S and 16S) and a mt-tRNAVal that 
assemble to form the 55S monosome (Chrzanowska-Lightowlers, Rorbach and 
Minczuk, 2017; Amunts et al., 2015). Mammalian mitoribosomes have undergone 
evolutionary changes leading to mitochondria specific features that differ to those of 
bacterial ribosomes. One of the most striking discrepancies is the proportion of RNA 
to protein content. Bacterial ribosomes are comprised of ~70% RNA and 30% protein. 
This ratio has been reversed in mammalian mitoribosomes, which are 70% protein 
content and just 30% RNA (Brown et al., 2014), resulting from an evolutionary loss of 
rRNA domains combined with extension of conserved proteins and gain of 
mitochondria specific proteins (Mai, Chrzanowska-Lightowlers and Lightowlers, 2017). 
Many of the more recently obtained mitochondria specific proteins are located on the 
periphery of the mitoribosome. Once believed to simply fill the structural gaps left 
behind by lost RNA components, it has since been demonstrated that these additional 
mitoribosomal proteins also convey a number of different functionalities including 
membrane association and mRNA recruitment (Greber and Ban, 2016). 
It has been proposed that these additional proteins could function in part as a protective 
layer, shielding the ribosomal RNA from the damaging levels of ROS present within 
mitochondria (Mai, Chrzanowska-Lightowlers and Lightowlers, 2017). The process of 
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mitochondrial translation can, therefore, be divided into three major stages: initiation, 
elongation and termination (Figure 1.7).
 
Figure 1.7 Mitochondrial translation. Diagram depicting the cyclical nature of the three stages of mitochondrial 
translation; Initiation, Elongation and Termination/Recycling. A = acceptor site. P = peptidyl tRNA site. E = 
polypeptide exit site
1.4.2 Translation initiation
Initiation of mitochondrial translation requires the recruitment of a mitochondrial mRNA 
transcript to the SSU of the mitoribosome. When not active in translation, the SSU is 
bound by mitochondrial initiation factor 3 (mtIF3) which blocks its association with the 
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LSU preventing 55S formation (Christian and Spremulli, 2009). Binding of an mRNA 
transcript at the mRNA entry channel of the SSU may be facilitated by the PPR-
containing mS39 protein with mRNA binding properties (Greber et al., 2015). In 
addition to the ‘universal’ AUG initiating codon, the mitochondrial translation system 
also recognises AUA and AUU as ‘start’ codons (Jukes, 1983). Upon the entry of an 
initiating codon of an mt-mRNA into the SSU entry site, formylated tRNAMet (tRNAfMet) 
is recruited by mitochondrial initiation factor 2 in its GTP bound state (mtIF2:GTP) to 
form an initiation complex with the SSU (Christian and Spremulli, 2010). Binding of 
tRNAfMet through a codon:anticodon interaction triggers the recruitment of the LSU to 
form the monosome, and the subsequent hydrolysis of mtIF2:GTP to mtIF2:GDP 
results in the release of both mtIF2 and mtIF3 from the SSU. The monosome can then 
enter the elongation phase of mitochondrial translation. 
1.4.3 Translation elongation
The formation of a ternary complex of elongation factors, along with an aminoacylated 
tRNA (aa-tRNA) binding at the acceptor site (A-site) of the mitoribosome, is required 
for elongation of nascent polypeptides. The elongation phase begins with the binding 
of GTP-bound mitochondrial elongation factor Tu (mtEFTu:GTP) to an aa-tRNA which 
directs the aa-tRNA  into the A-site of the mitoribosome. The formation of a correctly-
matched codon:anticodon between the bound mt-mRNA transcript and the aa-tRNA in 
the A-site, triggers hydrolysis of the mtEFTu:GTP to mtEFTu:GDP that is then released 
from the mitoribosome (Cai et al., 2000). This GTP hydrolysis catalyses the formation 
of a peptide bond at the peptidyl transferase centre (PTC) between the aa-tRNA within 
the A-site and the amino acid sitting at the adjacent peptidyl tRNA site (P-site). The 
tRNA occupying the P-site becomes deacylated as a result and is then displaced by 
the translocation of the bi-peptidyl tRNA from the A-site to the P-site driven by the 
hydrolysis of a second elongation factor, mitochondrial elongation factor (G1), from 
mtEFG1:GTP to mtEFG1:GDP. Regeneration of mtEFTu:GDP back to mtEFTu:GDP 
is carried out by mitochondrial elongation factor Ts (mtEFTS) which allows this process 




1.4.4 Translation termination and ribosome recycling
Upon entry of a ‘stop’ codon UAA or UAG into the A-site of the mitoribosome, 
mitochondrial translation release factor A (mtRF1a) is recruited (Christian and 
Spremulli, 2012). mtRF1a catalyses the hydrolysis of the ester bond between the 
peptidyl-tRNA occupying the A-site and the terminal amino acid of the complete 
nascent polypeptide. This GTP-dependent cleavage results in the release of the full 
length polypeptide through the exit tunnel of the LSU (Lightowlers and Chrzanowska-
Lightowlers, 2010). Following this release, the mitoribosome must undergo a recycling 
process to return to independent large and small subunits available for the initiation of 
a new translation event, also releasing the mRNA template and final terminating tRNA. 
Two proteins, mitochondrial ribosome release factor (mtRRF) and mitochondrial 
elongation factor G2 (mtEFG2), promote the dissociation of the mitoribosomal subunits 
in a GTP dependent manner (Tsuboi et al., 2009). A ribosome-dependent peptidyl-
tRNA hydrolase, ICT1, thought to be a structural component of the LSU, and C12orf65 
are believed to facilitate the hydrolysis and release of prematurely terminated peptidyl 
chains from any stalled mitoribosomes (Richter et al., 2010). 
1.4.5 IMM insertion
Following their synthesis by the mitoribosome, the 13 mtDNA encoded OXPHOS 
proteins are inserted into the IMM. Correct insertion of nascent polypeptides into the 
IMM is believed to be aided by a family of insertases. A major candidate for a human 
insertase that carries out this role, OXA1L, has been shown to directly interact with at 
least nine of 13 mtDNA encoded polypeptides and other nuclear encoded accessory 
subunits of OXPHOS complexes to aid insertion of newly synthesised proteins into 




1.5 Functions of mitochondria
Though best known as the main generators of cellular energy through OXPHOS, 
mitochondria are responsible for a number of different molecular mechanisms 
essential to normal cellular function (Osellame, Blacker and Duchen, 2012). 
Mitochondria are essential mediators of cellular calcium ion homeostasis, through their 
dynamic sequestration and release of calcium ions (Ca2+) which act as versatile 
intracellular signalling molecules with regulatory roles in a multitude of biochemical 
pathways. Uptake and release of Ca2+ by mitochondria is mediated by the highly 
selective mitochondrial calcium uniporter (MCU) and the electrogenic Na2+-Ca2+ 
exchanger respectively (Samanta, Mirams and Parekh, 2018). The TCA cycle and ATP 
synthesis are two mitochondrial processes regulated by Ca2+, while influx of calcium 
ions into mitochondria is an important step in apoptosis (Giorgi, Marchi and Pinton, 
2018).
Apoptosis, the process of programmed cell death, is driven by a number of sequential 
mitochondrial events. The Bcl-2 family of proteins regulate apoptosis through dynamic 
interactions of pro- and anti-apoptotic family members with the IMM (Cory and Adams, 
2002). The activation of pro-apoptotic Bak or Bax proteins, or the inhibition of anti-
apoptotic Bcl-2, permeabilises the OMM and triggers the cytosolic release of 
cytochrome c from the IMS (Kluck et al., 1997). This in turn activates a caspase 
cascade essential for proteolytic degradation of proteins during apoptosis (Salvesen 
and Dixit, 1997).
The process of iron-sulphur (Fe-S) cluster biogenesis also takes place within the 
mitochondrial matrix. Fe-S clusters are essential inorganic co-factors found in 
abundance within mitochondria and the cytosol (Beinert, Holm and Munck, 1997). Fe2+ 
ions are transported into the matrix of mitochondria by mitoferrin carriers (Richardson 
et al., 2010), while sulphide ions are released from cysteine by the cysteine 
desulphurase Nfs1 (Kispal et al., 1999). A backbone for cluster synthesis and formation 
is provided by the iron sulphur cluster assembly enzyme ISCU (Marinoni et al., 2012). 
Fe-S clusters are present within respiratory chain complexes I-IV, where they mediate 
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electron transfer through a chain of reactions and are therefore fundamental to 
oxidative phosphorylation (Brzoska, Meczynska and Kruszewski, 2006).
1.6 ATP production through oxidative phosphorylation 
The production of ATP through OXPHOS is a multi-step process that relies on a 
number of upstream metabolic reactions. Glycolysis, taking place in the cytosol, is a 
series of catabolic reactions resulting in the breakdown of glucose into two molecules 
of pyruvate. These pyruvate molecules can be imported into the mitochondrial matrix 
to feed into the tricarboxylic acid (TCA) cycle, the products of which - 3 molecules of 
NADH and 2 molecules of FADH2 - enter through complex I and complex II respectively 
and are utilised as substrates during oxidative phosphorylation (Wilson, 2017; Yellen, 
2018).
 
The process of oxidative phosphorylation is achieved by a system of five multi-subunit 
complexes embedded within the IMM. Complexes I-IV make up a set of four respiratory 
chain (RC) complexes forming the electron transport chain (ETC). The oxidation of 
NADH and FADH2 to NAD/FAD provides electrons that are transferred to the OXPHOS 
cofactor uniquinone (Q). Transport of electrons down the ETC is coupled with the 
translocation of protons from the matrix into the IMS, producing a proton gradient 
across the IMM. This electrochemical force is used by complex V, coupling the flow of 
protons back into the matrix with the synthesis of ATP (Mitchell, 1961) (Figure 1.8).
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Figure 1.8 Schematic and of OXPHOS complexes and their dual genetic origin. Five multimeric complexes 
are embedded within the inner mitochondrial membrane (IMM). Complexes I-IV form the electron transport chain, 
with cofactors ubiquinone (Q) and cytochrome c (cyt c) acting as mobile electron carriers. The transfer of electrons 
is coupled to the pumping of protons (H+) into the intermembrane space (IMS), generating an electrochemical 
gradient across the IMM. Complex V utilises this proton motive force to synthesise ATP. Each complex, with the 
exception of complex II, is comprised of a combination of mtDNA and nDNA encoded structural subunits and 
assembly factors. Complex II is entirely nuclear-encoded.
1.6.1 Complex I
Complex I (CI), NADH:ubiquinone oxidoreductase, is the first entry point for the ETC. 
A multiprotein structure containing 44 subunits and ~1,000 kDa in size, Complex I is 
the largest of the respiratory chain complexes. Seven of the 14 CI core subunits are 
encoded within the mtDNA, while the remainder of the core subunits, along with all 
accessory components, are nDNA encoded (Zickermann et al., 2015; Carroll et al., 
2006). The subunits of complex I assemble to form an ‘L shaped’ structure, with a 
hydrophobic arm embedded within the IMM and a hydrophilic arm extending into the 
matrix (Figure 1.9). This configuration can be divided into three functionally distinct 
modules; the N module, the Q module and the P module (Zickermann et al., 2015). 
The role of the N module is to bind and oxidise NADH, made available by the TCA 
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cycle. The released electrons are transferred onto a flavin mononucleotide (FMN) 
molecule, forming FMNH2 (Efremov and Sazanov, 2011). A chain of Fe-S clusters then 
form an electron transport cascade, transporting electrons down the Q module, 
ultimately reaching and reducing Q to ubiquinol (QH2). This transfer of electrons results 
in conformational changes in both the IMM and matrix arms to open a channel within 
the P module proton pump, allowing the movement of four protons into the IMS for 
every NADH molecule oxidised (Galkin and Moncada, 2017).
Figure 1.9 Structure and functional domains of complex I. The oxidation of NADH2 takes place within the N 
module (green) releases two electrons that are shuttled into the Q module (yellow) via a chain of iron-sulphur 
clusters (orange). Here, the electrons reduce ubiquinone to ubiquinol (bright green) inducing a conformational 
change in the P-proximal (Pp - purple) and P-distal domains (Pd - red) and resulting in the pumping of four protons 




Complex II (CII), or succinate:ubiquinone oxidoreductase, is the only complex within 
the OXPHOS system to be composed of subunits entirely encoded within the nuclear 
genome. With only four nuclear encoded structural subunits, SDHA, SDHB, SDHC and 
SDHD, succinate dehydrogenase is the smallest of the five complexes. SDHA and 
SDHB are hydrophilic proteins that project into the mitochondrial matrix to form the 
catalytic core while SDHC and SDHD form an anchor embedded firmly within the IMM 
to hold the complex in place and confer upon complex II the ability to transfer electrons 
(Sun et al., 2005) (Figure 1.10). The SDHA subunit harbours a covalently bound 
prosthetic flavin adenine dinucleotide (FAD) group which receives electrons for its 
upon oxidation of succinate to fumarate by SDHA. The released electrons are passed 
from FAD through three Fe-S clusters within SDHB. The SDHC/SDHD subunits then 
transfer these electrons to ubiquinone, reducing it to QH2.
Figure 1.10 Structure of complex II. SDHA (blue) and SDHA (green) extend into the mitochondrial matrix, 
anchored to the IMM by membrane bound  SDHC (yellow) SDHD (orange). Electrons gained from the oxidation of 
succinate to fumarate at SDHA are passed along three Fe-S clusters in SDHB too ubiquinone at the Q binding site 




Also known as ubiquinol:cytochrome c oxidoreductase, complex III (CIII) contains one 
mtDNA encoded subunit (cytochrome b) and 10 nDNA encoded subunits, forming a 
structure approximately 480 kDa in size (Benit, Lebon and Rustin, 2009) (Figure 1.11). 
Complex III functions as a symmetrical homodimer, with a catalytic core of cytochrome 
b and c subunits together with a Rieske Fe-S cluster protein (UQCRFS1) responsible 
for the transfer of electrons from QH2 to cytochrome b and cytochrome c (Fernandez-
Vizarra and Zeviani, 2018). This process is termed the Q cycle, and is coupled with the 
transport of two protons in to the IMS for every electron passed through CIII (Cramer, 
Hasan and Yamashita, 2011).
Figure 1.11 Crystal structure of dimeric complex III. Each of the 11 structural subunits of mammalian complex 





Complex IV (CIV), termed cytochrome c oxidase (COX) acts as the terminal oxidase 
in the ETC. At ~200 kDa in size, monomeric CIV is composed of 14 subunits, three of 
which (COXI, COXII and COXIII) are mtDNA encoded (Zong et al., 2018) (Figure 
1.12). Electrons accepted from reduced cytochrome c are transported through haem 
groups and copper centres of CIV and used to reduce O2 to H2O. The reduction of 
each O2 molecule is coupled to the transport of four protons into the IMS (Faxen et al., 
2005). 
Figure 1.12 Crystal structure of complex IV. Subunits are coloured and labelled with text in the same colours. 




As the final complex within the OXPHOS system, complex V (CV) is an ATP synthase 
made up 19 subunits, two of which (ATP6 and ATP8) are mtDNA encoded, assembled 
as two functional domains – F0 and F1. The F0 domain forms a ring-like structure 
spanning the IMM, while the F1 module extends into the matrix (Figure 1.13) (Von 
Ballmoos, Wiedenmann and Dimroth, 2009). The pore formed by the F0 domain acts 
as a proton channel, allowing the flow of protons from the IMS back into the matrix, 
driven by electrochemical gradient generated by the ETC. This movement of protons 
drives rotary movement of the catalytic F1 module, resulting in its synthesis of ATP 
from ADP and Pi. One ATP molecule is synthesised for every 2.7 protons translocated 
through the proton channel of complex V (Jonckheere, Smeitink and Rodenburg, 
2012).
Figure 1.13 Structure of complex V (ATP synthase). Schematic of the known crystal structure of complex V F1 
subunits δ (red), α/β (green), γ (turquoise) and ε (purple) and F0 subunits b (orange) c (blue). F0 subunit a is 




While often depicted as a chain of single, free-moving complexes, it is well 
demonstrated that individual respiratory chain enzymes are able to assemble into 
higher order structures of varying compositions. Blue-native polyacrylamide gel 
electrophoresis (BN-PAGE) experiments using mildly solubilised mitochondrial 
membranes allows the separation and visualisation of intact respiratory complexes and 
supercomplexes (Schagger and Pfeiffer, 2000). Structural evidence for the 
supramolecular organisation of OXPHOS complexes has been obtained through 
electron microscopy (Schafer et al., 2006). Complexes I, III and IV can assemble into 
three distinct arrangements; I+III2, III2+IV1-2 or I+III2+IV1-4 (known as the respirasome). 
ATP-synthase forms dimeric structures, while complex II appears to remain isolated 
with no higher order interactions. The most prevalent supercomplex in mammalian 




Mitochondrial disease is used as an umbrella term for the many different genetic 
disorders resulting from dysfunctional oxidative phosphorylation. With a prevalence 
estimated at 12.5 per 100,000 adults and 4.7 per 100,000 children, mitochondrial 
diseases are the most common group of inherited metabolic disorders (Gorman et al., 
2015; Skladal, Halliday and Thorburn, 2003).  
The clinical features associated with mitochondrial disorders are diverse. The 
spectrum of clinical disease includes multi-system and isolated organ dysfunction, 
resulting in a range of ‘syndromic’ presentations. However, many patients do not fit 
these classic syndromic archetypes, presenting at various stages of life, with markedly 
different disease severity and outcome (Gorman et al., 2016). Tissues with high energy 
demands are considered the most sensitive to defects in ATP synthesis and 
consequently heart, brain and skeletal muscle are the most commonly affected tissues 
(Frazier, Thorburn and Compton, 2019) while neurological deficits are the most 
commonly reported category of symptoms reported in mitochondrial disease patients 
(Parikh, 2010). However, patients carrying identical pathogenic variants in the same 
gene can present with quite different pathology, while those with similar clinical 
features may have distinct genetic aetiologies. For example, mutations in the nuclear 
gene POLG are reported in disorders with a broad phenotypic spectrum. The age of 
onset of POLG related disease ranges from infancy through to late adulthood, causing 
a number of distinct but phenotypically overlapping disorders (Rahman and Copeland, 
2019). Conversely, paediatric presentation of Leigh syndrome, characterised by 
neurodevelopmental delay and regression, axial hypotonia, failure to thrive, lactic 
acidosis and typical neuroimaging with bilateral symmetrical involvement of brainstem 
and basal ganglia. has been reported in patients with over 75 different monogenic 
causes to date (Schubert Baldo and Vilarinho, 2020). This extensive clinical and 
genetic heterogeneity makes the identification, characterisation and diagnosis of 
mitochondrial disease challenging. Further complicating matters, the clinical features 
of mitochondrial disease often overlap with other neurological or systemic diseases 
(Martikainen and Chinnery, 2015) (Figure 1.14).
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Figure 1.14 Clinical presentations of mitochondrial disease. The clinical features of mitochondrial can be 
classified into two groups; those with a neurological or those with non-neurological origins. Mitochondrial diseases 
are clinically heterogeneous and commonly present with dysfunction in a number of different organs or tissues
1.7.1 mtDNA disease
The mutation rate of mtDNA is 10-20 times higher than that of nuclear DNA (Brown, 
1980). One factor thought to play a part in the accumulation of polymorphisms in 
mtDNA is its proximity to DNA-damage inducing reactive oxygen species (ROS) that 
are produced through electron leaking during their movement along the ETC, along 
with a lack of histone protection on molecules of mtDNA (Yakes and Van Houten, 
1997).
The mitochondrial genome undergoes continuous cycles of replication, independently 
of the broader cell cycle. While pol γ possesses proofreading capability, mitochondria 
have fewer DNA repair mechanisms than those that function within the nucleus. 





































introduction of mtDNA polymorphisms (Hahn and Zuryn, 2019). Mutations in mtDNA 
can occur in the form of single nucleotide substitutions within the mRNA, tRNA or rRNA 
genes, or single, large-scale rearrangements (Taylor and Turnbull, 2005). 
1.7.1.1 Heteroplasmy and homoplasmy
Mutations in mtDNA can result in the co-existence of two variant mtDNA populations 
within a single cell, a concept named heteroplasmy. If all copies of mtDNA within a cell 
are identical, cells are described as homoplasmic. The concepts of heteroplasmy and 
homoplasmy become extremely pertinent in instances of mutations that give rise to 
dysfunctional mitochondria and disease (Taylor and Turnbull, 2005).
If cells contain a combination of wild-type (WT) and pathogenic mutated DNA, the level 
of heteroplasmy, sometimes referred to as the mutation load, can vary significantly. 
The mutation load of mutant mtDNA has positive correlation with both the chances of 
presenting a disease phenotype and the severity of any clinical presentations. This 
phenomenon is recognised as a ‘threshold effect’ whereby an OXPHOS dysfunction 
will not occur until the mutation load has reached a minimum percentage within a cell. 
This threshold typically lies between 60-80% mutant mtDNA, though varies between 
cell and tissue type, at which point the remaining WT mtDNA cannot achieve adequate 




Figure 1.15 Heteroplasmy and the threshold effect. Mitochondria can harbour two versions (wild-type and 
mutant) of mtDNA. The proportion of mutant mtDNA within a mitochondrion is known as heteroplasmy, which can 
lie anywhere between 0-100%. Mitochondria can usually tolerate lower levels of heteroplasmy while remaining 
biochemically normal. If heteroplasmy reaches a particular biochemical threshold, usually somewhere between 60-
80%, mitochondria demonstrate a biochemical defect manifesting in a respiratory chain deficiency.  
1.7.1.2 mtDNA point mutations
Point mutations in mtDNA have an estimated population prevalence of one in every 
5,000 people (Gorman et al., 2015). It has been reported that approximately 75% of 
mtDNA point mutations are inherited, while the remaining 25% occur as sporadic de 
novo mutations (Sallevelt et al., 2017). Disease causing mutations have been identified 
in all genes of the mitochondrial genome, of which mutations in tRNA genes are the 
most common (Lott et al., 2013; Elson et al., 2009). The most prevalent, and as such 
the more thoroughly characterised, mtDNA point mutation is m.3243A>G in the MT-
TL1 gene encoding mitochondrial tRNALeu(UUR). This mutation is responsible for 80% 
of mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS), 
though only 15% of m.3243A>G patients have MELAS. Other syndromes commonly 
associated with this point mutation are maternally inherited deafness and diabetes 
(MIDD) and progressive external ophthalmoplegia (PEO) (Boggan et al., 2019).
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1.7.1.3 Single, large-scale mtDNA deletions
With an estimated prevalence of 1.5 in 100,000, single, large-scale mtDNA deletions 
can range from 1.3-10kb in size, with the most common deletion spanning 4,977bp 
(Gorman et al., 2015). These deletions characteristically occur sporadically during 
embryonic development, meaning that the recurrence risk in future pregnancies is low 
(Chinnery et al., 2004). The three main clinical presentations associated with large 
scale mtDNA deletions are CPEO, Kearns-Sayre syndrome (KSS) and Pearson’s 
syndrome, all three of which share significant overlapping features such as PEO  
(Grady et al., 2014).eo
1.7.2 Nuclear mitochondrial disease
A mutation in any one of the estimated 1145 nuclear encoded mitochondrial proteins 
(Calvo, Clauser and Mootha, 2016) theoretically has the potential to result in 
mitochondrial dysfunction. As such, an ever-expanding number of nuclear genetic 
mutations are implicated in the causation of mitochondrial disease. These pathogenic 
variants are subject to Mendelian patterns of inheritance and therefore autosomal 
dominant, autosomal recessive, X linked and de novo mutations have all been 
identified. The first mitochondrial disease-causing mutation in a nuclear gene was 
identified in the SDHA gene in 1995, causing Leigh syndrome in two siblings 
(Bourgeron et al., 1995). Since 2012, an average of 22 novel nuclear disease genes 
have been implicated in mitochondrial disease each year (Frazier, Thorburn and 
Compton, 2019) almost entirely due to the availability and implementation of next 
generation sequencing technologies in diagnostic and research laboratories.
1.7.2.1 Nuclear disorders of mtDNA maintenance
The integrity of the mitochondrial genome can be affected as a result of defects in 
nuclear encoded proteins with roles in mtDNA replication, maintenance and 
transcription, resulting in secondary mtDNA depletions or large-scale deletions. 
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Pathogenic variants in POLG, the gene encoding the catalytic subunit of pol γ, are the 
most common single gene causes of inherited mitochondrial disorders (Hikmat et al., 
2017). In one Australian cohort, POLG  mutations accounted for 10% of adult cases 
(Woodbridge et al., 2013). At present, over 300 different pathogenic POLG variants 
have been deposited into the Human DNA Polymerase Gamma Mutation Database 
(https://tools.niehs.nih.gov/polg/). These mutations span the entirety of the amino acid 
sequence of POLG, some with autosomal recessive and others with autosomal 
dominant inheritance patterns. Functionally these POLG defects can cause decreased 
activity of Pol γ and stalling at the replication fork. The result of this mtDNA synthesis 
defect can be mtDNA depletion, mtDNA multiple deletion or a combination of both (El-
Hattab, Craigen and Scaglia, 2017). 
As with POLG defects, biallelic mutations in TWNK, the gene encoding the mtDNA 
helicase Twinkle, result in the stalling of replication and can cause qualitative defects 
in the form of mtDNA deletions or quantitative mtDNA depletion defects (Hebbar et al., 
2017). 
Autosomal recessive mutations (homozygous nonsense and homozygous missense 
variants) in the MGME1 gene have been reported in three families, resulting in both 
mtDNA depletion and multiple deletions. The mtDNA rearrangements identified in all 
affected patients are significantly larger than deletions characteristic of POLG-related 
mtDNA maintenance defects and include numerous duplications (Nicholls et al., 2014).
1.7.3 Diagnosing mitochondrial disease
Due to the complex nature of mitochondrial genetics, vast heterogeneity and broad 
clinical spectrum implicated in mitochondrial disease, a collaborative and 
multidisciplinary approach is most effective when seeking genetic diagnosis. 
Histopathological and biochemical investigation of patient muscle tissue has 
traditionally been, and remains, an important aspect of diagnostic investigation. Owing 
to its strong energy dependence, muscle is one of the most commonly affected tissues 
in both isolated organ and multi-system mitochondrial disease, rendering patient 
 
42 
muscle biopsies a very valuable diagnostic resource (Taylor et al., 2004). 
Immunofluorescent techniques developed in recent years can also utilise patient 
tissues to assess the abundance of a number of mitochondrial OXPHOS proteins 
simultaneously (Rocha et al., 2015). Alongside these tissue-based investigative 
techniques a range of molecular genetic tools are employed in the diagnosis of 
mitochondrial disease. The preferred genetic investigation undertaken in each case is 
determined by a number of factors including clinical characterisation, familial 
inheritance patterns and the results of any prior histopathological and biochemical 
studies (Thompson et al., 2019).
1.7.3.1 Histopathology and biochemistry
The basic morphology of patient muscle can be investigated through the application of 
stains such as haematoxylin and eosin (H&E) and modified Gomori trichrome. H&E 
staining will reveal the presence of a number of abnormalities to fibre shape and size. 
Modified Gomori trichrome is applied to visualise mitochondrial and endoplasmic 
reticulum membranes. The presence of ‘ragged red fibres’ (RRF) signifies the 
accumulation of mitochondria along the sarcolemma of myofibres, suggestive of 
mitochondrial proliferation in response to a respiratory chain defect (Joyce, Oskarsson 
and Jin, 2012).
A sequential cytochrome c oxidase/succinate dehydrogenase (COX/SDH) 
histochemical assay is regularly performed to provide a histopathological read out of 
respiratory chain function. The activities of complex II, which is entirely nuclear 
encoded, and complex IV, which is encoded by genes of both mtDNA and nDNA, are 
visualised. A mosaic pattern of COX-deficient fibres in the presence of normal SDH 
(CII) activity is can be indicative of a heteroplasmic mtDNA disease mechanism. Each 
muscle fibre harbours differing mutation loads that will only manifest as COX-deficient 
if above the mutation threshold. Widespread and generalised loss of COX reactivity is 
highly suggestive of respiratory chain dysfunction resulting from nuclear DNA 
mutations or pathogenic homoplasmic mtDNA variants (Taylor et al., 2004).
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The In vitro biochemical measurement of individual respiratory chain enzyme activities 
in both muscle and fibroblasts is another widely used diagnostic technique. The activity 
of each complex (I-IV) can be investigated through spectrophotometry measured, 
against the citrate synthase enzyme as a matrix marker, to identify any defects in 
enzymatic activity (Frazier et al., 2020).
1.7.3.2 Immunohistochemical assessments
The aforementioned histopathology based techniques do not assess the activity of 
complex I, despite complex I being one of the most commonly affected enzymes in 
isolated and combined OXPHOS deficiencies (Loeffen et al., 2000; Mayr et al., 2015). 
A more recently developed technique, named the quadruple immunofluorescent assay, 
targets NDUFB8 of complex I and COXI of complex IV along with porin (mitochondrial 
mass marker) and laminin (marker of myofibre boundaries) in single muscle fibres. 
This assay is able to give precise and reproducible protein quantification in large 
numbers of individual muscle fibres in mitochondrial disease patients with a range of 
genetic defects (Rocha et al., 2015).
1.7.4 Application of whole exome sequencing in mitochondrial disease
The earliest approaches to the identification of novel human disease genes relied on 
the use of linkage analysis across a number of affected and unaffected individuals. 
This method works to identify specific loci on individual chromosomes that are co-
inherited with disease, relying on the high probability that proximally close regions of 
chromosomes remain close following homologous recombination during meiosis 
(Pulst, 1999). While this approach remains in use, it is most powerful when utilised in 
large families/cohorts but is of limited value in individual cases of rare disease (Smith 
et al., 2011). The traditional approach to DNA sequencing, developed by Fred Sanger 
in 1977, utilised radioactively labelled chain-terminating nucleotides to generate 
libraries of products of random sizes that could then be visualised using 
autoradiography of polyacrylamide gels (Sanger, Nicklen and Coulson, 1977). The 
development of methods that allowed Sanger sequencing to be carried out in parallel 
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using capillary sensors marked the beginning of a rapid development and 
advancement of new massively parallel sequencing techniques, also termed ‘next 
generation sequencing’ (NGS) (Luckey et al., 1990). 
A number of different NGS platforms exist, with provider developing different 
technologies specific to the type of sequencing that will be carried out (gene 
targeted/panel/exome/genome) (Meera Krishna, Khan and Khan, 2019). Increased 
implementation of NGS to diagnostic pathways has resulted in the widespread 
application of whole exome (WES) (Figure 1.16) and whole genome sequencing 
(WGS) in rare disease. The human exome represents less than 2% of the total human 
genome, making WES a cost-effective method in the investigation of mendelian 
disease (Rabbani, Tekin and Mahdieh, 2014). Where candidate or targeted gene panel 
approaches to genetic diagnosis rely on neat phenotype-genotype correlations, 
WES/WGS are unbiased sequencing tools, that when used in conjunction with 
bioinformatic filtering pipelines, have proven to be extremely effective in the diagnosis 
of such a complex phenotypic spectrum.  WES has been incorporated into routine 
mitochondrial diagnostic pathways across the world, with some centres achieving 




Figure 1.16 Whole exome sequencing. Genomic DNA is sheared before being enriched for sequences 
corresponding to exons (coloured sections) which are then hybridised to biotinylated DNA baits (grey beads). DNA 
captured is amplified, then sequenced massively in parallel. Output sequences are mapped, aligned to a reference 
genome and then subject to calling of candidate causal variants.
1.7.5 Functional validation of putative pathogenic variants
 One possible outcome of WES or WGS is the identification of a previously reported 
variant in a known disease gene. In such cases, a genetic diagnosis can be confirmed 
with confidence. However, WES/WGS have several other possible outcomes. Novel 
variants may be identified in a known disease gene, in a gene of known function that 
has not been previously reported in association with mitochondrial disease or in a gene 
with unknown function. In each of these cases further functional characterisation of 
candidate variants is required in order to assign pathogenicity. The precise nature of 
each validation study is influenced by the information available pertaining to the 
candidate gene and identified variants, the mitochondrial processes that would be most 
likely affected in the presence of a defect, along with the availability of cells, tissues 
and genetic models (Figure 1.17). 
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As the term ‘mitochondrial disease’ refers specifically to disorders of energy 
production, the assessment of steady-state levels of various OXPHOS subunit proteins 
and complexes through SDS- and BN-PAGE with immunoblotting is a standard 
experiment utilised in the functional characterisation of patient cells and tissues. 
Immunoblotting with an antibody targeting a candidate protein is also rapid way of 
validating destabilising or loss of protein mutations. Other protein-based validation 
studies utilised in patient cells and/or tissues are complexome profiling to assess 
complex assembly (Alston et al., 2016) and [35S] metabolic labelling to interrogate 
mitochondrial translation (Bugiardini et al., 2019). Imaging-based studies, such as 
transmission electron microscopy and high-resolution confocal imaging, are useful 
when investigating disorders affecting mitochondrial morphology and dynamics (Janer 
et al., 2016).
Lentiviral studies can be used to confirm the pathogenicity of novel variants in patient 
cell lines that exhibit clear functional consequences, such as OXPHOS deficiencies or 
translation defects. Rescue of these defects upon the introduction of WT copies of the 
candidate gene is seen as the ‘gold-standard’ technique for assignment of variant 
pathogenicity (Metodiev et al., 2016) however, this is not an option if patient cell lines 
do not exhibit a biochemical defect. The generation of genetic models as an aid in the 
delineation of molecular mechanisms underlying disease variants can be extremely 
informative, particularly when patient cells/tissues are unavailable or biochemical 
defects are only present in a specific tissue. Suitable model systems can obtained 
through both cell line-based studies, including CRISPR/Cas9 knock-outs, or the 
genetic manipulation of whole organisms. 
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Figure 1.17 Workflow for the identification and validation of mitochondrial disease variants. The choice of 
appropriate genetic testing is directly influenced by the clinical information that is available. Full mtDNA sequencing 
is often carried out in patients with clinical features that strongly suggest a mitochondrial aetiology. If no mtDNA or 
syndrome-associated nuclear variants are identified, patients are candidates for trio WES or WGS. The five possible 
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outcomes of WES range from the identification of previously reported variant in a known disease gene to no clear 
candidate variants identified. The identification of a novel variant in a known disease gene, a novel disease gene 
or a disease gene of unknown function all require further functional work to varying extents. The approaches taken 
to confirm variant pathogenicity depend on the availability of patient tissues and/or cell lines. Segregation studies, 
respiratory chain enzyme activity assays and investigation into steady-state levels of OXPHOS proteins/the protein 
of interest are first line approaches in the assignment of pathogenicity. Any additional investigation into unique 
pathomechanisms of disease are chosen based on the function of proteins encoded by the identified disease gene. 
Abbreviations: Co‐IP (co‐immunoprecipitation); EMSA (electrophoretic mobility shift assay); FRET (fluorescence 
resonance energy transfer); iPSC (induced pluripotent stem cells); MELAS (mitochondrial encephalomyopathy, 
lactic acidosis, and stroke‐like episodes); MIDD (maternally inherited diabetes and deafness); OXPHOS (oxidative 
phosphorylation); SBF‐SEM (serial block‐face scanning electron microscopy); STED (stimulated emission 
depletion); TAP (transporter associated with antigen processing); TEM (transmission electron microscopy); WES 
(whole‐exome sequencing); WGS (whole‐genome sequencing); Y2H (yeast two‐hybrid). Figure adapted from 
(Thompson et al., 2019).
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1.8 Disorders of mitochondrial translation
Over one third of reported mitochondrial disease-causing nuclear defects are in genes 
encoding proteins with a role in mtDNA gene expression, encompassing mtDNA 
maintenance and replication through to mitochondrial transcription and translation 
(Thompson et al., 2019). Defects of mtDNA expression, specifically those affecting 
mitochondrial translation, will be the focus of this thesis. 
Mutations in a whole host of genes with roles in processes ranging from tRNA 
modification through to individual translation factors can compromise mitochondrial 
translation. Defects of mitochondrial translation represent a growing group of disorders 
causing both childhood- and adult-onset mitochondrial disease with a broad range of 
clinical presentations. Groups of disorders, such as those affecting mitochondrial 
aminoacyl tRNA synthetases (mt-tRNA aa-RS) and mitoribosomal subunits, show 
some commonalities in disease presentation but also help to highlight the clinical 






ELAC2, ERAL1, DHX30, FASTKD, GTPBP3, HSD17B10, 
LRPPRC, MTO1, MTPAP, MRM2, MTFMT, NSUN3, 




AARS2, CARS2, DARS2, EARS2, FARS2, GARS, GATB, 
GATC, HARS2, IARS2, KARS, LARS2, MARS2, NARS2, 




MRPS2, MRPS7, MRPS14, MRPS16, MRPS22, MRPS23, 




C12orf65, C12orf62, COA3, GFM1, GFM2, GUF1, OXA1L, 
RMND1, TACO1, TSFM, TUFM 
Table 1.1 Nuclear encoded genes implicated in disorders of mitochondrial translation. Genes with reported 
pathogenic variants resulting in defects of mitochondrial translation are categorised according to function. This list 
was compiled through comprehensive searches of the literature using the following key words and phrases: 
‘mitochondrial translation’ ‘mitochondrial protein synthesis’ ‘mitochondrial disease’ and is accurate as of June 2020.
Pathologies caused by mutations in all 19 mt-tRNA aa-RS have now been described. 
These disorders are often hallmarked by features of central nervous system (CNS) 
involvement such as leukodystrophy (AARS2, DARS2, EARS2, MARS2), 
encephalopathy (RARS2, NARS2, CARS2, IARS2, FARS2, PARS2, TARS2, VARS2), 
deafness or hearing loss (NARS2, PARS2, MARS2) (Webb et al., 2015; Mizuguchi et 
al., 2017) or Perrault syndrome (HARS2, LARS2) (Sissler, Gonzalez-Serrano and 
Westhof, 2017). However, non-CNS and isolated pathologies also occur in mt-tRNA 
aa-RS disease. Cardiomyopathy has been reported in patients with pathogenic 
variants in GARS, KARS, YARS2 and AARS2 (McMillan et al., 2014; Verrigni et al., 
2017; Riley et al., 2013; Sommerville et al., 2018), while two distinct syndromes, 
MLASA (mitochondrial Myopathy, Lactic acidosis and Sideroblastic Anaemia) and 
HUPRA (Hyperuricemia, Pulmonary hypertension, Renal failure in infancy and 
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Alkalosis), can be caused by mutations in the YARS2 and SARS2 genes respectively 
(Nakajima et al., 2014; Belostotsky et al., 2011). Along with the clinical heterogeneity 
between different mt-tRNA aa-RS disease genes, vast variability in disease 
presentation also exists within disorders of single aa-RS genes, such as AARS2. 
Through WES, pathogenic mutations in the AARS2 gene were first reported in an infant 
with fatal hypertrophic cardiomyopathy (Gotz et al., 2011) and then in two further 
families with cardiomyopathic clinical presentation in infancy (Sommerville et al., 
2018), consistent with the original report of AARS2 disease. However, a second 
distinct disease phenotype is seen in patients with AARS2 mutations, characterised by 
leukoencephalopathy with, in female patients, premature ovarian failure (Dallabona et 
al., 2014). The mutations reported across all 19 mt-tRNA aa-RS enzymes do not 
appear to follow any general trends in regard to the location of variants within core 
domains or at evolutionarily conserved residues. This, together with the variability in 
clinical presentation, both within and between the mt-tRNA aa-RS groups, suggests a 
number of different pathomechanisms underlying this broad group of diseases (Sissler, 
Gonzalez-Serrano and Westhof, 2017). 
The first disorder of mitochondrial translation caused by a mitoribosomal defect was 
identified in a patient with a nonsense mutation in the MRPS16 gene. The patient 
presented with neonatal lactic acidosis, agenesis of the corpus callosum and 
dysmorphism. Patient fibroblasts exhibited a severe mitochondrial translation defect 
and a combined OXPHOS deficiency, the latter also observed in patient muscle and 
liver homogenates (Miller et al., 2004). In the past 15 years, disease causing variants 
have been reported in genes for a further nine proteins of the mitoribosomal SSU: 
MRPS2, MRPS7, MRPS14, MRPS22, MRPS23, MRPS25, MRPS28 MRPS34 and 
MRPS39 (also known as PTCD3) (Gardeitchik et al., 2018; Menezes et al., 2015; 
Jackson et al., 2019; Saada et al., 2007; Kohda et al., 2016; Lake et al., 2017; Borna 
et al., 2019; Bugiardini et al., 2019; Pulman et al., 2019); and four of the LSU: MRPL3, 
MRPL12, MRPL24, MRPL44 (Galmiche et al., 2011; Serre et al., 2013; Carroll et al., 
2013; Di Nottia et al., 2020), taking the total number of reported MRP disease genes 
to 14. Although there is significant variation in clinical presentation, some common 
features are seen across the MRP cases. Disease-onset consistently occurs very early 
in life (neonatal or infantile) and almost all patients exhibit mild to severe/fatal lactic 
acidosis (Jackson et al., 2019; Gardeitchik et al., 2018). Many MRP defects result in 
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death early in life and the poor survival associated with these disorders may explain 
the small number of patients carrying pathogenic variants from the 80 mitoribosomal 
proteins that have been identified to date.
1.8.1 Mutations in mitochondrial translation factors
Alongside mitoribosomal mutations, affecting the core translation machinery, defects 
of individual mitochondrial translation factors have also been implicated in 
mitochondrial disease. The first nuclear disease gene to be identified associated with 
defective mitochondrial translation (Coenen et al., 2004), GFM1 encodes the 
elongation factor mtEFG1. Recessive variants in GFM1 have been reported in a total 
of 17 patients with early onset mitochondrial disease. Many of the early cases of GFM1 
disease were rapidly progressive and fatal before the age of two and a half years 
(Smits et al., 2011a; Balasubramaniam et al., 2012; Galmiche et al., 2012; Coenen et 
al., 2004; Antonicka et al., 2006; Valente et al., 2007). The brain imaging typically 
showed hypoplasia of corpus callosum, symmetrical cystic lesions in the white matter 
and involvement of basal ganglia. However, more recent cases of GFM1 disease 
demonstrate long term survival further into childhood, with a less severe clinical 
disease presentation (Brito et al., 2015; Simon et al., 2017). The loss of function 
mutations described in GFM1 result in generalised defects of mitochondrial translation, 
causing combined OXPHOS deficiencies. The severity of OXPHOS deficiency in each 
case appears to correlate with the residual amount of expressed mtEFG1. Patients 
with a higher residual steady-state level of mtEFG1 tend to exhibit a less severe 
OXPHOS defect (Brito et al., 2015). Recessive mutations in the TSFM gene encoding 
another elongation factor, mtEF-Ts, have been described in a number of cases of early 
onset mitochondrial disease resulting in death in early infancy, or a more slowly 
progressing childhood onset cardiomyopathy with ataxia and a neurological phenotype 
(Smeitink et al., 2006b; Vedrenne et al., 2012; Calvo et al., 2012; Emperador et al., 
2017).
In addition to defects of translation elongation, pathogenic variants in initiation factors 
have also been identified. The protein methionyl tRNA formyltransferase (MTFMT), 
encoded by the MTFMT gene, carries out formylation of a tightly regulated proportion 
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of the general Met-tRNAMet pool to provide Met-tRNAs for both mitochondrial 
translation initiation and elongation (Takeuchi et al., 1998). Autosomal recessive 
variants in the MTFMT gene were first identified as pathogenic in two cases of Leigh 
syndrome (Tucker et al., 2011), but have since been implicated in a range of Leigh-
like encephalomyopathic presentations, along with one case of relapsing-remitting 
attacks of neurological dysfunction more reminiscent of a de-myelinating disease 
(Haack et al., 2014; Pena et al., 2016). 
Initiation factor RMND1 is responsible for the anchoring and stabilisation of the 
mitoribosome in close proximity to sites of mt-mRNA maturation. Combined and 
isolated OXPHOS defects have both been observed in RMND1 disease patients, along 
with decreased steady-state levels of mitoribosomal proteins and defects of 
mitochondrial translation (Janer et al., 2015; Ng et al., 2016). The clinical disease 
spectrum of RMND1 variants ranges from fatal encephalomyopathy with lactic acidosis 
to developmental delay, sensorineural deafness, hypotonia and renal disease (Garcia-
Diaz et al., 2012; Janer et al., 2015; Ng et al., 2016). The disease onset varies from 
severe infantile encephalomyopathy culminating in death to, childhood-onset 
nephropathy with longer survival (Garcia-Diaz et al., 2012; Janer et al., 2015). 
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1.9 Aims and Objectives
This PhD was funded by The Lily Foundation as part of their WES project; A UK wide 
recruitment of patients for whole exome sequencing through three highly specialised 
mitochondrial diagnostic and research centres in Newcastle, Oxford and London. As 
part of this wider project, The Lily foundation fund a number of PhD studentships and 
postdoctoral scientists to work on WES, bioinformatic analysis and functional 
characterisation of novel mitochondrial disease genes. Within the WES Project, 202 
families have been screened to date with a diagnostic yield of 73%. Although my work 
has been funded as part of the UK based Lily WES project, it is collaborative 
relationships between clinicians and researchers from across the globe that underpin 
WES gene discovery. A large proportion of the patient investigations presented 
throughout the following chapters have been the result of collaborations with 
international diagnostic and research centres.
While seeking to expand current knowledge of molecular genetic mechanisms 
underlying mitochondrial disease, this work is also of significant diagnostic value. 
Assigning pathogenicity to novel genes/variants in mitochondrial disease provides 
affected patients with firm genetic diagnoses and can expand reproductive options for 
families considering future pregnancies.
My interest in defects of mitochondrial translation began with the investigation of 
patients carrying novel variants in known disease genes encoding mitochondrial 
translation factors. As my PhD progressed the scope of this research broadened to 
include disorders of mitoribosomal proteins upon the identification of variants in novel 
mitoribosomal LSU disease genes. The objective of the research presented within this 
thesis is to functionally validate candidate mitochondrial disease gene variants 
identified through whole exome sequencing, with a focus on disorders of mitochondrial 
translation, thus contributing to the ever-growing signature of nuclear genetic 





Chapter 2 : Materials and methods
2.1 Materials
2.1.1 Equipment
Analogue Tube Roller ThermoScientific 
Aspiration System Vacusafe Integra 
Benchtop Centrifuge 5417R (Refrigerated)  Eppendorf 
Benchtop Centrifuge 5418 Eppendorf 
Benchtop Centrifuge, Universal 32 Hettich 
Benchtop Electrophoresis Digital Slab Gel Dryer Savant 
Cellometer Auto 1000 Bright Field Cell Counter Nexcelom 
Class II Microbiological Safety Cabinet, BH-EN-2004 Faster 
CO2 Cell Culture Incubator, MCO-18AIC Panasonic 
CoolCell Cell Freezing Container  Biocision 
Dry Heat Block Techne 
Electrophoresis Unit, HU10 Mini-Plus Horizontal Unit Scie-Plas 
Falcon Cell Strainer FisherScientific 
Falcon Round-Bottom FACS Tubes FisherScientific 
Genetic Analyser, ABI 3130xl Applied Biosystems 
Imaging System, ChemiDoc MP Bio-Rad 
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LED Microscope, Leica DM IL Leica 
Microcentrifuge, Technicomini Griffin Education 
Mighty Small SDS-PAGE System Hoefer 
Mini-Protean Tetra Cell system Bio-Rad 
MoFlo Astrios Cell Sorter Beckman Coulter 
NanoDrop Spectrophotometer, ND-1000 ThermoScientific 
Nucleofector 2b Device Lonza 
OptimaTM TLX Ultracentrifuge Beckman Coulter 
Orbital Shaker, SSL1 Stuart 
Pestle and Mortar CoorsTek 
pH Meter 3510 Jenway 
Plate Reader, SpectraMax M5e Multimode Molecular Devices 
Stirrer, Ceramic Plate U151  Stuart 
Thermal Cycler, Veriti 96 Well Applied Biosystems 
Ultra-Turrax homogeniser (IKA)  IKA 




96-Well PCR Plate, Semi-Skirted, Clear StarLab 
Cell Line Nucleofector Kit V Lonza 
Cellstar Disposable Tubes (5 mL, 10 mL, 25 mL) Greiner Bio-One 
Cellstar Falcon Tubes (50 mL) Greiner Bio-One 
Cellstar Tissue Culture Flasks (25cm2, 75cm2)  Greiner Bio-One 
Chromatography Paper, 3mm Whatman 
DNeasy Cell and Tissue Kit Qiagen 
Flat-bottom 6 Well Plates TPP 
Flat-bottom 96 Well Plate TTP 
Immobilon-P PVDF membrane (0.45 µm) Merck 
Nunc-Cryotube Vials Thermo-Scientific 
PCR tubes (200 μL) StarLab 
Plasmid Miniprep Kit Monarch 
RNeasy Mini Kit Qiagen 
Sarogold Pro Food Wrap Sarogold 
Scalpel Swan-Morton 
Stericup-GP, 0.22μm, Polyethersulfone, 500 mL Merick-Millipore  
Ultracentrifuge Tubes Beckman Coulter 
Universal tubes, 20 mL Starlab 
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2.1.3 Chemicals and reagents
2.1.3.1 General reagents
Dulbecco’s Phosphate buffered saline X1 (DPBS) Gibco 
EDTA Sigma-Aldrich 
Emetine Dihydrochloride Sigma-Aldrich 
Glycerol Sigma-Aldrich 
Phenylmethylsulphonyl Fluoride (PMSF) Roche 
Pierce Protease Inhibitor Cocktail Tablet ThermoFisher 





Dulbecco’s Modified Eagle Medium Gibco 
Foetal Bovine Serum (FBS) Gibco 
Lipofectamine RNAiMAX ThermoFisher 
MEM Non-essential Amino Acid Solution (100X) Sigma-Aldrich 
MEM Vitamins Gibco 
Minimum Essential Media Gibco 
Opti-MEM Reduced Serum Media Gibco 
Penicillin and Streptomycin Solution Gibco 
siGENOME siRNA Horizon 
Sodium pyruvate Gibco 




2.1.3.3 SDS-PAGE and western Blot
Acrylamide/Bis-acrylamide, 30%, 29:1 Bio-Rad 
Amersham ECL Prime  GE Healthcare 
Blue Wide Range Protein Ladder Cleaver Scientific 
Dried Skimmed Milk Powder Marvel 
Glycine Sigma-Aldrich 
N, N, N’, N’- Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Polysorbate 20 (Tween-20) Acros Organics 
Protein Assay Dye Reagent Concentrate Bio-Rad 
Sodium Dodecyl Sulphate (SDS) Sigma-Aldrich 
Trisma Base Sigma-Aldrich 
2.1.3.4 [35S] Metabolic labelling
Easy Tag Express Protein Labelling Mix  
(73% L-met, 22% L-cys) 
Perkin-Elmer 
L-Methionine Sigma-Aldrich 




Chloramphenicol Duchefa Biochemie 
KCl Sigma-Aldrich 
Magnesium Acetate Sigma-Aldrich 
NH4Cl Sigma-Aldrich 
Sucrose Sigma-Aldrich 
Trichloroacetic Acid (TCA) Sigma-Aldrich 
2.1.3.6 Polymerase chain Reaction
Ambion™ Nuclease-free water Invitrogen 
Colourless GoTaq Reacting Buffer, 5X Promega 
Deoxyribonucleotide Triphosphate (dNTP) Mix, 2mM Bioline 
GoTaq G2 DNA Polymerase, 5U μl-1 Promega 




Agarose (Molecular Grade) Bioline 
GeneRuler 100bp Plus DNA Ladder ThermoFisher 
GeneRuler 1kb Plus DNA Ladder ThermoFisher 
SYBR Safe DNA Gel Stain, 10,000X Invitrogen 
Tris-Acetate-EDTA (TAE) Buffer Formedium 
2.1.3.8 Sanger sequencing
Big Dye Terminator v3.1 Cycle Sequencing Kit Applied Biosystems 
Exonuclease I, 20U μL-1 Thermo Scientific 
FastAP, thermosensitive Alkaline Phosphatase, 1U μl-1 Thermo Scientific 
Hi-Di formamide Applied Biosystems 
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2.1.3.9 Plasmid cloning and transfection 
10x Buffer 2.1 NEB 
10x PNK Buffer NEB 
2x T7 Ligase Buffer NEB 






LB Broth Miller 
LB Broth with Agar Miller 
pSpCas9(BB)-2A-GFP (PX458) Addgene 
SOC Media Sigma-Aldrich 
Subcloning Efficiency DH5α Chemically Competent Cells NEB 
T4 PNK Enzyme NEB 




5x Reaction Buffer Promega 
Hotstart GoTaq G2 polymerase Promega 
M-MLV Reverse Transcriptase Promega 
M-MLV Reverse Transcriptase Buffer Promega 
MgCl2 Promega 






Reagent Final Concentration 
Dulbecco’s Modified Eagle Media (DMEM) High Glucose - 
Foetal Bovine Serum (FBS) 10% 
Non-Essential Amino Acids 1x 
Penicillin/Streptomycin 1% 
Uridine 50 µg/mL 
2.1.4.2 Cell lysis buffer
Reagent Final Concentration 
Tris-HCl pH7.4 50 mM 
NaCl 130 mM 
MgCl2 2 mM 
Nonidet P-40 1% 
Protease Inhibitor Tablet 1x 




Reagent Final Concentration 
Tric-Hcl pH 8.0 10 mM 
EDTA 1 mM 
Triton-X 1% 
EGTA 0.5 mM 
Sodium Deoxycholate 0.1% 
SDS 0.1% 
NaCl 140 mM 
PMSF (added just before use) 1 mM 
2.1.4.4 Sample dissociation buffer
Reagent Final Concentration 
Tris-HCl pH 6.8 6.25 mM 
SDS 2% 
Glycerol 10% 
DDT 100 mM 
Bromophenol Blue 0.01% 
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2.1.4.5 12% Resolving gel
Reagent Final Concentration 
Tris-HCl pH 8.5 380 mM 




2.1.4.6 3.75% Stacking gel
Reagent Final Concentration 
Tric-HCl pH 6.8 125 mM 






2.1.4.7 1x Running buffer
Reagent Final Concentration 
Trisma Base 25mM 
Glycine 192 mM 
SDS 0.1% 
2.1.4.8 1x Transfer Buffer
Reagent Final Concentration 
Trisma Base 25mM 




Reagent Final Concentration 




2.1.4.10 Sucrose gradient buffer
Reagent Final Concentration 
Tris-HCl pH 7.2 50 mM 
Magnesium Acetate 10 mM 
NH4Cl 40 mM 
KCl 100 mM 
PMSF 1 mM 
Chloramphenicol 50 μg/mL 
2.1.4.11 DNA isolation reagent
For 20 samples: 
Reagent Volume 
DirectPCR Lysis Reagent 1  mL 
Proteinase K 40 μL 
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2.1.4.12 PCR master mix
Reagent Final Concentration 
GoTaq Reaction Buffer 1x 
dNTPs 200 μM 
GoTaq G2 Polymerase 1.25u 
Fwd/Rev Primer Mix 1.25 μM 
















PRABI-Doua Pôle Rhône-Alpes de Bioinformatique Site Doua 
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2.1.6 Online web tools
Tool Access Link 


































Tool Access Link 







2.2.1 Patient recruitment and ethical guidelines
Patients were recruited via the NHS Highly Specialised Service for Rare Mitochondrial 
Disorders and the NHS Highly Specialised Mitochondrial Diagnostic Service in 
Newcastle upon Tyne. Patient and control tissue samples were stored within the 
Newcastle Mitochondrial Research BioBank (REC reference: 16/NE/0267) and 
obtained from the Diagnostic laboratory via a tissue and DNA request form. In 
agreement with the Declaration of Helsinki, all individuals or their guardians provided 
written informed consent before undergoing clinical evaluation and diagnostic genetic 
testing.   
 
Appropriate age-matched control skin fibroblast cell lines, control cardiac tissue 
samples and control skeletal muscle samples were obtained from the NHS Highly 
Specialised Service for Rare Mitochondrial Disorders. 
 
76 
Table 2.1 Details of Individual Patient Referral and Recruitment





Royal Manchester Children’s Hospital, UK 2015 
GFM2 
Patient 2 





Sapienza University, Rome, Italy 2016 
MRPL47 
Patient 1 
King Saud university , Riyadh, Saudi Arabia 2017 
MRPL47 
Patient 2 
King Saud university , Riyadh, Saudi Arabia 2017 
MRPL47 
Patient 3 
Helmhotz Centre, Munich, Germany 2018 
MRPL65 
Patient 1 





Children’s Hospital of Michigan, USA 2019 
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2.2.2 Maintenance of human cell lines
Patient skin fibroblasts, age-matched control skin fibroblasts, HEK293 and U2OS cell 
lines were cultured in vented T75 or T25 flasks (unless otherwise stated) with Growth 
Media at 37°C in 5% CO2. Cells were monitored regularly with a benchtop LED 
Microscope. When cell confluency reached ~80%, cells were trypsinised with 1x 
TrypLE Express, resuspended in an equal volume of growth media and pelleted in a 
universal tube via centrifugation at 1,200 rpm. The supernatant was subsequently 
disposed of, and the pellet was resuspended in 1 mL of growth media. The 1 mL cell 





 is a commercially available human embryonic kidney cell line 






 is an osteosarcoma derived cell line. Cells from this line will be 
referred to as U2OS cells throughout this text.
2.2.2.1 Harvesting of cells
To harvest cells for subsequent lysis, 1 mL of cell suspension, as described in 2.2.2, 
was aliquoted into a single 1.5 mL eppendorf tube and centrifuged at 3,000 rpm in a 
benchtop centrifuge (Eppendorf 5418)  or 3 minutes at room temperature. The resulting 




2.2.2.2 Freezing and storage of cells
For long-term storage, cell pellets obtained following the centrifugation step in 2.2.2.1 
were resuspended in 0.5 mL of FBS with 10% DMSO, then aliquoted into a cryostorage 
vial and placed in a CoolCell Cell Freezing Container. The CoolCell was placed in a -
80°C freezer for a minimum of 24 hours before tubes were transferred into a liquid 
nitrogen storage vessel.
2.2.2.3 siRNA transfection
Cells were transfected with siRNA in 6 well plates for 6 days. A prewarmed mixture of 
250 μL of Opti-MEM, 2.5 μL of 20 μM siRNA and 2 μL of Lipofectamine was prepared 
for each well and left at room temperature for 15 minutes. Cells were harvested and 
counted using a Cellometer Auto 1000 Bright Field Cell Counter, then diluted into 
1.25 mL aliquots containing 80,000 (U2OS) or 100,000 (fibroblast) cells for seeding 
into each individual well. 6 well plates were placed at 37°C with 5% CO2. After 3 days, a 
second mixture of 250 μL of Opti-MEM, 2.5 μL of 20 μM siRNA and 2 μL of 
Lipofectamine was prepared for each well and left at room temperature for 15 
minutes. Each mixture was combined with 1.25 mL of pre-warmed Opti-MEM. All 
media was removed from growing cells, avoiding cell disturbance or detachment. A 
1.544 mL Opti-MEM/siRNA/Lipofectamine mixture was added to each well for 





2.2.3.1 Preparation of human cell lysate
Cell pellets were resuspended in approximately 50 μl of cell lysis buffer per 10 mg of 
cell pellet. Samples were vortexed for 30 seconds and centrifuged at 1000g for 3 
minutes to pellet nuclei and any unbroken cells. The supernatant was then transferred 
to a fresh 1.5 mL Eppendorf tube, snap frozen in liquid nitrogen and stored at -80°C. 
2.2.3.2 Preparation of human muscle lysate
Approximately 10-20 mg of frozen (in liquid nitrogen) muscle was powdered in a pestle 
and mortar, suspended in 1 mL RIPA buffer and transferred to a 1.5 mL microcentrifuge 
tube. The muscle homogenate was then vortexed 5 times for 15 seconds with 15 
second intervals on ice followed by a 45 minute incubation on ice. The homogenate 
then underwent two 5 second homogenisation steps using an Ultra-Turrax tissue 
homogeniser. The final muscle lysates were prepared by centrifugation at 14,000g for 
10 minutes at 4 °C, retaining the supernatant before snap freezing in liquid nitrogen.
2.2.3.3 Bradford assay
Measurement of protein concentration was carried out using the Bradford assay. 1 and 
2 μL of cell or tissue lysates alongside standard curve standard curve (0, 2, 5, 10, 15 
and 20 μL) volumes of BSA were added to a final volume of 800 μL of dH2O. 200 μL 
of protein assay dye reagent was added to both the lysate and BSA standard curve 
mixtures. The samples were vortexed for a few seconds, then incubated for 5 minutes 
at room temperature. 200 μL aliquots of each sample were added to a 96 well plate. 
The absorbance at 595nm of samples was measured on an ELx800 microplate reader. 
The optical density of samples relative to the BSA standard curve were used to 




Precipitation of proteins was carried out through the addition of an equal volume of 
20% trichloroacetic acid (TCA) followed by a 30 minute incubation on ice. The samples 
were then centrifuged at 15,700g for 15 minutes at 4°C. The resulting pellets 
underwent 3 washes with 200 μL of cold acetone. The final pellets were air dried then 
resuspended in 1x sample dissociation buffer.
2.2.3.5 SDS-PAGE
Casting and running of polyacrylamide gels was performed using the Bio-Rad Mini-
Protean® Tetra Cell system, unless otherwise specified. Gels were cast with resolving 
phases of 12% polyacrylamide. Addition of isopropanol on top of the resolving matrix 
as it was setting allowed a flat and even gel surface to form. Isopropanol was removed 
after polymerisation had occurred and washed 3 times with water before the addition 
of a 3.75% stacking gel on top. Lysates used for SDS-PAGE were incubated with 5x 
sample dissociation buffer for 15-20 minutes at 37°C to denature and introduce a 
negative charge to proteins prior to loading. SDS-PAGE was performed in 1x running 
buffer at a stable 200V.
2.2.3.6 Western blotting and immunodetection
Proteins separated by SDS-PAGE were transferred onto a PVDF membrane using the 
Mini Trans-Blot module Bio-Rad system. PVDF membrane was submerged in 100% 
methanol for 15 seconds to activate and then left to equilibrate in transfer buffer for ~1 
minute. The SDS-PAGE gel and activated membrane were then sandwiched between 
double layers of 3 mm Whatman filter papers and sponges within a cassette, prior to 
being placed into the transfer tank containing 1x transfer buffer. Transfer was 
performed at a stable 100V for 1 hour at 4°C.
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Following transfer, the PVDF membrane was blocked with 5% milk/TBS-T for 1 hour 
at room temperature before incubation with primary antibodies. Dilution of primary 
antibodies in 5% milk/TBS-T was carried out, as described in Table 2.2, for overnight 
incubation at 4°C with membrane agitation. The following morning, 3 x 10 minute 
washes of the membrane in TBS-T were carried out, prior to incubation with the 
appropriate secondary antibody for 1 hour at room temperature with membrane 
agitation. The membrane was then subjected to 3 further 10 minute TBS-T washes, 
before the application of ECL prime reagent (GE healthcare) incubated for a minimum 
of 5 minutes. The resulting chemiluminescent signals were visualised using the 































































1:1,000 43 Mouse Monoclonal 




Antibody Dilution Host Species Clonality 
Anti-Mouse 
Secondary 
(P0260, Dako)  




1:3,000 Swine Polyclonal 
Table 2.3 Secondary antibodies used for immunoblotting. 
2.2.3.7 Sucrose gradient
To generate a linear 10-30% sucrose gradient, 10% and 30% mixtures of sucrose in 
sucrose gradient buffer were made up in individual falcon tubes. A syringe was used 
to add 0.5 mL of 10% sucrose solution into the bottom of an ultracentrifuge tube. A 
second syringe was used to add 0.5 mL of 30% sucrose solution into the tube, below 
the first 10% sucrose layer. A gradient was generated using the 107 Gradient Master 
Ip (BioComp) set to ‘TLS55, short sucrose 10%-30%, 55 seconds’. The gradient was 
then placed at 4°C for 60 minutes.
Once gradients had been prepared, 100 μL of cell lysate containing 700 μg of protein 
was carefully added to the top of the gradient. The tube was then centrifuged using the 
OptimaTM TLX Ultracentrifuge (rotor TLS 55) at 39,000 rpm (100,000g) for 2 hours 
and 15 minutes at 4°C. Following ultracentrifugation, eleven 100 μL fractions were 
collected, each taken from the top of the gradient. Fractions were stored at -20°C for 
subsequent SDS-PAGE and western blot analysis. 
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2.2.4 [35S] Metabolic labelling
Using cells that had reached a confluency of 80%, growth media was replaced with 
DMEM free of methionine and cysteine and incubated at 37°C for 10 minutes. This 
was repeated twice, before the media was replaced with methionine/cysteine free 
DMEM supplemented with 10% dialysed FBS and 100 μg/mL emetine dihydrochloride 
(to inhibit cytosolic translation) and incubated at 37°C for a further 10 minutes. 20 
μL/mL of [35S]-methionine/cysteine mix (Perkin-Elmer Easy Tag Express protein 
labelling mix NEG-772, 73% L-met, 22% L-cys) was then added to each flask and cells 
were left to incubate at 37°C for 1 hour. Cells were washed in standard growth medium 
supplemented with methionine and then harvested in TrypLE Express, pelleted and re-
suspended in PBS (plus protease inhibitor and 1mM PMSF). The protein concentration 
of each sample was determined using a standard Bradford assay (2.2.3.3). 20-50 μg 
of each radiolabelled sample was loaded onto a 15% SDS-PAGE gel and 
electrophoresed at 20mA for 2 hours. The gel was fixed overnight (3% glycerol, 10% 
glacial acetic acid, 20% methanol), stained with Coomassie brilliant blue for an 
indication of loading, and then dried under a vacuum at 70°C for 2 hours, prior to signal 




2.2.5.1 DNA extraction from human cells
DNA was extracted from growing 96 well cell culture plate clonal populations by first 
trypsinising cells with 200 μL of 1x TrypLE Express. 50 μl of trypsinised cell suspension 
was used to re-seed and continue cell culture, while the remaining 150 μl  was 
transferred into a 96 well PCR plate and centrifuged at 12,000 rpm to pellet cells. The 
supernatant was removed and 50 μL of DNA isolation reagent solution was added to 
each well, disturbing the pellet. The plate was incubated at 56°C for 16 hours shaking 
at 300rpm. The plate was then incubated at 95°C for 10 minutes and end samples 
were stored at -20°C.
For extraction of DNA from T75 cell culture flasks for SNP analysis, a Qiagen DNeasy 
Blood & Tissue Kit (cat no. 69504) was used following the manufacturer’s spin column 
quick-start protocol.
2.2.5.2 Primer design
Custom-designed forward and reverse primers were generated using Primer3Plus The 
generated primer sequences were checked for common single nucleotide 
polymorphisms (SNPs) using SNPCheck3. 
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Target Forward Reverse 
GFM2 
Exon 8 
GCACACTCCCCTTCACACTT  TGGAATCATCAAGAAGCCACT 
GFM2 
Exon 9 


















Table 2.4 Custom primers used for PCR and Sanger sequencing.
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2.2.5.3 DNA amplification by PCR
PCR amplification of target DNA was performed by adding 1.0 μl of sample DNA to 
24.0μl of Go Taq PCR master mix and subjecting samples to the following PCR 
programme:
1 cycle 94ºC 4 minutes 
30 cycles 94ºC 45 seconds 
 62ºC 45 seconds 
 72ºC 45 seconds 
1 cycle 72 ºC 5 minutes 
Hold 4ºC ∞ 
2.2.5.4 DNA gel electrophoresis
For gel electrophoresis of PCR products, either 1.0 g (1% gel) or 3.0 g (3% gel) of 
agarose was dissolved in 100 mL of 1x TAE buffer. 4 μL of SYBR Safe was added to 
the solution which was then poured into a casting cassette and comb. The gel was left 
to solidify and then submerged in 1x TAE buffer prior to loading. An appropriate ladder 
marker was loaded alongside DNA samples containing a 1:1 mixture of PCR products 
and loading dye. The agarose gel was typically electrophoresed at 80V for 30-50 





PCR products were treated with ExoFAP for clean up prior to cycle sequencing. 
Duplicates of 5 μL of PCR product were added to 1.5 μL of ExoFAP. The samples were 
mixed and briefly spun down. The mixture was heated according to the following 
programme: 37°C for 15 minutes then 80°C for 15 minutes, finishing with a hold at 4°C. 
Sanger sequencing of amplified gene products was subsequently carried out in 
accordance with BigDye® Terminator v3.1 Cycle Sequencing Kit (cat no. 4337455) 
manufacturing protocol with the following program: 
1 cycle 96 ºC 1 minutes 
35 cycles 96 ºC 10 seconds 
 50 ºC 5 seconds 
 60 ºC 4 minutes 




2.2.6.1 RNA extraction from human cells
RNA was extracted from fibroblasts grown to 80% confluency in a T75 flask, using the 
Qiagen RNeasy Mini Kit (cat no. 74104) , following the manufacturer’s quick-start 
protocol.
2.2.6.2 Reverse transcription
For synthesis of cDNA, 1 µg of RNA, 1 µl of random hexamers (250 μg/mL) and 
nuclease free H2O were combined up to a final volume of 15 µl. This mixture was 
incubated at 70ºC for 5 minutes and then placed immediately on ice for 1 minute. A 
second mixture containing 5 µl of M-MLV reverse transcriptase buffer, 2.5 µl of 20 mM 
dNTPs, 0.5 µl of RNasin, 1 µl of M-MLV reverse transcriptase and 1 µl of RNAse free 
H2O was added and the total mixture incubated at 37ºC for 60 minutes. This sample 
was kept at -80ºC, for long-term storage.
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2.2.6.3 Second strand synthesis
For second strand synthesis of reverse transcription generated cDNA, 1 µl of cDNA 
was added to a master mix containing 5 µl of 5x Promega reaction buffer, 2.5 µl of 2 
mM dNTPs, 2 µl of 25 mM MgCl2, 2.5 µl of 10 µM primer mix, and 0.2 µl of 5 U/µl 
Hotstart GoTaq G2 polymerase. The mixture was made up to 25 µl with nuclease free 
H2O. The final mixture was subject to the following PCR cycling program: 
1 cycle 95 ºC 2 minutes 
30 cycles 95 ºC 1 minute 
 62 ºC 1 minute 
 72 ºC 1 minute 
1 cycle 72 ºC 10 minutes 
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2.3 CRISPR/Cas9 gene editing
2.3.1 sgRNA oligo design
Three freely available web tools, Benchling, ZiFit Targeter and CRISPR.MIT were 
used for the design of four sgRNA oligos (Error! Reference source not found.). These 
online resources identified suitable 20 nucleotide regions located directly adjacent to 
PAM sites and ranked the guide sequences based on predictions of high target 
specificity with low off-target binding.













Table 2.5 Custom sgRNA Oligos for use in CRISPR/Cas9 Studies
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2.3.2 Plasmid vector manipulation
2.3.2.1 sgRNA oligo annealing
For the annealing of short guide RNA oligos, 1 µl of forward oligo and 1 µl of reverse 
oligo (both at 100 µM) were mixed with 1 µl of 10x PNK buffer, 1 µl of ATP, 1 µl of T4 
PNK enzyme and made up to 10 µl with ddH2O. This mixture was treated to the 
following heating program: 37°C for 30 minutes then 95°C for 5 minutes then placed 
in a boiling water bath and allowed to cool for 45 minutes to room temperature. The 
final sample is stored at -20°C.
2.3.2.2 Backbone cutting
In order to cut the Px458 vector at the multiple cloning site, 1 µl of BbsI restriction 
enzyme and 2 µl of 10x Buffer 2.1 was added to 1 µg of PX458 plasmid, then the 
total volume was made up to 20 µl with ddH2O. This mixture was incubated for 1 
hour at 37 °C.
The total 20 µl mixture was combined with 3.5 µl of 1M Tris-HCl pH 9.0, 1 µl of 10% 
SDS and 1 µl of alkaline phosphatase. This mixture was incubated at 37 °C for 30 
minutes followed by a 50°C incubation for a further 30 minutes. 1 µl of 0.5 M EDTA 
was then added and the treated plasmid was gel purified.
2.3.2.3 Ligation
For the ligation of the plasmid vector with sgRNA molecules, 50 ng of BbsI digested 
PX458 plasmid (from section Error! Reference source not found.) was added to a 
ligation mixture containing 2 µl of annealed oligo duplex (from section Error! 
Reference source not found. and diluted 1:200 in ddH2O), 5 µl of 2x T7 Ligase 
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Buffer, 1 µl of T7 Ligase and made up with ddH2O to a total volume of 11 µl. This 
reaction was incubated for 30 minutes at room temperature.
2.3.2.4 Restriction endonuclease DNA digestion
Double digests of PX458 were carried out using 500 ng of plasmid DNA obtained from 
bacterial minipreps (Error! Reference source not found.), added to a mixture 
containing 0.5 µl of BbsI restriction enzyme, 0.5 µl of EcoRI restriction enzyme, 2 
µl of 10x Buffer 2.1 and made up to 10 µl with ddH2O. This reaction was incubated 
at 37 °C for 2 hours and then run on a 1% agarose gel to check digestion product 
sizes.
2.3.3 Plasmid transfection
For transfection of cells with a pSpCas9(BB)-2A-GFP (PX458) plasmid, an Amaxa® 
Cell Line Nucleofector® Kit V (cat no. VVCA-2003) was used. U2OS cells were grown 
an 80% confluency, trypsinised, counted and diluted into 100μL aliquots of Cell Line 
Nucleofector® solution containing 1 million cells. 2 µg plasmid DNA or 2 µg 
pmaxGFP® Vector (control) was added to the solution and cells were transferred into 
a kit-provided cuvette. Cuvettes were inserted into the Nucleofector® device and 
subject to program X-001. 500 µL of growth media was then added to the cuvette and 
the entire contents transferred into a 6 well plate and allowed to recover for 24-48 
hours. 
2.3.4 Single cell sorting
Following recovery of post-transfection cells, each population was at ~2-3 million cells. 
Cell populations were trypsinised and resuspended in 500-600μl of PBS (+ 1-2% FBS) 
in individual FACS tubes to the Core Flow Cytometry Facility. Cells were strained 
through 40μm filters to prevent clumping and were then stained with DAPI (0.1µg/mL-
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10µg/mL) before sorting with a MoFlo Astrios EQ Cell Sorter. The Astrios machine 
sorted cells into single cell wells of a 96 well plate based on positive DAPI signal and 
GFP signal indicating live cells with successful nucleofection. Two 96 well plates were 
sorted for each of the sgRNA plasmids alongside single plates of pmaxGFP® Vector 
cell and no-cell controls. The single cells were then left to proliferate into clonal 




2.3.5.1 Propagation and storage
Subcloning efficiency DH5α chemically competent cells were used in cloning 
experiments. Competent cells were grown at 37°C in plates of 4% LB broth with agar 
that had been autoclaved prior to pouring.
Transformed strains were stored in 18% glycerol 4% LB stocks and then kept at -80°C 
for future use. For defrosting and propagation a small amount of glycerol stock was 
scraped on a 4% LB broth agar plate and left to grow at 37°C overnight.
2.3.5.2 Transformation
Heat shock was used for the transformation of DH5α cells. 4 µl of ligation reaction 
from section Error! Reference source not found. was added to 40 µl of 
subcloning efficiency DH5α cells. This mixture was left on ice for 30 minutes and then 
treated to heat shock at 42°C for 45 seconds. Following heat shock, the mixture was 
placed back on ice for 2 minutes. 950 µl of pre-warmed SOC media was added prior 
to incubation for 1 hour at 37°C in a shaking incubator. The mixture was centrifuged 
at 15,000g for one minute and the pellet was resuspended in 200 µl of SOC media. 
This suspension was spread out onto LB agar plates supplemented with 100 µg/mL 
ampicillin and incubated at 37°C overnight.
2.3.5.3 Colony screening
Individual transformed clones were picked and spread onto fresh LB+ampicillin plates 
then incubated overnight at 37°C. Half of each colony was resuspended in 40 µl of 
10% Triton-X and frozen at -80°C for 30 minutes. The suspension was then defrosted 
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and centrifuged at 15,000g for 5 minutes at 4°C. The supernatant was kept and used 
to set up PCR using sgRNA forward primer with PX458 plasmid reverse primer. The 
presence of an insert was checked by electrophoresis of PCR product on 1% agarose 
gel.
2.3.5.4 Isolation of plasmid DNA
Plasmid positive cells were propagated on LB+Ampicillin agar plates overnight at 
37°C. Single colonies were picked and propagated overnight in 5-7 mL of 2.5% LB 
broth supplemented with 100 µg/ml ampicillin at 37°C. Cells were pelleted through 
centrifugation for 2 minutes at 16,000g and plasmid was isolated using the 





Chapter 3 : Defects of mitochondrial translation factors in 
mitochondrial disease
3.1 Introduction
The complex process of mitochondrial translation requires a multitude of different 
proteins, along with 22 mt-tRNAs and two ribosomal RNAs, that must all function in 
concert. As discussed in 1.8, disorders of mitochondrial translation can result from 
mutations within a wide range of different genes in both the mitochondrial and nuclear 
genomes. A growing number of genes encoding mitoribosomal proteins are implicated 
in early-onset mitochondrial disease presentations (Pulman et al., 2019). 
Mitochondrial translation factors, those proteins directly involved in the initiation, 
elongation and termination stages of mitochondrial translation, are another well 
documented group of genes with the potential to cause disorders of mitochondrial 
translation when mutated. Genetic variants affecting mitochondrial translation factors 
characteristically result in combined OXPHOS deficiencies due mtDNA origin of some 
subunits of OXPHOS complexes I, III, IV and V, while the spectrum of resulting clinical 
phenotypes is broad (Pearce, Nezich and Spinazzola, 2013). In 2006 the elongation 
factor mtEF-G1, encoded by the GFM1 gene, was the first mitochondrial translation 
factor to be implicated in disease (Antonicka et al., 2006). In the years following, in 
part due to the application of next generation sequencing techniques within the rare 
disease field, novel pathogenic variants have been described in a number of genes 
encoding mitochondrial translation factors including the mitoribosome recycling factor 
GFM2, elongation factors TSFM and TUFM and the termination factor C12orf65 
(Fukumura et al., 2015; Glasgow et al., 2017; Shamseldin et al., 2012; Valente et al., 
2009; Shimazaki et al., 2012; Antonicka et al., 2010). This chapter will focus on the 
investigation of novel variants in genes encoding two of these mitochondrial translation 
factors, GFM2 and TSFM.
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3.1.1 mtEF-G2: a mitochondrial translation factor
The human genes GFM1 and GFM2 encode the proteins mtEF-G1 and mtEF-G2 
respectively. These genes are homologs of the highly conserved bacterial translation 
elongation factor G (EF-G) (Hammarsund et al., 2001). In prokaryotes, EF-G catalyses 
the translocation tRNAs sitting in the A- and P-sites of the ribosome into the P and E 
sites, facilitating translation elongation (Wintermeyer and Rodnina, 2000; Rodnina et 
al., 2000). Bacterial EF-G also works alongside ribosome recycling factor (RRF) to 
play a crucial role in the dissociation of the post-termination ribosome complex (PoTC) 
and the recycling of the ribosome at the end of each translation event (Hirokawa et al., 
2006). The EF-G equivalent in eukaryotic cytosolic translation is EF-2 (Rapp et al., 
1989), while the mitochondrial translation system possesses both mtEF-G1 and mtEF-
G2 as functional counterparts of prokaryotic EF-G (Hammarsund et al., 2001). 
Prokaryotic EF-G and the eukaryotic cytosolic protein EF-2 possess both elongation 
and ribosome recycling properties. However, it has been demonstrated that these 
roles are split between the two mitochondrial translation homologs mtEF-G1 and 
mtEF-G2. Mitochondrial mtEF-G1 requires GTP for its translocation function during 
the elongation stage of translation, whereas mtEF-G2 is not active during translation 
elongation. Instead, mtEF-G2 interacts with RRF to enable mitoribosome recycling 
(Tsuboi et al., 2009). In light of these findings, it was proposed that the translation 
factor be renamed RRF2, reflective of its ribosome recycling activity (Christian, Haque 
and Spremulli, 2009). Unlike bacterial EF-G, mtEF-G2 does not require GTP 
hydrolysis in order to disassemble the monosome. Instead, GTP hydrolysis is required 
for the release of mtEF-G2 itself from the newly disassembled LSU (Tsuboi et al., 
2009). 
3.1.2 GFM2 in mitochondrial disease
Prior to the work presented here, two sets of sibling pairs with pathogenic variants in 
the GFM2 gene had been identified through WES and reported in the literature. The 
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clinical presentations of these patients included microcephaly, simplified brain gyral 
pattern with insulin dependent diabetes in the first family and Leigh syndrome 
complicated by arthrogryposis multiplex congenita in the second (Fukumura et al., 
2015; Dixon-Salazar et al., 2012). The functional characterisation of the molecular 
mechanisms underlying disease in these patients was limited to the demonstration of 
nonsense mediated mRNA decay of GFM2 transcripts the first patients identified 
(Fukumura et al., 2015).
3.1.3 mtEF-Ts: a mitochondrial translation elongation factor
The mitochondrial elongation factor mtEF-Ts, encoded by the nuclear TSFM gene, 
acts as a guanine nucleotide exchange factor for EF-Tu promoting the formation of 
EF-Tu/GTP from EF-Tu/GDP. This exchange allows EF-Tu/GTP to form a ternary 
complex with aminoacylated mt-tRNAs, for their transport to the mitoribosomal A-site. 
In the A-site, a correct codon-anticodon interaction results in the hydrolysis of GTP 
and the release of EF-Tu/GDP to begin a new cycle (Chiron, Suleau and Bonnefoy, 
2005). 
3.1.4 TSFM in mitochondrial disease
Pathogenic variants in the TSFM gene were first identified in 2012 in two unrelated 
paediatric patients with the same homozygous c.997C>T, p.(Arg333Trp) mutation. 
Despite harbouring an identical TSFM variant, each patient presented with a distinct 
clinical phenotype. Smeitink et al. reported that their first patient experienced fatal 
mitochondrial encephalopathy, alongside muscle weakness, hypotonia, 
rhabdomyolysis and epilepsy, while a second patient presented with hypertrophic 
cardiomyopathy with general hypotonia without any further neurological involvement 
(Smeitink et al., 2006b).
A further thirteen patients with disease-causing TSFM variants have been reported in 
the years following these two initial cases. There is significant heterogeneity in the 
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clinical presentation of TSFM related disease, though patients can be sub-categorised 
into two clear groups, based on age of onset and disease severity. Disease onset in 
the first seven cases to be reported was extremely early, with presentation of severe 
symptoms in the congenital or neonatal period. Despite each patient displaying an 
individual combination of symptoms, some of the more common clinical features 
included hypotonia, respiratory failure and hypertrophic cardiomyopathy. All seven of 
these patients died within their first weeks/months of life (Smits et al., 2011a; Calvo et 
al., 2012; Shamseldin et al., 2012; Vedrenne et al., 2012; Smeitink et al., 2006b). 
The following six patients to be reported with pathogenic variants in the TSFM gene 
were adults surviving into their late teens, twenties and thirties. These patients 
presented with milder phenotypes in infancy or childhood. Similar to the early onset 
cluster of patients, the clinical features of each adult patient vary significantly, though 
optic atrophy, ataxia and hypertrophic cardiomyopathy are common to most cases 
(Ahola et al., 2014; Emperador et al., 2017; Perli et al., 2019; Traschutz et al., 2019). 
Most recently, Scala et al. identified a five-year-old boy with 
encephalocardiomyopathy, sensorineural hearing loss and spontaneously regressing 
lesions on brain MRI. The hypertrophic cardiomyopathy symptoms in this patient 
remain relatively stable with little progression or worsening over time (Scala et al., 
2019). 
The data presented here describes the clinical and biochemical profiles of two 
paediatric patients with novel variants in the GFM2 gene, and one adult patient with 
novel compound heterozygous variants in the TSFM gene, in order to assign 
pathogenicity and broaden the clinical manifestations associated with variants in each 
gene. As discussed in 1.9, confirming pathogenicity in such cases is of vast diagnostic 
value to patients and their families, while also providing insight into the molecular 




3.2.1 GFM2 Patient 1
Patient 1, a 13-year-old male, is the first child of healthy non-consanguineous parents 
and has a healthy younger brother. Pregnancy was complicated by intrauterine growth 
restriction and he was born at term by normal vaginal delivery weighing 2.0 kg. He had 
asymptomatic hypoglycaemia in the neonatal period and mild jaundice and was tube 
fed initially. He subsequently had a urinary tract infection and required orchidopexy for 
an undescended right testis. 
Developmental delay was first noted at 2.5 years in relation to language and 
communication skills; he had acquired his first words at 12–18 months, but did not put 
words together until aged 3 years. From 5 years onwards, he has become increasingly 
dysarthric. He has used a knife and fork from 3 years of age but has never been able 
to write. He started walking at 14 months and could run at 4 years, but he 
subsequently developed a dystonic posture of his right foot and spasticity in both legs, 
leading to toe walking and loss of ambulation at 8 years; he currently mobilises by 
crawling. He has been continent since 2 years of age. He has a normal head 
circumference, normal vision and hearing and no involuntary movements or seizures 
and continues to make slow academic progress.
Cranial MRI showed symmetrical bilateral high signal on T2-weighted images in the 
caudate, putamen and cerebellar dentate nucleus. There were also abnormalities in 
the corpus callosum and the subcortical white matter of the cerebral and, particularly, 
the cerebellar hemispheres, with further abnormal areas in the deep white matter 
(Figure 3.1). CSF lactate was elevated on two occasions at 3.2 and 3.4 mmol/L 
(normal range, 0.7–2.1 mmol/L). Sequencing of the mitochondrial genome and 
the NFU1 gene both failed to detect pathogenic variants. This patient was referred by 
Dr.Andrew Morris, Alder Hey Children's Hospital NHS Foundation Trust.
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Figure 3.1 MRI of Patient 1. MRI demonstrates bilateral T2 hyperintensities involving supratentorial white matter 
(yellow arrows), head of caudate nucleus (white arrows), putamen and genu and splenium of the corpus callosum 
(A) characterised by low T1 signal suggesting irreversible tissue damage (B). Right (R) and left (L) are indicated.
3.2.2 GFM2 Patient 2
Patient 2, a 9-year-old female, is the second child of consanguineous parents 
originating from Syria. Born following an uneventful pregnancy at full term, 
development was unremarkable in the first 2 years of life. At the age of 2 years and 
2 months, involuntary movements of the left hand were reported and within a few 
months, these had extended to involve all four limbs. Muscle strength and mass 
deteriorated and she lost the ability to walk at 4 years, to sit at 5 years and 
subsequently lost the ability to speak. At the age of 6 years, she presented with her 
first seizure and has subsequently developed a severe epilepsy disorder. Clinical 
assessment reveals severe global developmental delay, myopathic facies with an 
open mouth appearance and drooling, severe axial hypotonia with hypertonic limbs 
and dystonic involuntary movements. Communication was restricted to phonetic 




Lactate was repeatedly elevated in both serum, to 4.1 mmol/L, and CSF, to 3.1 
mmol/L, (normal <2.5mmol/L). Cranial MRI showed diffuse hyperintensities on T2-
weighted imaging of the periventricular and central white matter with associated 
volume loss and atrophy of corpus callosum as well as T2 hyperintense defects of 
bilateral putamen and head of caudate nucleus (Figure 3.2). EEG revealed multifocal 
seizure activity.
Figure 3.2 MRI of Patient 2. MRI demonstrates extensive T2 hyperintensities associated with volume loss 
involving bilateral periventricular and central white matter (A, B, yellow arrows) and defects involving both putamina 




This 36-year-old female patient was born at term to non-consanguineous healthy 
parents. Early psychomotor development was normal, however gross-and fine-motor 
clumsiness with frequent falls were observed in infancy. This was followed by mild 
muscle weakness and reduced limb coordination. Genetic screening for 
spinocerebellar and Friedreich’s ataxias was negative. These symptoms remained 
stable until the patient reached the age of 27 when she experienced worsening fatigue 
and dyspnoea and was referred to the Cardiomyopathies Unit of San Camillo-Forlanini 
Hospital, Rome. Echocardiography revealed a mildly dilated left ventricle (LV), LV end-
diastolic diameter (LVDD) of 51 mm and ejection fraction (EF) of 21%, consistent with 
dilated cardiomyopathy. Serum lactate levels were slightly increased (3.70 mmol/L; 
control <2.2 mmol/L). LV function progressively decreased, despite therapeutic 
intervention. At the age of 33 years, echocardiography showed a hypokinetic and 
dilated LV, LVDD of 54 mm, ventricular septum thickness of 10 mm and EF of 15%. 
The patient underwent cardiac transplant a few months later. This patient was referred 




3.3 Results: GFM2 
3.3.1 Histopathological and biochemical studies
Due to the presentation of muscle related clinical features in Patient 1, a skeletal 
muscle biopsy was obtained for histopathological and biochemical investigations. No 
marked structural abnormalities were identified upon H&E staining of skeletal muscle 
from Patient 1 (Figure 3.3A). Oxidative enzyme histochemistry showed intense SDH 
activity and a generalised decrease in cytochrome c oxidase activity throughout the 
muscle section (Figure 3.3B-C). Sequential COX-SDH histochemistry confirmed a 
widespread COX deficiency in the presence of normal SDH activity (Figure 3.3D).
Figure 3.3 Histochemical investigation of patient skeletal muscle and biochemical analysis of skeletal 
muscle and fibroblasts. (A) Haematoxylin and eosin stain. Succinate dehydrogenase (SDH) (B), cytochrome c 
oxidase (COX) (C) and COX-SDH histochemistry (D). Respiratory chain enzyme activity measurements in the 
skeletal muscle of Patient 1 (E), the fibroblasts of Patient 1 (F) and the fibroblasts of Patient 2 (G) normalised to 
citrate synthase. (red: controls, blue: patient). Control datasets for skeletal muscle and fibroblast biochemistry are 
based on n=25 normal samples, normalised and set to 100% with error bars to represent standard deviation. These 
 
107 
data were generated by Langping He and Gavin Falkous. Figure adopted and amended from (Glasgow et al., 
2017).
The assessment of respiratory chain enzyme activities in the muscle of Patient 1 
revealed impaired complex IV activity, while the activities of complexes I and II were 
both within the limits of the standard deviation of control values (Figure 3.3E). 
Fibroblast cells from Patient 1 appear to express a mild combined OXPHOS defect 
affecting complexes I and IV, with residual enzyme activities approximately 60% of the 
average of control fibroblasts (Figure 3.3F). Complex activity measurements in the 
fibroblasts of Patient 2 revealed a severe complex IV deficiency, while activity of 
complex II is two-fold higher than controls. Complex I and III activities are within the 
control range (Figure 3.3G). 
3.3.2 Variant identification, confirmation and segregation studies
WES of Patient 1 identified compound heterozygous variants in the GFM2 gene, a 
c.569G>A single nucleotide substitution in exon 8 resulting in an arginine to glutamine 
missense change at residue 190 (p.(Arg190Gln)) and a c.636delA single nucleotide 
deletion in exon 9 producing a frameshift mutation and premature termination codon 
(p.(Glu213Argfs*3)). WES of Patient 2 revealed a homozygous c.275A>C variant in 
exon 5 of GFM2, predicted to cause a tyrosine to serine missense change at residue 
92 (p.(Tyr92Ser)). Sanger sequencing of the probands plus their respective parents 




Figure 3.4 Segregation of recessive GFM2 variants. Familial pedigrees and Sanger sequence data 
demonstrating recessive inheritance of GFM2 variants in Patients 1 (top) and 2 (bottom) from heterozygous 
parents. Figure adopted and amended from (Glasgow et al., 2017).
3.3.3 Missense residue conservation and in silico pathogenicity predictions
Conservation and in silico pathogenicity predications were carried out in order to 
assess the possible structural and functional importance of amino acids affected by 
missense mutations. Multiple sequence alignment and assessment of the evolutionary 
conservation of each missense variant demonstrates that the Arg190 residue is 
conserved in mammals, and amphibians, but is less so in more distant species such 
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as Danio rerio and Caenorhabditis elegans. The region flanking the p.(Arg190Gln) 
change is similarly conserved throughout most higher order species (Figure 3.5). The 
residue affected by the homozygous p.(Tyr92Ser) variant in Patient 2 is conserved 
from humans through to Caenorhabditis elegans with only Drosophila melanogaster 
varying from the conserved tyrosine to phenylalanine. The surrounding region is 
extremely well conserved (Figure 3.5).
Figure 3.5 Multiple sequence alignment of mtEF-G2 regions surrounding each missense variant. Mutant 
and Wildtype human mtEF-G2 sequence aligned alongside orthologs from 8 further species to visualise 
evolutionary conservation of each affected residue and surrounding sequence. 
All three GFM2 variants are extremely rare; the c.564A>G, p.(Arg190Gln) allele, 
harboured by Patient 1, is present in 5/276,072 alleles on gnomAD (MAF = 0.00002) 
but never in a homozygous state, while the other c.636delA, p.(Glu213Argfs*3) variant 
found in Patient 1 and the c.275A>C, p.(Tyr92Ser) variant present in Patient 2 are 
unreported in the database (https://gnomad.broadinstitute.org/).
In silico pathogenicity prediction tools generated consistent results for the 
p.(Tyr92Ser) missense variant belonging to Patient 2, this change was classified as 
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likely to affect protein function according to all in silico prediction tools used. SIFT and 
aGVFD classified the p.(Arg190Gln) change in Patient 1 as unlikely to interfere with 
protein function while Mutation Taster, PolyPhen and CADD scores were supportive 
of a deleterious effect (Table 3.1). CADD scores of 32 for c.569G>A and 27.2 for 
c.275A>C, predict that these variants are in the top 0.01 and 0.1% of deleterious single 





















Table 3.1 Assessment of missense GFM2 variants using a panel of  in silico pathogenicity prediction tools. 
Output of each in silico pathogenicity prediction tool when assessing missense changes p.(Arg190Gln) (Patient 1 
– first row)) and p.(Tyr92Ser) (Patient 2 – second row). Deleterious predictions are shaded in red, tolerated 
predictions are shaded in green. Align GVGD uses Grantham scores of evolutionary distance alongside sequence 
conservation to categorise missense changes into one of six classes. Class C0 = class containing variants least 
likely to interfere with protein function, Class C55 = class containing variants second most likely to interfere with 
protein function. Combined annotation dependent depletion (CADD) scores are calculated using an array of 
different tools assessing variants and simulated mutations. A CADD score of 20 classifies a variant as within the 
top 1% of most deleterious SNVs in the genome. A CADD score of 30 classifies a variant as within the top 0.1% of 
most deleterious SNVs in the genome. All web-based tools are freely available - see Materials and Methods section 
2.1.6. 
3.3.4 Western blot analysis of patient fibroblasts and skeletal muscle
In order to assess the impact of the GFM2 variants on OXPHOS complex stability, 
investigation into the steady-state levels of individual OXPHOS complex subunits in 
fibroblasts were carried out, revealing patient-specific differences. There was an 
extremely mild decease in the abundance of OXPHOS proteins in the fibroblasts of 
Patient 1, primarily affecting subunits of complexes I (NDUFB8) and IV (COXI and 
COXII) (Figure 3.6A), while the fibroblasts of Patient 2 exhibited a clear decrease in 
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the steady-state levels of subunits of complex I (NDUFB8), complex III (CYTB and 
CORE2) and complex IV (COXI and COXII) (Figure 3.6A). Skeletal muscle sample 
from Patient 1 was obtained, however no tissue samples from Patient 2 were available. 
Skeletal muscle lysates from Patient 1 exhibited a marked decrease in steady-state 
levels of complex IV components COXI and COXII, with subunits of each of the other 
OXPHOS complexes relatively unchanged compared to controls (Figure 3.6B).
Figure 3.6 Western blot analysis in fibroblasts and skeletal muscle. Whole cell lysates from fibroblasts of 
Patient 1 and Patient 2 subjected to SDS-PAGE and western blotting using with antibodies against NDUFB8, SDHA 
(loading control), CORE2, CYT B, COXI, COXII and ATP5B (A). Skeletal muscle lysate from Patient 1 subjected 
to SDS-PAGE and western blotting using antibodies against NDUFB8, SDHA (loading, CORE2, COXI, COXII, 
ATP5A and SDHA (loading) and mtEF-G2 (B). Figure adopted and amended from (Glasgow et al., 2017). Data 
shown is representative of three independent repeats.
Attempts at detecting mtEF-G2 signal in fibroblasts using a commercial antibody 
repeatedly resulted in the presence of non-specific bands. Consequently, investigation 
into the steady-state level of mtEF-G2 was only possible in the skeletal muscle of 
Patient 1, which produced clear signal. The abundance of mtEF-G2 protein in patient 
skeletal muscle lysate was decreased to approximately 50% of the controls (measured 
using an ImageLab densitometry tool) (Figure 3.6B).
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3.3.5 [35S] translation assay in growing fibroblasts
Due to the defects on OXPHOS subunits identified in patient fibroblasts (Figure 3.6A), 
and the role of mtEF-G2 as a mitoribosomal recycling factor, it was important to assess 
mitochondrial translation in patient cell lines. A [35S] metabolic labelling assay was 
performed in order to assess whether these GFM2 variants cause impairment of de 
novo mitochondrial protein synthesis in growing fibroblast cells as a potential 
pathomechanism responsible for the observed OXPHOS defects. Cytosolic translation 
was inhibited through addition of 100 μg/mL emetine to culture media, in order to 
obtain signal from only protein synthesis occurring within mitochondria. Cells were 
incubated for one hour with radiolabelled methionine/cysteine, harvested, and 
separated via SDS-PAGE. The resulting bands correspond to the mtDNA encoded 
proteins that were synthesised within the 1 hour pulse incubation. In the case of both 
patients there does not appear to be any effect on the incorporation of radiolabelled 
methionine/cysteine into newly synthesised mtDNA encoded proteins, except in the 
case of ND1, where there is no corresponding band in either patient (Figure 3.7). 
While it appears that signal in the lane containing labelled sample from Patient 2 is 
generally lower, this is a result of lower loading of total sample as can be seen on the 
Coomassie stain panel. 
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Figure 3.7 [35S] methionine/cysteine incorporation in growing fibroblasts as a measure of de novo 
mitochondrial protein synthesis. Signal detected from fixed and dehydrated SDS-PAGE gel using Typhoon 
Phosphorimager. Bands are visible for radiolabelled COXI, ND4, cyt b. ND2, ND1, COXIII, COXII and ATP6. 





3.4.1 Histological, histochemical and biochemical studies
Masson trichrome staining of cardiac tissue from both the right and left ventricles 
revealed multiple foci of myocardial fibro-adipose replacement (Figure 3.8A-B). 
Myocytes lost from the RV were mostly replaced with adipose tissue (Figure 3.8A), 
while myocardial replacement in the LV was mostly fibrous (Figure 3.6B). Sequential 
COX-SDH histochemistry revealed a severe and widespread COX deficiency in 
explanted cardiac tissue (Figure 3.8C-D).
Biochemical assessment of respiratory chain enzyme activities revealed a severe 
defect in the activity of complex IV alongside a small decrease in complex I activity 
that remains within the range of standard deviation (Figure 3.8E).
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Figure 3.8 Histological, histochemical and biochemical investigation of patient cardiac tissue. Masson 
trichrome performed on right ventricle (RV) (A) shows abundant connective tissue (blue) replacement of 
cardiomyocytes (red). Arrows denote adipose tissue, asterisks denote fibroadipose replacement. Foci of scarring 
(blue) are present in the left ventricle (LV) (B). Scale bars are 250um. Combined COX/SDH staining of RV and LV 
(C-D). Biochemical analysis of mitochondrial respiratory chain enzyme activities performed on cardiac tissue 
homogenate from proband (blue) and controls (red) (E). Control datasets for fibroblast biochemistry are based on 
n=25 normal samples, normalised and set to 100% with error bars to represent standard deviation. Data contributed 
by Elena Perli, Annalinda Pisano and Langping He. Figure adopted and amended from (Perli et al., 2019).
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3.4.2 Variant identification, confirmation and segregation
Complete mitochondrial genome sequencing was performed. All variants identified 
were previously reported non-pathogenic polymorphisms within the MitoMap database 
(www.mitomap.org), excluding a mtDNA mutation as causative of disease. 
Whole exome sequencing lead to the identification of two novel, heterozygous variants 
in the TSFM gene (NM_001172697.1): One missense mutation c.505C>T, 
p.(Leu169Phe) and one frameshift mutation c.408_409delGT, p.(Leu137Glyfs*24) 
resulting in a shift in the translational reading frame and the generation of a premature 
truncation 24 codons downstream of the deletion. Sanger sequencing confirmed the 
compound heterozygous state of these variants in the proband. The c.505C>T 
mutation was found to be present in a heterozygous state in the proband’s mother. An 
unaffected sibling had two wild-type TSFM alleles. While a paternal DNA sample was 
not available, the genotyping of the proband’s mother and sister is consistent with 
segregation of recessive TSFM variants within the family (Figure 3.9). 
Figure 3.9 Segregation of recessive TSFM variants. Familial pedigree and Sanger sequencing data 
demonstrating recessive inheritance of compound heterozygous variants in the proband and homozygous wildtype 
alleles in her unaffected sibling. Figure adopted and amended from (Perli et al., 2019).
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3.4.3 Missense residue conservation and in silico pathogenicity prediction
The missense c.505C>T mutation identified in this patient has not been reported 
before and is not present within the gnomAD variant browser 
(https://gnomad.broadinstitute.org/), nor has it been previously detected in large-scale 
sequencing studies (http://evs.gs.washington.edu/EVS/). The mutation results in the 
exchange of a highly conserved leucine residue for phenylalanine (Figure 3.10). 
Figure 3.10 Multiple sequence alignment of mtEF-Ts region surrounding missense variant. Mutant and 
Wildtype human mtEF-Ts sequence aligned alongside orthologs from 7 further species to visualise evolutionary 
conservation of each affected residue and surrounding sequence.
The use of five different in silico pathogenicity prediction tools produced varied results 
(Table 3.2). Mutation Taster, Polyphen and CADD predict this missense Leu169Phe 
change to be damaging. The mutation has a CADD score of 26.7, indicating it is 
among the top 1% of the most deleterious substitutions that could occur within the 
human genome (https://cadd.gs.washington.edu/). However Align GVGD and SIFT 














Table 3.2 Assessment of missense TSFM variant using a panel of  in silico pathogenicity prediction tools. 
Output of each in silico pathogenicity prediction tool when assessing missense change c.505C>T, p.(Leu169Phe). 
Deleterious predictions are shaded in red, tolerated predictions are shaded in green. Align GVGD uses Grantham 
scores of evolutionary distance alongside sequence conservation to categorise missense changes into one of six 
classes. Class C0 = class containing variants least likely to interfere with protein function, Combined annotation 
dependent depletion (CADD) scores are calculated using an array of different tools assessing variants and 
simulated mutations. A CADD score of 20 classifies a variant as within the top 1% of most deleterious SNVs in the 
genome. All web-based tools are freely available – see Materials and Methods section 2.1.6.
3.4.4 Steady-state levels of mtEF-Ts, EF-Tu and mtEF-G1
Western blot analysis was performed by collaborators, Elena Perli and Annalinda 
Pisano, on patient cardiac tissue lysate alongside non-failing heart (NFH) and failing 
heart (FH) control lysates to investigate the impact of these compound heterozygous 
TSFM variants on steady-state levels of mtEF-Ts alongside two further elongation 
factors EF-Tu and mtEF-G1. mtEF-Ts was dramatically decreased in patient cardiac 
tissue when compared to both NFH and FH. There was also a marked decrease in 
steady-state EF-Tu protein. Abundance of mtEF-G1 protein, a mitochondrial 
elongation factor with no direct mtEF-Ts or EF-Tu interaction, was unchanged (Figure 
3.11A).
Similarly, mtEF-Ts protein levels in patient fibroblasts were severely decreased. 
However rather than decreased in abundance, the steady-state level of EF-Tu 
appeared to be upregulated, though this upregulation is mild when taking into account 
the overloading of patient sample indicated by GAPDH signal. The steady-state level 
of mtEF-G1 was unaffected, as also seen in cardiac tissue lysate (Figure 3.11B).
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Figure 3.11 Western blot analysis of translation factors in patient cardiac tissue and fibroblasts. Cardiac 
tissue (A) and fibroblast (B) lysates immunoblotted for mtEF-Ts, EF-Tu and mtEF-G1 alongside GAPDH as a 
loading control. NFH = non-failing heart control. FH = failing heart control. C = control. Data contributed by Elena 
Perli and Annalinda Pisano. Figure adopted and amended from (Perli et al., 2019).
3.4.5 Western blot analysis of OXPHOS proteins
Investigation into the stability of OXPHOS subunit proteins was carried out through 
western blot analysis, performed on patient cardiac tissue and fibroblast lysates 
alongside age matched controls. There was no decrease in abundance of OXPHOS 
subunits identified in patient fibroblasts when compared to age-matched controls 
(Figure 3.12A). However, a marked decrease of NDUFB8 (CI) and an almost 




Figure 3.12 Western blot analysis of OXPHOS subunits in patient fibroblasts and cardiac tissue. Patient 
fibroblast whole cell lysate immunoblotted for NDUFB8, SDHA (loading control), CORE2, COXI and ATP5B (A). 
Patient cardiac tissue lysate immunoblotted for NDUFB8, SDHA, CORE2, COXI and ATP5A with PORIN as a 






Western blot analysis of patient fibroblasts demonstrated differential effects at the 
steady-state protein level for each of these patients. While patient 2 shows decreased 
steady-state levels of OXPHOS subunits NDUFB8 (CI), CYTB and CORE2 (CIII), and 
COXI and COXII (CIV), revealing a combined OXPHOS deficiency, steady-state 
NDUFB8, COXI and COXII levels were only very mildly decreased in Patient 1 when 
compared to controls (Figure 3.6A). However, the abundance of COXI and COXII 
protein in the skeletal muscle of Patient 1 was severely decreased, demonstrating a 
much clearer clear complex IV deficiency (Figure 3.6B). These results are in 
accordance with the original diagnostic assessment of individual respiratory chain 
enzyme activities in the skeletal muscle of Patient 1, which detected a complex IV 
activity of approximately 40% of controls (Figure 3.3E). Tissue specific discrepancies, 
such as the difference in severity of OXPHOS defect between the fibroblasts and 
muscle of GFM2 Patient 1, are not uncommon in defects of mitochondrial translation. 
Mutations in mt-aaRS genes often demonstrate much clearer OXPHOS deficiencies 
in high energy tissues than glycolytic fibroblasts, producing tissue-specific 
manifestations in the heart, skeletal muscle and brain (Boczonadi, Jennings and 
Horvath, 2018). 
The abundance of mtEF-G2 protein the skeletal muscle of Patient 1 was approximately 
50% of controls (Figure 3.6B). The c.636delA, p.(Glu213Argfs*3) heterozygous GFM2 
variant identified in Patient 1 results in a frame shift and premature stop codon. It is 
therefore highly likely to encode a non-functional truncated version of mtEF-G2 that 
will be targeted for degradation. The 50% residual mtEF-G2 can be consequently be 
attributed to protein resulting from the allele carrying the c.569G>A, p.(Arg190Gln) 
variant, suggesting that this missense change affecting residue 190 has no significant 
impact on mtEF-G2 stability. 
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Consideration of the levels of sequence conservation at missense residue sites and 
in silico pathogenicity predictions might offer a possible explanation for the distinct 
difference in the severity of the OXPHOS defect in the fibroblasts of patients 1 and 2. 
While both missense variants affect residues with strong evolutionary conservation 
(Figure 3.5), all five of the pathogenicity prediction tools predicted the p.(Tyr92Ser) 
missense variant to have some deleterious effect on protein function or stability, 
whereas only three predicted a p.(Arg190Gln) to be as damaging. These tools are 
predictions only and must be interpreted with caution. However, if the heterozygous 
p.(Arg190Gln) present in Patient 1 is tolerated slightly more than the homozygous 
p.(Tyr92Ser) missense change in Patient 2, it may account for the fibroblasts of Patient 
1 exhibiting a milder OXPHOS defect.
Despite mtEF-G2 playing an important role in the termination and mitribosome 
recycling stage of translation, [35S ] metabolic labelling revealed no marked decrease 
in the incorporation of [35S] methionine/cysteine in growing fibroblasts as a measure 
of de novo mitochondrial protein synthesis. A lack of translation defect might have 
been expected in the fibroblasts of Patient 1, due to there being only a very mild 
OXPHOS defect in these cells. However, finding the fibroblasts of Patient 2 to have 
[35S] signal comparable to controls (Figure 3.7) was unexpected, considering their 
clear combined OXPHOS defect upon western blotting (Figure 3.6A). Mitoribosome 
recycling occurs primarily upon completion of a full protein synthesis cycle, following 
the release of the nascent peptide, to disassemble the post-termination complex 
(PoTC) made up of the LSU, SSU, deacylated tRNA and mRNA transcript (Koripella 
et al., 2019). It is likely that dysfunctional mtEF-G2 would not prevent incorporation of 
amino acids throughout the synthesis of individual peptides, as the translocase mtEF-
G1 functions during elongation but mtEF-G2 does not exert its function until 
termination has occurred (Christian, Haque and Spremulli, 2009). The incubation 
period for the [35S] metabolic labelling used in this translation assay was one hour, 
which may not be long enough for signal resulting from incorporated methionine 
cysteine to be affected by a quality control system. Repeating the experiment with a 
one hour pulse followed by several chases of different lengths might reveal differences 
in the subsequent stability of labelled mtDNA encoded proteins between patient and 
control cell lines. 
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The affected missense residues of both Patient 1 and Patient 2 reside within domain 
1 of the 5 domains belonging to mtEF-G2. This domain is responsible for guanine 
nucleotide binding and is very similar to the GTP binding domains of other translational 
GTPases. Swapping of domain 1 between mtEF-G1 and mtEF-G2 does not affect their 
translocase and recycling activities respectively (Tsuboi et al., 2009). GTP hydrolysis 
is not required by mtEF-G2 for the splitting of the PoTC but is necessary for mtEF-G2 
release from the LSU that has been freed from the PoTC. Therefore, if the missense 
changes reported here primarily affect GTP binding, it is possible that mutant mtEF-
G2 is less efficient only at its own recycling, remaining bound to the LSU for longer 
and decreasing the amount of free mtEF-G2 available to other post-termination 
complexes.
Prior to its identification as a ribosome recycling factor, mtEF-G2 was postulated to 
play a role in quality-control of mitochondrial translation. Overexpression of mtEF-G2 
was demonstrated to suppress a translation and respiratory chain defect phenotype 
in the myoblasts of a 3243A>G MELAS patient (Sasarman, Antonicka and 
Shoubridge, 2008). A mechanism for mtEF-G2-mediated quality-control is yet to be 
investigated. Feedback from mtEF-G2 as an influence on the stability of newly 
synthesised mtDNA encoded OXPHOS proteins, as is suggested by the 
overexpression data in MELAS patient myoblasts, might offer an explanation for the 
discrepancy between the results of the translation assay and the clear OXPHOS 




Cardiomyopathy is a common clinical feature of TSFM related disease, found in 10 
out of the 13 reported patients. However, development of hypertrophic 
cardiomyopathy in the index patient investigated within this report is unique, due to its 
manifestation later in adulthood. All previous TSFM cardiomyopathies presented in 
early infancy (Smits et al., 2011a; Calvo et al., 2012; Vedrenne et al., 2012; Smeitink 
et al., 2006b) or later in childhood (Ahola et al., 2014; Emperador et al., 2017; Scala 
et al., 2019). 
Steady-state levels of mtEF-Ts are severely decreased in both patient fibroblasts and 
cardiac tissue, indicative of the c.505C>T, p.(Leu169Phe) mutant protein being 
unstable and the c.408_409delGT, p.(Leu137Glyfs*24) mutation resulting in nonsense 
mediated mRNA decay. However, while loss of mtEF-Ts in patient cardiac tissue 
appears to result in a destabilisation of EF-Tu, patient fibroblast cells exhibit increased 
steady-state EF-Tu protein in comparison with controls (Figure 3.11). Similarly, a 
combined OXPHOS defect affecting complexes I and IV is observed in patient 
myocardium, but not in fibroblasts (Figure 3.12). These findings are in accordance 
with the tissue specific nature of disease in this patient, with a presentation with 
primarily cardiac involvement alongside very mild and stable form of ataxia. 
It was demonstrated in the first report of TSFM as a nuclear mitochondrial disease 
gene that overexpression of EF-Tu was able to rescue a combined OXPHOS defect 
in patient fibroblasts. This rescue is attributed to the re-stabilisation of the EF-Tu-
mtEF-Ts complex due to increased availability of EF-Tu (Smeitink et al., 2006b). 
Control skin fibroblasts have been shown to be very sensitive to changes in the ratio 
of EF-Tu and mtEF-Ts. The overexpression of either elongation factor, or the 
overexpression of both simultaneously, results in a reduction in rate of mitochondrial 
translation between 20-40% (Antonicka et al., 2006). 
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Adaptive upregulation of EF-Tu expression has been previously reported and 
implicated in tissue specific patterns of OXPHOS and translation defects in patients 
with compound heterozygous mutations in the GFM1 gene. In this case the 
upregulation of EF-Tu in patient heart impacted the ratio of EF-Tu:mtEF-Ts, increasing 
from 1:6 in controls to 1:2 in patient cardiac tissue. The severity of translation defect 
in these patients varied significantly between tissues, with cardiac tissue being the 
least affected. The authors hypothesised that this shift in the EF-Tu:EF-TS ratio could 
slow EF-Tu recycling and bring this stage of elongation in line with the subsequent 
function of mtEF-G1, thus ameliorating the translation defect within cardiac tissue 
(Antonicka et al., 2006).
It is possible that the lack of OXPHOS defect in the fibroblasts of the patient presented 
in this chapter is the result of a compensatory mechanism of EF-Tu overexpression. 
The exact mechanism underpinning this EF-Tu overexpression remains unclear. A 
deeper understanding of any post-trancriptional and post-translational modifications 
of individual mitochondrial translation factors in patient and control cell lines and 
tissues would be extremely valuable in the study of adaptive responses and tissue 
specific patterns found within this group of disorders.
3.6 Concluding remarks
In summary, three patients carrying previously unreported variants in the GFM2 and 
TSFM genes have been identified through the application of WES. The diagnostic and 
experimental data presented in this chapter have confirmed the segregation of these 
rare recessive variants and demonstrated the detrimental impact of mutant mtEF-G2 
and mtEF-Ts on steady-state levels of oxidative phosphorylation, confirming 
pathogenicity in all three patients. The tissue-specific differences identified, both within 
and between patients, illustrates the complexity of the underlying pathomechanisms 
and highlights the gap in our current understanding of tissue specific adaptation and 





Chapter 4 : A homozygous variant in the MRPL47 large subunit 
mitoribosomal gene as a novel cause of mitochondrial disease
4.1 Introduction
Ribosomes are large ribonucleoprotein complexes that are responsible for driving 
protein synthesis within the cytosol of all eukaryotic and prokaryotic cells. All 
ribosomes are comprised of two asymmetrical subunits: The SSU recruits mRNA and 
allows translation of the transcripts by selecting the cognate aminoacyl-tRNA 
molecules. The LSU contains the peptidyl transfer centre (PTC), the catalytic site 
responsible for the formation of peptide bonds between amino acids of growing 
polypeptide chains which then leave the LSU through the polypeptide exit tunnel 
(Greber and Ban, 2016).
4.1.1 Structure and function of the mitoribosome
The existence of active ribosomes within isolated mitochondria was first noted in 1958 
(McLean et al., 1958). Mitochondria possess translation machinery distinct to that of 
the cytosol, as a remnant of their α-proteobacterial ancestry. Mitoribosomes, required 
for the synthesis of proteins encoded by the mitochondrial genome, have undergone 
evolutionary changes in composition, structure and function diverging significantly 
from their bacterial counterparts. The release of increasingly high-resolution cryo-EM 
(cryogenic electron microscopy) structural models in the last two decades has shed 
further light on the specialised features of the mammalian mitoribosome machinery 
(Sharma et al., 2003; Amunts et al., 2015).
One of the most striking evolutionary adaptations of the mitoribosome can be seen in 
the relative amounts of protein and ribosomal RNA. Bacterial ribosomes are 
composed of 70% RNA and 30% protein, whereas this ratio is reversed, at 30% RNA 
and 70% protein, in the mammalian mitoribosome (Greber and Ban, 2016). This shift 
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in composition has been driven by the evolutionary loss of large ribosomal RNA 
domains, the extension of conserved ribosomal proteins and the acquisition of 
mitochondria-specific ribosomal proteins. Many of the more recently evolutionary 
acquired MRPs are located on the periphery of the mitoribosome (Brown et al., 2014) 
(Figure 4.1), which has been postulated to act as a protective barrier shielding the 
core machinery from damaging ROS, while a few mitochondria-specific proteins fill the 
structural spaces left behind by lost ribosomal RNA domains (Pietromonaco, Denslow 
and O'Brien, 1991; Lightowlers, Rozanska and Chrzanowska-Lightowlers, 2014). 
Figure 4.1 Structure and composition of the mammalian mitoribosome. RNA and protein components of the 
55S mammalian mitoribosome (left) and evolutionary conservation of mitoribosomal proteins (right). Figure 
adapted from (Greber et al., 2015) and (Greber and Ban, 2016). 
Bacterial ribosomes are built around three ribosomal RNA molecules, a 16S rRNA 
within the SSU, a 23S rRNA at the core of the LSU and a 5S rRNA within the central 
protuberance of the LSU. In mammalian mitoribosomes a structural tRNA, mt-tRNAPhe 
or mt-tRNAVal, is present within the LSU central protuberance, replacing 5S rRNA 
which is not present within the mammalian mitochondrial genome (Chrzanowska-
Lightowlers, Rorbach and Minczuk, 2017). The functional core of the mammalian 
mitoribosome has remained highly conserved throughout evolution. All tRNA binding 
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A-, P- and E-sites, that occupy the inter-subunit space of the bacterial ribosome, have 
been preserved (Greber and Ban, 2016). 
Biogenesis of mitoribosomes requires the synthesis and assembly of ~80 proteins and 
3 structural RNA molecules in a coordinated fashion. Research into the key factors 
involved in this process is ongoing and our understanding of the mechanisms 
underlying mitoribosome biogenesis remains relatively basic. Studies using stable 
isotope labelling of amino acids in cells (SILAC) followed by sucrose gradient 
fractionation and proteomics demonstrated that a subset of MRPs associate with the 
mtDNA nucleoid, indicating that the initial steps of mitoribosome assembly occur 
proximally to this site (Bogenhagen, Martin and Koller, 2014). An RNA binding 
GTPase, ERAL1, is believed to bind 12S rRNA for its stabilisation prior to insertion 
into the SSU (Uchiumi et al., 2010). Three further GTPases have been demonstrated 
to play roles in mitoribosome assembly. Mtg1 and Mtg2 are membrane bound 
GTPases that interact with the immature LSU (Kotani et al., 2013), while C4orf14 is 
believed to be involved in SSU assembly (He et al., 2012). MPV17L12, a protein found 
within nucleoids that is dependent on mtDNA, is thought to contribute to both the 
assembly and stability of the mitoribosome at the IMM (Dalla Rosa et al., 2014). Two 
RNA helicases, DDX28 and DHX30, and a Fas-activated serine-theronine kinase 
(FASTKD2), each residing within RNA granules, are also thought to be required for 
mitoribosome biogenesis (Antonicka and Shoubridge, 2015). Depletion of a core RNA 
granule protein component, GRSF1, results in the accumulation of SSU sub-
assemblies, indicating it may also be involved in mitoribosome assembly (Antonicka 
et al., 2013) .
Mitochondrial mRNA transcripts lack a 5’ UTR (untranslated region) and therefore do 
not carry Shine-Dalgarno sequences that recruit the ribosome in the initiation stage of 
bacterial translation. The mechanism by which mitoribosomes recognise start-codons 
is therefore unique. Binding of a 5’AUG depends on the presence of a formylated 




The signal recognition particle system that is employed within the cytosol, coupling the 
synthesis of hydrophobic proteins with their membrane insertion, is absent in 
mitochondria (Pool, 2005). To compensate for this, in order to prevent protein 
aggregation and precipitation, mitoribosomes are anchored to the inner mitochondrial 
membrane in close proximity to membrane insertion machinery (Liu and Spremulli, 
2000). This allows nascent peptides to be rapidly inserted into the IMM as they leave 
the polypeptide exit site of the mitoribosome.
4.1.2 Mitoribosomal mutations in human disease
An increasing number of MRPs are implicated in mendelian human pathologies. To 
date, recessive variants in ten SSU genes and four LSU genes have been reported in 
the literature (Table 4.1). These defects typically result in combined respiratory chain 
defects and cause a wide, and often severe, range of clinical presentations. 
Mammalian mitoribosomal protein nomenclature has historically been determined by 
the presence of the MRP within either the large subunit (MRPL) or the small subunit 
(MRPS) of the mitoribosome, followed by an identifying integer. A recently proposed 
naming system attempts to unify the nomenclature of mitoribosomal proteins with 
proteins belonging to cytoplasmic, and prokaryotic ribosomes (Greber and Ban, 2016). 
However, as almost all previously published mitoribosomal disease genes are 
reported under the original naming system, the same nomenclature will be used 
throughout the following text.
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Infantile Alive at 11 years 
FTT, DD, sensorineural deafness, 
hypoglycaemia, redundant skin on 
hands and abdomen, dysmorphic 
features 
↑ lactate, ↑ liver 
enzymes, ↑ serum 




Muscle: ↓CII, ↓CIII, 
↓CIV 








Infantile Alive at 11 years 
DD, sensorineural deafness, 
hypoglycaemia, ID, exercise intolerance 
↑ lactate, ↑ excretion 
of Krebs cycle 
intermediates 
Fibroblasts: ↑CII, ↓CIII, 
↓CIV 
Muscle: ↑CII, ↓CIV 








Infantile Died at 14 years 
 
FTT, sensorineural deafness, 
hepatomegaly and liver failure, 
hypoglycaemia, renal dysfunction, 
encephalopathy 
 
↑ lactate, ↑ fumarate, 
↑ 3- hydroxybutyrate, 
↑ C6-C10 dicarboxylic 
acids 
Fibroblasts: ↓CI, CIV 
Muscle: ↓CI 















Infantile Alive at 17 years 
 
Sensorineural deafness, 
hypoglycaemia, primary hypogonadism, 
primary adrenal failure, mild learning 
difficulties 
 
↑ lactate, ↑TSH, ↑ 
urea, creatine 
Muscle: Normal 









Neonatal Alive at 5 years 
 
HCM (receded by 5 years of age), FTT, 




acidosis’; ↑ lactate, ↑ 
alanine, 










Neonatal Died at 3 days 
Dilation of cerebral ventricles and 
agenesis of corpus collosum on foetal 
ultrasound, FTT, hypotonia, redundant 
skin on neck 
‘Severe metabolic 




Muscle: ↓CI, ↓CII+III, 
↓CIV, ↓CV 
















Antenatal Died before 1 month 
 
Generalised oedema on foetal 
sonogram, subcutaneous oedema at 
birth, muscle hypotonia, HCM, renal 
tubulopathy 
 
↑ lactate, ↑ ammonia 
Fibroblasts: ↓CIV 








Antenatal Died before 1 month 
Generalised oedema on foetal 
sonogram, subcutaneous oedema at 
birth, muscle hypotonia, HCM, renal 
tubulopathy 










Antenatal Died before 1 month ‘affected similarly to siblings 1 and 2’ 
‘affected similarly to 














Antenatal Alive at 5.5 years 
 
FTT, antenatal microcephaly, stable 
HCM, Cornelia de Lange-like 
dysmorphic features, redundant skin on 
neck, muscle hypotonia, 
leukoencephalopathy, transient 




acidosis’; ↑ lactate, ↑ 
urinary TCA-cycle 
intermediates 
Fibroblasts: ↓CI, ↓CIII, 
↓CIV 






Neonatal Died at 3 days 
Agenesis of the corpus callosum and 
periventricular cysts, atrial and 
ventricular septal defects with a 
coronary artery fistula 
 
‘Severe lactic 
acidosis’; ↑ lactate, ↑ 
ammonia, ↑ lactaturea 









Neonatal Alive at 4 years 
DD, hypotonia, mild dysmorphic 
features, Leigh-like brain lesions, 
mosaic Down syndrome, oxygen 
dependence, tetraspasticity, 
nasogastric tube feeding 
 
↑ lactate, ↑ pyruvate, 
↑ urine organic acids 
N/A 













Adolescence Alive at reporting 
Delayed puberty, primary ovarian 
insufficiency with hypergonadotrophic 
hypergonadism, small uterus, delayed 
bone age 
 










Childhood Alive at reporting 
Primary ovarian insufficiency, elevated 
gonadotrophins,  fibrotic ovaries without 
follicles 
 










Adolescence Alive at reporting 
Delayed puberty, primary ovarian 


















Adolescence Alive at reporting 
 
Amenhorroea, mild facial dysmorphism, 
delayed bone age, delayed puberty, 
primary ovarian insufficiency with 
hypergonadotrophic hypergonadism, 
small uterus, mild osteoporosis, 
bilateral axonal polyneuropathy 
 
↑ gonadotropins, ↓ 
oestrogens, ↑ lactate, 






























Antenatal Alive at reporting 
 
Intrauterine growth-restriction, DD, 
choreoathetoid distal limb movements, 
muscle weakness and dystonia, 
dysphagia, partial agenesis of corpus 
collosum and underdevelopment of 
frontal and parietal temporal regions on 



















Antenatal Alive at 30 years 
 
Intrauterine growth retardation, FTT, 
DD, microcephaly, dysphagia, facial 
dysmorphism,  sensorineural deafness, 
hepatomegaly, hypoglycaemia, bilateral 
lesions in globus pallidus and cerebellar 
atrophy on MRI 
 
↑ lactate, ↑ alanine, ↑ 
liver enzymes, ↑ 






















Infantile Died at 9 months DD, microcephaly, episodic tachypnoea ↑ lactate, ↑ alanine 
Fibroblasts: ↓CI, ↓CIV 
Muscle: ↓CI, ↓CIII, ↓CIV 
Liver: ↓CI, ↓CIV 







Infantile Alive at 17 years 
 
Hypotonia, DD,  non-verbal, 
microcephaly, horseshoe kidney, 
mild coarsening of facial features, 
extropia and ptosis, kyphoscoliosis, 
bilateral choreoathetoid movements, 
atrophy of extremities with hypertonia, 
contractures at most joints 
 
 














Infantile Alive at 14 years 
DD, choreoathetoid spastic 
quadriplegia, abnormal MRI, non- 
verbal, microcephaly, mild coarsening 
of facial features, strabismus, scoliosis, 
dystonia, mild contractures at most 
joints 
 







Infantile Alive at 7 years 
 
Transient nystagmus, intermittent ptosis 
and alternating extropia, involuntary 
movements, developmental regression, 
axial hypotonia, limb hypertonia, 
contractures at the knees and ankles, 
non-verbal, suspected sleep apnoea, 
dysmorphic facies, premature puberty 
 
↑ lactate, ↓ ammonia 









Infantile Alive at 2 years 
DD, dysconjugate eye movements, 
dysphagia, suspected sleep apnoea 
 
 
















Neonatal Died at 8 months 
Developmental regression, axial 
hypotonia, pyramidal syndrome of the 
lower limbs, and dystonia, 




















Died at 1 year and 4 
months 
 
Intrauterine growth defect, limb rigidity, 
myoclonus, nystagmus, psychomotor 
regression, bilateral optic atrophy, 
bilateral hearing loss, bilateral lesions 
involving ventral side of the medulla, 
cerebral peduncle thalamus, caudate 
nucleus, and putamen of the basal 
ganglia on MRI 
 
N/A 






















Infantile Died at 17 months 
 
FTT, dyspnoea, hypotrophy, 
hepatomegaly, HCM 
 
↑ lactate, ↑ liver 
enzymes 
Fibroblasts: ↓CIV 













Infantile Died at 15 months 
FTT, HCM, similar disease course to 
sibling 


















Infantile Alive at 3 years 
 
Hepatomegaly, liver dysfunction, HCM 




↑ lactate, ↑ alanine, ↑ 
liver enzymes 












Infantile Alive at 3 years 
Hepatomegaly, liver dysfunction, HCM 
(stable), FTT, hypergyria of the cortical 
brain on MRI 
 
↑ lactate, ↑ alanine, ↑ 
liver enzymes 

















Died at 2 years 
 
Severe general hypotrophy, FTT, 
muscle weakness, psychomotor delay, 
trunk hypotonia, mild hepatomegaly, 
intermittent nystagmus, cerebellar 
ataxia and tremor, mild dysmorphic 
facial features, tonic seizure, lesions in 
white matter and basal ganglia on MRI 
↑ lactate, ↓ plasma 
IGF1 
Fibroblasts: ↓CI, ↓CIV 
Muscle: ↓CII+III, ↓CIV 
Liver: ↓CII+III, ↓CIV 
Serre, et al. 
(2013) 
 
2ST  Antenatal Pregnancy terminated   




3ST  Antenatal Pregnancy terminated   









Infantile Alive at 14 years 
 
Developmental regression, spasticity 
and dystonic posturing of distal upper 
and lower limbs, dyskinetic facial 
grimacing, ID, choreoathetosis of limbs 





Muscle: ↓CI, ↓CIII, 
↓CIV, ↓CIV 















Infantile Died at 6 months 
 
HCM, mild steatosis in all 











Infantile Alive at 14 years 
 
HCM (stable and asymptomatic after 2 
years), steatosis of liver, mild granular 
pigmentation in the retina 
 












Infantile Alive at 8 years 
 
Feeding difficulties in infancy, exercise 
intolerance, non-obstructive HCM, mild 
hepatopathy, muscle weakness 
 
↑ lactate, ↓ free 

















Neonatal Alive at 26 years 
Exercise intolerance, learning 
difficulties, hemiplegic migraine, 
tapetoretinal dystrophy, non-obstructive 
HCM, Leigh-like lesions in the 
thalamus, basal ganglia, and 
cerebellum on MRI 
‘Metabolic acidosis’ Heart: ↓CI, ↓CIV 
 
Table 4.1 Mitoribosomal pathologies: Variants reported to date with associated clinical and biochemical presentations. FTT = failure to thrive; DD = developmental 
delay; HCM = hypertrophic cardiomyopathy; ID = intellectual disability; S indicates siblings, numbered for distinction where multiple sibships presented within single report; C 
indicates cousins; T indicates twins; ↓ and ↑ used to denote decreases and increases in biochemical markers and OXPHOS enzyme activities or steady-state levels; OXPHOS 
defect listed where demonstrated biochemically or at the steady-state level.
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While the clinical spectrum of these pathologies is broad, there are some clear 
overlapping features common to a number of different mitoribosomal disorders. 
Severe lactic acidosis, a common finding in mitochondrial disease, is also a frequently 
reported clinical feature in mitoribosomal defects. Of the 38 patients currently reported 
in the literature, 30 individuals suffered from elevated levels of lactate (Table 4.1), 
while acidosis in a number of cases was fatal (Miller et al., 2004; Baertling et al., 2015). 
A hypertrophic cardiomyopathy phenotype is reported in cases of MRPS14, MRPS22, 
MRPL3 and MRPL44 disease, affecting a total of 13 patients (Jackson et al., 2019; 
Smits et al., 2011b; Saada et al., 2007; Galmiche et al., 2011; Carroll et al., 2013; 
Distelmaier et al., 2015), while nine MRP patients, harbouring mutations in MRPS22, 
MRPS34, MRPS39 or MRPL44 presented with Leigh syndrome or a Leigh-like 
phenotype (Kilic et al., 2017; Lake et al., 2017; Borna et al., 2019). One of the most 
striking similarities in this group of pathologies is an extremely early age of disease 
onset; clinical presentation occurred at the antenatal/neonatal stage or in early infancy 
in almost all MRP patients, a distinguishing feature from many other forms of 
mitochondrial disease. Four patients, with missense mutations in the MRPS22 gene 
are the only exception to this pattern of early-onset disease, presenting with a distinct 
phenotype of primary ovarian insufficiency presenting only in later 
childhood/adolescence (Chen et al., 2018).
4.1.3 Defects of the LSU
The earliest report of a LSU gene implicated in mitochondrial disease describes the 
use of a combination of SNP genotyping and WES to identify compound heterozygous 
variants, c.950C>G (p.Pro317Arg) and 225-kb deletion in the MRPL3 gene in four 
siblings. The clinical presentation of these patients included hypertrophic 
cardiomyopathy, hepatomegaly and psychomotor retardation. The identified 
mutations caused a severe decrease in steady-state MRPL3 levels, resulting in the 
defective assembly of the LSU. Patient fibroblasts and muscle exhibited combined 




Hypertrophic cardiomyopathy was also reported in all four previously reported cases 
of MRPL44 disease. A homozygous c.467T>G (p.Leu156Arg) missense mutation in 
the MRPL44 gene was first identified in a sibling pair. While the older sibling died at 
the age of six months, the hypertrophic cardiomyopathy phenotype in the second 
sibling became stable and asymptomatic at two years of age. The Leu156Arg change 
resulted in decreased levels of MRPL44 protein, demonstrated in patient fibroblasts. 
A combined OXPHOS deficiency was present in patient cardiac and skeletal muscle 
(Carroll et al., 2013). Two further patients with missense mutations in the MRPL44 
gene are reported, presenting with a slowly-progressing multisystem disease with 
cardiac, kidney and neurological involvement (Distelmaier et al., 2015).
The third LSU gene to be implicated in mitochondrial disease was MRPL12. A 
homozygous c.542C>T (p.Ala181Val) variant was identified in a patient presenting at 
birth with severe general hypertrophy and growth defect followed by fatal neurological 
and cardiac distress  (Serre et al., 2013). A combined respiratory chain defect was 
observed in patient fibroblasts, heart and liver. Steady-state levels of MRPL12 and a 
number of other LSU proteins were significantly decreased, resulting in a defect of 
global mitochondrial translation in patient fibroblasts.
Most recently, MRPL24 was characterised as the fourth LSU gene harbouring 
mitochondrial disease variants. A homozygous c.272T>C (p.Leu91Pro) mutation was 
identified in a patient presenting in infancy with a complex movement disorder, 
intellectual disability and developmental regression. Patient fibroblasts and muscle 
homogenate demonstrated a dramatic decrease in MRPL24 protein. A defect affecting 
subunits of OXPHOS complexes I, IV and V was observed in patient muscle. Steady-
state levels of several other LSU proteins were also reduced, while sucrose gradient 
fractionation of mitoribosome in patient fibroblasts revealed significant destabilisation 
of the LSU (Di Nottia et al., 2020).
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4.1.4 Assigning pathogenicity to a variant in a novel LSU gene
Of the ten previously reported SSU genes with reported pathogenic variants, five are 
core evolutionary conserved subunits with bacterial ribosome homologs (MRPS2, 
MRPS7, MRPS14, MRPS16 and MRPS28), while the remaining five genes encode 
mitochondria-specific mitoribosomal proteins (MRPS22, MRPS23, MRPS25, 
MRPS34 and MRPS39). With 52 protein subunits, the mammalian LSU contains 22 
more individual proteins than the mammalian SSU. However, with only four LSU genes 
published in association with mitochondrial disease to date, defects of LSU MRPs 
remain extremely rare. Three of these genes, MRPL3, MRPL12 and MRPL24, are 
conserved from bacterial counterparts, while MRPL44 is unique to the mitoribosome.
The mammalian MRPL47 gene, encoding a protein of the same name, is homologous 
to the bacterial rpmC gene, encoding RPL29. MRPL47 is a constitutive subunit of the 
ring of proteins that surround the polypeptide exit site of the mitoribosomal LSU 
(Greber et al., 2014). This ring of proteins surrounding the exit tunnel are highly 
conserved from the bacterial ribosome, however the sequence of MRPL47 has 
undergone significant divergence from bacterial RPL29 such that it is almost past 
homology detection limits (Smits et al., 2007).
This chapter will outline work undertaken to characterise the molecular mechanisms 
underlying disease in three unrelated paediatric patients with a novel homozygous 






Patient 1, a 4 year-old female, is the first child of healthy consanguineous parents of 
Arab ethnicity from Saudi Arabia. The patient was delivered at term, but required 
admission to the neonatal intensive care unit for 10 days due to hypoglycaemia, 
hyperammonaemia and metabolic acidosis. She presented later at the age of 2 years 
5 months with hypoglycaemic seizure, occurring while sleeping, with very low blood 
sugar preceded by mild febrile illness and poor feeding. Neurological examinations 
have been normal. Laboratory investigations showed low blood sugar on presentation, 
metabolic acidosis, high ammonia with high ketones and lactate. Her weight and 
height are normal for her age and there are no motor or language developmental 
delays. Lactate continues to be persistently high at 3-6 mmol/L (normal <2.5 mmol/L). 
This patient was referred by Dr.Malak Ali Alghamdi, College of Medicine and University 
Hospitals, King Saud University.
4.2.2 Patient 2
Patient 2, a 3 year-old female, is the first child of healthy consanguineous parents of 
Arab ethnicity from Saudi Arabia. Patient 2 was healthy at birth, with weight, height 
and head circumference measurements within normal ranges. At two days of age the 
patient was admitted to NICU with hypoglycaemia and metabolic acidosis related to 
febrile illness and poor oral intake. At 17 months she presented with persistent 
vomiting preceded by URTI complicated by moderate to severe dehydration and 
associated with lactic acidosis and metabolic acidosis. Recurrent attacks of 
hypoglycaemia, keto-acidosis with failure to thrive prompted a genetic and metabolic 
work up at the age of 17 months. Neurological examinations have been normal. Liver 
enzymes were modestly elevated and liver ultrasound revealed increased echotexture 
consistent with hepatic steatosis. At last examination, height and head circumference 
measurements had fallen to below the 3rd centile. This patient was referred by 
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Dr.Malak Ali Alghamdi, College of Medicine and University Hospitals, King Saud 
University.
4.2.3 Patient 3
Patient 3, a 17 year-old female, is the second child of healthy non-consanguineous 
parents originating from Germany. Born at full term, this patient was healthy at birth 
but the neonatal period was complicated by hypoglycaemia (1.11 mmol/L, normal 
range 4.0-6.0 mmol/L). In the context of febrile illness a diagnosis of hypothyroidism 
was made, but a L-thyroxine supplementation could be stopped in the follow-up 
appointments. Developmental delay was reported in infancy, with delayed speech and 
walking. The patient has moderate intellectual disability. Febrile seizures began at 
three and a half years of age and increased in frequency over time. Despite continued 
treatment with anti-epileptics, she experiences one (self-limiting after 2-3 minutes) 
seizure per week. At the age of 15 the patient developed acute liver failure 
(encephalopathy, vomiting, abdominal pain) which resolved after treatment. This 
patient was referred by Dr. Saskia Wortmann, Department of Human Genetics, 





Diagnostic WES, carried out at Centogene (https://www.centogene.com), identified a 
segregating homozygous nonsense variant in both Patient 1 and 2. The mutation, 
c.646C>T, is located within the nuclear gene MRPL47 (NCBI Reference Sequence: 
NM_020409.2) and produces a premature stop codon resulting in early truncation at 
the protein level (p.Arg216*). This truncation occurs at amino acid 216 of 250 in exon 
7, the final exon, of MRPL47.
WES of Patient 3, carried out in the lab of Professor Holger Prokisch at the Institute of 
Human Genetics, Helmholtz Centre Munich, identified the same c.(646C>T) truncating 
variant. Trio Sanger sequencing confirmed segregation of this variant (Figure 4.2). 
This variant is present in the gnomAD browser at an allele frequency of 0.00001205 
(3 heterozygous alleles out of 248942), but is not found in a homozygous state.
Skin biopsies for all three patients were obtained and shipped to Newcastle for culture 
and functional investigation. However, the fibroblasts of Patient 1 did not recover upon 
arrival. For this reason, the following data has been acquired using the cells of patients 
2 and 3 only. 
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Figure 4.2 Familial pedigrees of MRPL47 Patients. Familial pedigrees to demonstrate recessive inheritance of 
the same homozygous c.646C>T, p(Arg218*) truncating variant in each Patient.
4.3.2 Western blot analysis of MRPL47 and OXPHOS proteins
To investigate the impact of c.(646C>T) introducing a premature truncation at position 
216 of MRPL47, western blot analysis using a commercially available antibody was 
carried out. This revealed undetectable levels of full-length MRPL47 protein in the 
fibroblasts of patients 2 and 3 (Figure 4.3). 
Figure 4.3 Western blot analysis of MRPL47 patient fibroblasts. Whole cell lysates from fibroblasts of Patient 
2 and Patient 3 were probed with antibodies against MRPL47 and VDAC1 (loading control) on the left panel. 
Antibodies targeting NDUFB8, SDHB (loading) CORE2, COXII and ATP5A were applied (right panel). Data shown 
is representative of three independent repeats.
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Investigation into steady-state levels of individual OXPHOS subunits demonstrated 
moderately decreased NDUFB8 and COXII, indicating a combined OXPHOS defect 
affecting complexes I and IV (Figure 4.3). 
4.3.3 [35S] translation assay in growing fibroblasts 
A translation assay using [35S] labelled methionine/cysteine was carried out in order 
to assess the consequence of a loss of full-length MRPL47 from the tunnel exit region 
of the mitoribosome in relation to de novo protein synthesis in growing patient 
fibroblasts. This metabolic labelling assay was carried out over a 1 hour incubation 
period, in the presence of 100 μg/mL emetine for cytosolic translation inhibition. 
Through the measurement of signal resulting from incorporation of [35S] labelled 
methionine/cysteine into newly synthesised mitochondrial proteins in the fibroblasts of 
patients 2 and 3, alongside controls, a generalised defect of mitochondrial translation 
was detected (Figure 4.4). This defect appears to affect all detectable proteins 




Figure 4.4 [35S] methionine/cysteine incorporation in growing MRPL47 patient fibroblasts as a measure of 
de novo mitochondrial protein synthesis. Signal detected from fixed and dehydrated SDS-PAGE gel using 
Typhoon Phosphorimager. Bands are visible for radiolabelled COXI, ND4, cyt b. ND2, ND1, COXIII, COXII and 
ATP6. Even loading is demonstrated through a Coomassie stain on the bottom panel.
4.3.4 siRNA knock-down of MRPL47 in patient and control cell lines
Investigation into the specificity of a previous commercial MRPL47 antibody through 
siRNA knockdown of MRPL47 resulted in an incidental finding in the fibroblasts of 
Patient 2. Treatment of MRPL47 siRNA in the patient cells led to the exacerbation of 
the combined OXPHOS defect affecting complexes I and IV. Steady-state levels of 
NDUFB8 and COXI were greatly decreased when Patient 2 fibroblasts were treated 
with MRPL47 siRNA (Figure 4.5), in comparison with non-targeting siRNA treatment, 
indicating a much more severe defect upon MRPL47 knockdown. This finding 
suggests there to be some residual and functional MRPL47 protein in patient 
fibroblasts, despite full-length protein being undetectable (Figure 4.3). Sample taken 
from the patient fibroblasts treated with non-targeting siRNA were overloaded in 




Figure 4.5 siRNA knockdown of MRPL47 in patient fibroblasts, control fibroblasts and U2OS cells. Patient 
2 fibroblasts, control fibroblasts and a U2OS cell line were transfected with either MRPL47 siRNA (siL47) or non-
targeting siRNA (siNT) with a second transfection on day three and harvested on day six. SDS-PAGE of whole cell 
lysis was followed by immunoblotting with antibodies againt NDUFB8, SDHA (loading control) and COXI. Data 
shown is representative of two independent repeats.
4.3.5 Western blot analysis of 25kDa MRPL47 species
In order to identify a truncated protein species that might be mediating the response 
to MRPL47 siRNA knockdown identified in 4.3.4, further siRNA studies were carried 
out using the fibroblasts of patients 2 and 3 alongside controls. In no-treatment, and 
non-targeting siRNA treatment conditions, the use of MRPL47 antibody and 
subsequent over-exposure of blot on detection revealed an approximately 25 kDa 
species. This band disappears in cell lysates harvested from MRPL47 siRNA 
treatments (Figure 4.6). 
Figure 4.6 Over-exposure of blot with siRNA knockdown of MRPL47 in patient and control fibroblasts. 
Whole cell lysates of patient and control fibroblasts were harvested following a six-day treatment with MRPL47 or 
non-targeting siRNA, with no siRNA cells as a second control, were subject to SDS-PAGE and immunblotted for 
MRPL47 only. A second species corresponding to a 25 kDa MRPL47 protein is present in the lysates taken from 
patient fibroblasts in the non-targeting and no siRNA conditions only.
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Using the commercial antibody, full-length MRPL47 appears on a western blot at 
approximately 28 kDa. The expected decrease in size resulting from a loss of the final 
35 residues of MRPL47 has been estimated using the Science Gateway Protein 
Molecular Weight Calculator tool
(https://www.sciencegateway.org/tools/proteinmw.htm). Uniprot fasta sequence 
UniProtKB - Q9HD33 (RM47_HUMAN) was used to calculate the size of full-length 
and truncated protein. This tool predicted MRPL47 protein corresponding to the full 
250 residue sequence to weigh 29.46 kDa and protein generated from a shorter 216 
residue sequence to weigh 25.53 kDa (Figure 4.7). Using these predictions, the 
overall decrease in size resulting from a premature truncation at residue 216 would be 
3.93 kDa. The 25 kDA species identified upon over-exposure of blots incubated with 
MRPL47 antibody is consistent with this estimated size difference (Figure 4.6). This, 
combined with the decrease in intensity of the bands upon treatment with siRNA 
targeting MRPL47 is highly indicative of the truncated version of MRPL47 retaining 
some stability. 
Figure 4.7 Molecular weight predictions of full-length and mutant MRPL47.Science gateway protein molecular 
weight calculator predictions for sequences corresponding to the 250 residue wild-type MRPL47 protein and a 216 
residue truncated MRPL47 protein. Fasta sequence was obtained from the Uniprot website 
(https://www.uniprot.org/) and corresponds to UniProtKB - Q9HD33 (RM47_HUMAN).
 
157 
4.3.6 Investigation of MRPL47 assembly within the LSU 
Following the identification of the truncated MRPL47 protein stable at low steady-state 
levels, it was important to ascertain whether this protein retains any function and 
whether it is incorporated into the LSU of the mitoribosome. Sucrose gradient 
ultracentrifugation fractionation of samples containing 700 μg of total protein, followed 
by TCA precipitation of each fraction, was used to address this question. SDS-PAGE 
of fractions 1-11 and immunoblotting of mitoribosomal subunits determines the 
sedimentation profiles of the LSU and SSU. DAP3 and MRPL65 antibodies were used 
to attribute the SSU to fractions 4-5 and LSU to fractions 6-7. Bands corresponding to 
MRPL47 could be detected in LSU fraction 6 and 7 with low signal strength in 
comparison to the control (Figure 4.8). This weak signal for MRPL47 was detected at 
a slightly lower molecular weight in Patient samples when measured using the protein 
ladder and compared to controls. This confirms that, while severely decreased at the 




Figure 4.8 Sucrose gradient ultracentrifugation and immunoblotting to investigate MRPL47 in 
mitoribosome assembly. 700 μg of total protein from the fibroblasts of patients 2 and 3 was separated on a linear 
10-30% sucrose gradient. Following ultracentrifugation, eleven fractions were taken and TCA precipitated for 
protein enrichment, then run on SDS-PAGE gels and immunoblotted for MRPL47, MRPL65 and DAP3. Fractions 
4 and 5 (red) contain proteins of the SSU. Fractions 6 and 7 (blue) contain proteins of the LSU. Data shown is 
representative of two independent repeats.
4.3.7 Investigation into LSU and monosome stability 
Further sucrose gradient ultracentrifugation experiments were carried out in order to 
assess the impact of severely decreased and truncated MRPL47 protein on the 
stability of the mitoribosomal LSU and monosome. Centrifugation over a longer period 
of time, followed by the sampling of seventeen fractions allows visualisation of signal 
corresponding to the monosome alongside the LSU and SSU. The fibroblasts of 
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Patient 2 consistently exhibit decreased levels of large subunit proteins MRPL3, 
MRPL37, MRPL12 and MRPL28, within both the LSU and the monosome (Figure 
4.9). Immunoblotting for SSU protein MRPS15 reveals no equivalent decrease in the 
SSU but a comparable decrease in signal in monosomal fractions. These data suggest 
destabilisation of the LSU and the monosome as a result of the Arg216* MRPL47 mutant 
protein. 
Figure 4.9 Sucrose gradient ultracentrifugation and immunoblotting to investigate LSU and monosome 
stability. 900 μg of total protein from the fibroblasts of Patient 2 and a control line were separated on a linear 10-
30% sucrose gradient. Following centrifugation at 79,000 g for 15 hours at 4°C, 17 fractions were taken and 




The identification of a homozygous c.646C>T (p.Arg216*) variant in three unrelated 
patients adds to a rare, but growing, number of pathogenic mutations in mitoribosomal 
proteins. Of the pathogenic variants reported to date in genes encoding mitoribosomal 
proteins, 14 have been demonstrated to result in a moderate to severe destabilisation 
and decrease in steady-state levels of the mutant protein (Gardeitchik et al., 2018; 
Menezes et al., 2015; Miller et al., 2004; Chen et al., 2018; Smits et al., 2011b; 
Bugiardini et al., 2019; Pulman et al., 2019; Lake et al., 2017; Borna et al., 2019; 
Galmiche et al., 2011; Serre et al., 2013; Di Nottia et al., 2020; Carroll et al., 2013). In 
the majority of cases this leads to a destabilisation of the mitoribosomal subunit of 
which the affected protein is a constituent, and in one MRPL12 case assembly and 
stability of both the LSU and SSU is affected (Serre et al., 2013). Interestingly, while 
variants in all four previously reported LSU genes implicated in mitochondrial disease 
have resulted in decreased steady-state levels of the affected protein, three of these 
mutant proteins have been shown to continue be incorporated as a structural 
component of the mitoribosome (Serre et al., 2013; Di Nottia et al., 2020; Carroll et al., 
2013). 
While a premature ‘stop’ codon at MRPL47 residue 216 of 250 results in a complete loss 
of full length protein (Figure 4.3), a ~25 kDa truncated version of MRPL47 remains 
stable at very low steady state levels (Figure 4.6) and is able to assemble as a 
structural component of the LSU (Figure 4.7). Despite this, the fibroblasts of patients 
2 and 3 exhibit a clear and global defect of mitochondrial translation when subjected 
to a [35S] metabolic labelling assay (Figure 4.4). This appears be the result of 
destabilisation of the LSU and mitoribosomal monosome (Figure 4.9), and results in 
a combined OXPHOS defect affecting subunits of complexes I and IV at the steady-
state level (Figure 4.3).
While these data clearly demonstrate the pathogenicity of this novel variant, further 
work will help to elucidate the precise mechanism underlying the mitochondrial 
translation defect. At present, it is unclear whether mitoribosomal function is impeded 
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by a structural impact on the tunnel exit region of the LSU resulting from the 
incorporation of a truncated version of MRPL47, by decreased availability of mutant 
MRPL47, or through a combination of both.
To answer this question, I plan to carry out two parallel rescue experiments, over-
expressing either wild-type MRPL47 or p.Arg216* mutant MRPL47, in patient 
fibroblasts. If the translation defect observed in patient fibroblasts can be rescued by 
over-expression of mutant MRPL47, this would indicate that the pathomechanism is 
driven primarily by low steady-state levels of MRPL47. If rescue can only be achieved 
through the expression of wild-type MRPL47, it is most likely that a structural 
consequence of mutant MRPL47 on the LSU is underpinning this generalised 
translation defect. It remains possible that both decreased steady-state levels and 
aberrant folding of MRPL47 within the LSU are contributing to this disorder in 
translation, in which case one might expect to see a degree of improvement in 
translation efficiency and restoration of OXPHOS in both rescue experiments. 
4.5 Concluding remarks
In conclusion, a novel truncating variant in the MRPL47 gene has been identified in 
three unrelated paediatric mitochondrial disease patients presenting in early infancy 
with overlapping clinical presentations including metabolic acidosis, epilepsy and liver 
involvement. The data presented within this chapter has demonstrated the impact of 
this variant on MRPL47 size and stability, confirmed a detrimental impact on the 
assembly of the LSU and monosome, and revealed a global translation defect that 
results in a combined OXPHOS defect in patient fibroblasts. These data have 
assigned pathogenicity to this variant, confirming genetic diagnosis in three families 
and expanding our current understanding of LSU disorders. Future rescue 
experiments should be carried out to investigate any impact that truncated MRPL47 





Chapter 5 : Investigation of novel variants in MRPL65 encoding a 
large mitoribosomal subunit 
5.1 Introduction
The functional validation of novel and extremely rare disease variants is, for the most 
part, reliant on the study of patient biopsies and samples. When investigating novel 
variants to assign pathogenicity it is important to understand the underlying disease 
pathomechanisms within cells and tissues that are of relevance to the affected patient. 
However, the acquisition of patient samples for functional testing is not always 
possible. In such cases, it is important to consider cell line models, or whole-organism 
options, for the modelling of specific variants in order to obtain evidence of their 
pathogenicity (Thompson et al., 2019). 
5.1.1 CRISPR/Cas9: A genome editing tool
One emerging technique, now extensively used for the generation of cell-line and 
animal models of disease-causing mutations, is CRISPR/Cas9 genome editing. The 
CRISPR/Cas system is a naturally occurring adaptive immune response mechanism 
employed by eubacteria and archaea for the destruction of foreign viral or plasmid 
DNA or RNA (Horvath and Barrangou, 2010) that has subsequently been modified 
and optimised for use as a gene-editing tool. CRISPR, standing for Clustered 
Regularly Interspaced Short Palindromic Repeats, was first identified in 1987 within 
the genome of Escherichia coli as 29 nucleotide repeat fragments of genomic DNA 
interspaced by 32 nucleotide variable sequence fragments (Ishino et al., 1987). Many 
of the variable fragments within CRISPR regions were later found to correspond to 
viral genomic regions (Pourcel, Salvignol and Vergnaud, 2005). 
CRISPR associated (Cas) genes, identified due to their proximity to the CRISPR locus 
(Jansen et al., 2002), encode nucleases with the ability to introduce double strand 
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breaks (DSBs) in specific and targeted regions of DNA (Garneau et al., 2010). Also 
adjacent to the CRISPR array is trans activating CRISPR RNA (tracrRNA), that is 
complimentary to the primary CRISPR array transcript and aids in transcript 
processing into individual CRISPR RNA (crRNA) molecules carrying ~20 nucleotide 
sequences complimentary to the target foreign DNA (Deltcheva et al., 2011). The 
crRNA-tracrRNA complex interacts with the Cas encoded protein to form an active 
RNA guided nuclease (Karvelis et al., 2013). This ribonuclease complex interacts with 
a ~2-4 nucleotide protospacer adjacent motif (PAM), lying immediately adjacent to 
target DNA sequences, where the sequence-specific cleavage is carried out and DSBs 
are introduced (Mojica et al., 2009). Three different classes of CRISPR/Cas systems 
exist endogenously, grouped into types I, II and III, based on similarities in the 
sequences and structures of the constituent Cas proteins (Makarova et al., 2011). The 
type II CRISPR/Cas system is reliant on a single Cas protein (Cas9) (Figure 5.1A), 
and has therefore been the most simple to develop into a sophisticated tool for genome 
editing (Ma, Zhang and Huang, 2014). Cas9 from Streptococcus pyogenes possesses 
two nuclease domains: The HNH domain, for cleavage of the DNA strand 
complimentary to the crRNA, and the RuvC-like domain for cleavage of the non-
complimentary strand (Nishimasu et al., 2014).
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Figure 5.1 Structure and function of the type II CRISPR/Cas9 system. (A) The genomic organisation, 
transcription processing and assembly of CRISPR/Cas9 elements in an endogenous environment. (B) An 
engineered CRISPR/Cas9 system used for targeted genome editing directed by a sgRNA. Figure adopted from 
Lino, Christopher A et al. (2018).
The utilisation of CRISPR/Cas9 as a genome editing tool has been achieved through 
the design of short guide RNAs (sgRNAs) that encompass both the tracrRNA and 
crRNA elements of the endogenous CRISPR/Cas system (Figure 5.1B) (Jinek et al., 
2012). These guide RNA are typically complimentary to genomic DNA 18-24 
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nucleotides in length, lying adjacent to a 2-4 nucleotide PAM sequence (Zhang, Wen 
and Guo, 2014). Introduction of a DSB at a precise and targeted region of the nuclear 
genome triggers a cellular DNA repair by non-homologous end joining (NHEJ) 
response. NHEJ is an error-prone process and can therefore result in the introductions 
of insertions and deletions (indels) at the site of DSB repair which have the potential 
to disrupt or eliminate gene function to generate target gene knock-outs (Iliakis et al., 
2004). 
Delivery of a CRISPR/Cas9 system into model systems can be achieved via three 
main routes: A delivery plasmid encoding both the Cas9 nuclease and a guide RNA, 
a mixture of separate mRNAs encoding the Cas9 nuclease and a guide RNA or a 
delivery of a Cas9 protein and guide RNA formed as a ribonuclease complex (Lino et 
al., 2018). The applications of CRISPR/Cas9 technology, both as a basic science 
research tool and as a therapeutic approach, are continuously expanding (Rodriguez-
Rodriguez et al., 2019).
5.1.2 CRISPR/Cas9 studies in mitochondrial research
In the field of mitochondrial research, genome-wide CRISPR/Cas9 death screens and 
CRISPR interference (CRISPRi) screens have been utilised for the identification and 
annotation of genes encoding proteins previously unknown to be essential to 
OXPHOS and energy metabolism (Arroyo et al., 2016; Mendelsohn et al., 2018). 
Knock-out models of nuclear genes associated with mitochondrial disease are shown 
to be extremely useful in instances when samples of clinically affected tissues are 
scarce. Induced pluripotent stem cell (iPSC) lines have been used in the generation 
of DGOUK CRISPR/Cas9 knockout cells. The DGOUK gene encodes a mitochondrial 
kinase required for the phosphorylation of purine deoxyribonucleosides. Patients with 
DGOUK deficiencies suffer from mitochondrial depletion, often manifesting as 
progressive liver disease. Differentiation of DGOUK CRISPR/Cas9 knockout iPSCs 
into hepatocyte-like cells has enabled the study of mitochondrial dysfunction and the 
application of drug screens within a clinically relevant cell type (Jing et al., 2018).
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5.1.3 MRPL65: A mitoribosomal LSU gene 
As discussed in 4.1.3, pathogenic variants in genes encoding proteins of the 
mitoribosomal LSU remain extremely rare, with only four LSU genes implicated in 
mitochondrial disease to date (Galmiche et al., 2011; Carroll et al., 2013; Serre et al., 
2013; Di Nottia et al., 2020). Detailed within this chapter are investigations into the 
molecular mechanism underpinning disease in two unrelated paediatric mitochondrial 
disease patients harbouring novel variants in the MRPL65 gene which were deemed 
to be the likely cause of the patients’ clinical presentation. A lack of available patient 
biopsy material has driven a need to generate an MRPL65 knockout cell line and this 
work will focus on the use of a CRISPR/Cas9 genome editing system to achieve that 
goal. Having previously been believed to be a constituent of the SSU named MRPS30, 
the name of this gene was recently changed to MRPL65. Cryo-EM studies of 
mitoribosomal structure revealed that MRPL65 protein forms a heterodimer with 
homologous MRPL37, together occupying a void left behind after the evolutionary loss 





This female patient was the second child of healthy, non-consanguineous, Lebanese 
parents. The patient was healthy at birth, but developed jerky eye movements at the 
age of 2 weeks, which, by the age of 2 months, progressed to nystagmus with poor 
tracking. An eye examination revealed bilateral optic nerve atrophy. The patient 
demonstrated axial hypotonia and worsening dystonic limb movements. By 6 months 
the patient had developed myoclonic limb jerks, which over the course of one month 
progressed into infantile spasms. At the age of 1 year, she exhibited oromandibular 
dyskinesia with snouting and tongue thrusting movements. The patient’s hypotonia 
worsened significantly and she developed severe muscle weakness. Head growth was 
poor, falling off the centiles, and the patient had poor feeding. Lactate was elevated at 
6.98mmol/L (normal <2.5mmol/L). The patient died at 3 years of age.
The older sister of the index patient died after exhibiting clinical findings very similar 
to those described above. Histochemical analysis of a muscle biopsy was carried out 
in a laboratory at the American University of Beirut at the time and reported to 
demonstrate COX deficiency, however no tissue has been available for further 
analysis. Brain MRI was reported as normal.
Diagnostic WES of Patient 1, and a deceased sibling, carried out at Centogene 
(https://www.centogene.com), identified compound heterozygous variants in the 
MRPL65 gene (NCBI Reference Sequence: NM_016640.3). One of the variants, 
c.(601+5G>A) is a single base substitution located 5 nucleotides into the first intron of 
MRPL65 and is therefore predicted as likely to impact splicing. This variant has a 
CADD score of 21.9, indicating it is in the top 1% of possible damaging single 
nucleotide variants in the human genome. The second variant is a nonsense mutation, 
c.(382G>T), resulting in a premature ‘stop’ codon (p.Glu128*) at amino acid 128 of 
439 (Figure 5.2). This variant has a CADD score of 34, indicating it is in the top 0.1% 
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of deleterious possible mutations. Both of these variants are absent from the gnomAD 
population database. This patient was referred by Dr.Rose-Mary Boustany and 
Dr.Rolla Shbarou, Department of Pediatrics and Adolescent Medicine, American 
University of Beirut.
Figure 5.2 Familial pedigree of MRPL65 Patient 1. Familial pedigree to demonstrate the recessive inheritance 
of compound heterozygous c.382G>T, p.(Glu128*); c.601+5G>A, p.(?) MRPL65 variants.
5.2.2 Patient 2
This male patient is the second child of healthy, unrelated parents, both of Lebanese 
ethnic origin and investigated in the US. The parents of Patient 2 had experienced 
three prior miscarriages. The patient first presented at 18 months of age with an 
unsteady gait. A progressive ataxia has persisted throughout childhood, alongside a 
tremor and mild global developmental delay while optic atrophy and nystagmus were 
noted in later childhood. Repeat brain MRI studies revealed a progressive cerebellar 
atrophy and nerve conduction studies identified diffuse axonal sensory neuropathy. 
The patient is currently alive at 12 years of age. Diagnostic WGS of Patient 2 identified 
a homozygous c.(601+5G>A) variant in the MRPL65 gene (Figure 5.3), the same 
splice variant identified in Patient 1. This patient was referred by Dr.Vinod Misra and 




Figure 5.3 Familial pedigree of MRPL65 Patient 2. Familial pedigree to demonstrate the recessive inheritance 




5.3.1 MRPL65 cDNA studies in Family 1
Given that the truncating MRPL65 variant present in Patient 1 occurs less than one 
third of the way into the protein, it is very unlikely to lead to the synthesis of functional 
MRPL65 protein. Two PCR primer pairs were designed to investigate the impact of 
the second MRPL65 variant, c.(601+5G>A), on splicing. The first pair was designed 
to amplify exons 1-2, and the second to amplify exons 1-4 producing 673bp and 915bp 
products respectively (Figure 5.4). These experiments were conducted using RNA 
extracted from fixed tissue of Patient 1 and their deceased sibling, which had been 
shipped to the Newcastle Highly Specialised Mitochondrial Diagnostic Service. 
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Figure 5.4 Schematic of MRPL65 primers and expected PCR product. Binding sites of each primer targeting 
MRPL65 and the size of PCR products resulting from specific primer pairs used throughout chapter. Intronic regions 
are depicted with red dashed line.
Following reverse transcription and second strand synthesis of cDNA, neither primer 
pair were able to amplify MRPL65 product in patient samples(Figure 5.5). Both primer 
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pairs successfully amplified MRPL65 using cDNA generated from control RNA 
samples. Patient samples were successfully used as controls for cDNA studies of 
other genes within the diagnostic service, suggesting that the c.(601+5G>A) variant 
may result in MRPL65 aberrantly spliced mRNA transcripts that are targeted for 
nonsense mediated mRNA decay.
Figure 5.5 cDNA studies in Family 1. RNA samples of Patient 1 (P1) and an affected sibling (P1S) were used for 
reverse transcription and second strand synthesis to investigate the potential impact of a c.(601+5C>A) variant on 
splicing of MRPL65 mRNA transcripts. Two primer pairs were used for the PCR amplification of exons 1-2 (left 
panel) and exons 1-4 (right panel). Asterisks indicate cDNA bands corresponding to correctly sized PCR products 
in control samples.
5.3.2 MRPL65 knockdown in U2OS control cells
No skin or tissue biopsies from Patient 1 have been available for further investigation 
into the effect of these compound heterozygous MRPL65 variants on mitochondrial 
function. Due to the inherent pathogenic nature of the truncating variant and the 
apparent absence of MRPL65 cDNA, knock-down of MRPL65 expression was carried 
out to assess the impact of decreased MRPL65 in U2OS cells. Cells treated with an 
MRPL65 siRNA smart-pool, containing siRNA molecules targeting four different 
regions of MRPL65 sequence, demonstrate almost undetectable steady-state levels 
of COXI and COXII, while NDUFB8 and CORE2 are also decreased (Figure 5.6). This 
indicates that decreased abundance of MRPL65 protein results in a severe combined 
OXPHOS defect affecting complexes I, III, and IV. The combined OXPHOS deficiency 
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is likely to be the result of impaired mitoribosomal function leading to a defect of 
mitochondrial translation. 
Figure 5.6 Western blot analysis of MRPL65 knock-down U2OS cells. Whole cell lysates from U2OS cells 
treated with an MRPL65 siRNA smart pool, U2OS cells treated with a non-targeting siRNA and an untreated U2OS 
control. MRPL65 antibody was applied to confirm successful knock-down. Antibodies detecting SDHA, NDUFB8, 
COXI, COX II and CORE2 were used to investigate the impact of MRPL65 knockdown on OXPHOS. Data shown 
is representative of three independent repeats.
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5.3.3 Generating an MRPL65-targeting PX458 CRISPR/Cas9 plasmid 
Due to the clear and very severe, steady-state OXPHOS protein defect resulting from 
MRPL65 knock-down, and given the lack of available patient cell lines, I decided to 
generate a MRPL65 CRISPR/Cas9 knockout cell line as the best approach to 
investigate the potential mechanisms underlying disease in Family 1. As neither 
MRPL65 variant carried by patient 1 is missense (being a splice variant and a loss of 
function truncating variant) an MRPL65 knock-out cell line was thought to be the best 
representative model of the combined functional consequences of these two variants. 
A PX458 plasmid expressing Cas9 from Streptococcus pyogenes, 2A-EGFP, and with 
a cloning backbone for sgRNA insertion was purchased from Addgene. In order to 
target the Cas9 nuclease to MRPL65, four sgRNA sequences were designed for 
subsequent insertion into the PX458 plasmid through backbone cutting and ligation 
reactions. Competent DH5α cells were transformed using PX458 inserted with each 
of the four sgRNA oligos. DH5α clonal colonies were grown from populations 
transformed with sgRNAs 1, 2 and 4 plasmids, and plasmid DNA isolated. Double 
restriction digests, using BbsI and EcoRI restriction enzymes were used to identify 
plasmids in which sgRNA insertion had been successful. The PX458 plasmid contains 
one BbsI restriction site and two EcoRI restriction sites. Insertion of a short guide 
sequence destroys the PX458 BbsI restriction site, resulting in only two digestion 
products identifiable upon gel electrophoresis. If short guide insertion has not 
occurred, the plasmid will be digested at the BbsI restriction site along with the EcoRI 
site, resulting in three digestion products (Figure 5.7).
 
176 
Figure 5.7 Diagram depicting test digest of PX458 plasmid. Px458 plasmids contain a single BbsI restriction 
site and two EcoRI restriction sites. BbsI was used for backbone cutting for sgRNA insertion. When incubated with 
BbsI and EcoRI, sgRNA negative plasmids will be cut into three linear products at 738bp, 3,231bp and 5,274bp in 
length. The BbsI restriction site is destroyed in sgRNA positive plasmids, resulting in only two linear digestion 
products at 738bp and 8,505bp in size.
Double restriction digests demonstrated that all but one of the purified sgRNA-inserted 
plasmids were successful. Samples from three clones of PX458 sgRNA 1, two clones 
of PX458 sgRNA 2 and one clone of PX458 sgRNA 4 each generated two digestion 
products at 738 and 8,505 base pairs in length. Sample from clone 3 of PX458 sgRNA 
2 generated two incorrectly sized bands, indicating that insertion of sgRNA 2 had not 
been achieved (Figure 5.8). 
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Figure 5.8 Test digest identification of sgRNA positive PX458 plasmids. Product from test double digests of 
miniprep purified sgRNA-inserted PX458 plasmid DNA and unmodified PX458 plasmid DNA. Single digest 
unmodified plasmid, undigested unmodified plasmid and undigested sgRNA1-inserted PX458 plasmid were used 
as negative controls.
5.3.4 Sequencing the BbsI region of PX458 plasmid
Sequencing of each sgRNA positive clone was undertaken to check that each full short 
guide had been inserted without the introduction of any sequence errors. A primer pair 
targeting the BbsI restriction site region of the PX458 plasmid was used for PCR and 
Sanger sequencing to confirm the presence of each sgRNA sequence (Figure 5.9). 
An sgRNA positive clone was confirmed for sgRNAs 1, 2 and 4, each of which were 
used for the nucleofection of wildtype U2OS cell populations alongside nucleofection 
of a single U2OS cell population a pmaxGFP Vector as a control. As both the PX458 
plasmid and the pmaxGFP control vector express GFP, each transfected population 
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was sorted into single cell populations using flow cytometry selecting for cells with 
GFP fluorescence. 
Figure 5.9 Example sequence confirmation of error-free sgRNA 1 insertion into PX458 plasmid. The BbsI 
restriction region of each sgRNA positive PX458 plasmid was sequenced in order to confirm the error-free insertion 
of full short guide sequences. Sequence traces were searched for the entire sgRNA sequence (highlighted in blue) 
using FinchTV software.
5.3.5 PCR screens of transfected U2OS clones
PCR screens of MRPL65 exon 1 were carried out on all clonal populations grown from 
each single sorted cell to identify clones that generate bands of a different size to 
isogenic control GFP clones and control genomic DNA, indicating insertions or 
deletions in MRPL65. Lanes containing multiple bands were noted as containing likely 
heterozygous mutants (red), lanes containing single bands that looked larger or 
smaller than control bands were noted as possible homozygous mutants (blue) and 
lanes containing bands identical to control were noted as possible wild-type clones 
(green) (Figure 5.10). 
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Figure 5.10 PCR screening of post-transfection U2OS clonal populations. Genomic DNA was extracted from 
each post-transfection clonal population for PCR using primers targeting MRPL65 exon 1. Samples of genomic 
DNA extracted from U2OS cells transfected with pmaxGFP vector and wildtype U2OS cells were used as controls. 
PCR products were run on long 3% agarose gels to maximise resolution between bands with subtle differences in 
size. Red arrows indicate likely heterozygous mutants that exhibit two MRPL65 bands of different sizes. Blue 
arrows depict possible homozygous mutants that run as a single band of a different size to controls. Green arrows 
highlight suspected wildtype clones that appear to run as bands identical in size to controls. This gel illustrates the 
PCR screening of 15 out of a total of 96 screened clones. 
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5.3.6 Sequencing MRPL65 to identify mutant clones
A total of 18 clones, six targeted with each sgRNA, were selected from the PCR 
screens for Sanger sequencing of MRPL65 exon 1. Both suspected mutants and 
suspected wild-type clones were sequenced. Sequence data demonstrated the 
introduction of mutations in 12 of the 18 clones and confirmed each sgRNA to be 
successful in targeting the Cas9 nuclease to exon 1 of MRPL65. However, no 
homozygous mutants were identified. Example chromatograms are shown in (Figure 
5.11, Figure 5.12 and Figure 5.13).
Figure 5.11 Example sequence confirmation of sgRNA 1 targeted MRPL65 mutation. Sanger sequencing of 
clone 1B-E11, generated through transfection with sgRNA 1 positive PX458 plasmid, identified the introduction of 
mutations at the site of sgRNA 1 binding proximal to the PAM site. The resulting sequencing file contains multiple 
frameshift traces that are not clear enough to resolve the precise nature of the mutations. As neither trace appeared 
to correspond to wild-type MRPL65 sequence, this clone was classified as a bi-allelic mutant. Sequence data for 
wild-type genomic U2OS DNA is provided as a control.
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Figure 5.12 Example sequence confirmation of sgRNA 2 targeted MRPL65 mutation. Sanger sequencing of 
clone 2A-E11, generated through transfection with sgRNA 2 positive PX458 plasmid, identified the introduction of 
mutations at the site of sgRNA 2 binding proximal to the PAM site. Two sequence traces are visible at this site, one 
of which corresponds to wild-type MRPL65 indicating this clone to be a mono-allelic mutant. Sequence data for 
wild-type genomic U2OS DNA is provided as a control.
Figure 5.13 Example sequence confirmation of sgRNA 3 targeted MRPL65 mutation. Sanger sequencing of 
clone 4B-E11, generated through transfection with sgRNA 4 positive PX458 plasmid, identified the introduction of 
mutations at the site of sgRNA 4 binding proximal to the PAM site. Two sequence traces are visible at this site, one 
of which corresponds to wild-type MRPL65 indicating this clone to be a mono-allelic mutant. Sequence data for 
wild-type genomic U2OS DNA is provided as a control.
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While unable to assign precise genotypes, clones exhibiting sequence traces that 
corresponded to multiple mutant alleles were classified as ‘bi-allelic mutants’ (Figure 
5.11) while clones that still displayed one clear wild-type trace were classified as 
‘mono-allelic mutants’ (Figure 5.12, Figure 5.13).
5.3.7 Western blot analysis of U2OS clones
In order to identify any successful knock-out clones, six clones were grown for cell 
lysis and western blotting to investigate the steady state levels of MRPL65. Two bi-
allelic and two mono-allelic mutants were investigated, alongside two wild-type clones 
as isogenic controls. Despite the introduction of suspected deleterious mutations, 
surprisingly all the mutant cell lines failed to demonstrate the loss of steady-state 
MRPL65 levels (Figure 5.14). 
Figure 5.14 Western blot analysis of mitoribosomal proteins in U2OS CRISPR clones. Whole cell lysates 
were generated from two ‘bi-allelic’ and two ‘mono-allelic’ mutant clones, alongside two clones with a wild-type 
genotype (confirmed through Sanger sequencing) as isogenic controls. SDS-PAGE and Immunoblotting with 
MRPL65 antibody was carried out in an attempt to identify a knock-out clone. Antibodies for two other LSU proteins 
MRPL47 and MRPL11 were also interrogated; Beta-actin was used as a loading control.  
One bi-allelic mutant appeared to have two bands corresponding to MRPL65 protein, 
however, none of the mutants appeared to have decreased levels of other LSU 
proteins (Figure 5.14), or any protein subunits of OXPHOS complexes (Figure 5.15).  
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This suggests that, in addition to there being no successful complete knock-out of 
MRPL65, the mutations introduced in each clone did not have any deleterious effects 
on MRPL65 function or downstream impact on the LSU and OXPHOS. 
Figure 5.15 Western blot analysis of OXPHOS proteins in U2OS CRISPR clones. Whole cell lysates were 
generated from two suspected ‘bi-allelic’ and two suspected ‘mono-allelic’ mutants alongside two clones with 
wildtype genotype. SDS-PAGE and immunoblotting with NDUFB8, SDHA, CORE2, COXII and ATPB was used to 
interrogate the steady state levels of protein subunits of complexes I-IV. SDHA was used as an indication of equal 
loading. 
5.3.8 SNP genotyping of WT U2OS cells
The MRPL65 gene is located on the P arm of Chromosome 5 (cytogenetic band 5p12). 
In order to identify any aneuploidy affecting this region within the clones, genomic DNA 
was extracted from wildtype U2OS cells and sent for single nucleotide polymorphism 
(SNP) genotyping, kindly carried out by Dr.Simon Zwoliński at the NHS Northern 
Genetics Service, International Centre for Life, Newcastle upon Tyne. DNA was 
analysed for 850,000 SNPs using the Illumina CytoSNP-850K v1.2 BeadChip 
microarray. The results from this array revealed the U2OS population to have an 
extremely abnormal karyotype, consistent with the known genome instability of cancer 
derived cell lines, with no fully diploid chromosomes. Copy number across 
Chromosome 5 was determined using the LogR ratio as a function of B-allele 
frequency. The entire P arm of Chromosome 5 is within a region of tetraploidy, 
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meaning that there are four copies of all genes encoded within this region, including 
the MRPL65 gene (Figure 5.16). 
Figure 5.16 SNP genotyping of Chromosome 5 in a wildtype population of U2OS cells. Log R ratio and B-
allele frequency across the entirety of Chromosome 5 allows the identification of copy number changes. Areas of 
homozygosity have B-allele frequencies of either 1 or 0. Areas of allelic balance and heterozygous SNPs have B-
allele frequencies of 0.5. Regions of allelic imbalance will have intermediate value B-allele frequencies. LogR ratio 
corresponds to normalised measure of total probe intensity of all alleles at each given SNP. If a duplication is 
present, LogR ratio increases. The region of Chromosome 5 containing the MRPL65 gene has a B-allele frequency 
indicating balanced heterozygosity and an increased LogR ratio to indicate duplication. From this, the copy number 
variation of the region is determined as tetraploidy. 
To obtain a complete MRPL65 knock-out cell line using this population of U2OS cells, 
all four MRPL65 alleles must be targeted by the Cas9 nuclease to achieve gene 
disruption through NHEJ. If the starting population of cells had been diploid in this 




5.3.9 PCR screens of transfected HEK293 clones
Due to the tetraploidy region identified in Chromosome 5 encompassing the MRPL65 
gene in U2OS cells, HEK293 cells were chosen as a second cell line to transfect with 
each sgRNA positive PX458 plasmid. Cells were GFP sorted and single cell clonal 
populations were grown. PCR screening of HEK293 clones using primers to amplify 
exon 1 of MRPL65 revealed multiple clones producing three bands (Figure 5.17). This 
indicates that the wild-type HEK293 population are also subject to a copy number 
duplication in the region of Chromosome 5 containing the MRPL65 locus. 
Figure 5.17 PCR screening of post-transfection HEK293 clonal populations. Genomic DNA was extracted 
from each post-transfection HEK293 clonal population for PCR using primers targeting MRPL65 exon 1. Genomic 
DNA extracted from HEK293 cells transfected with pmaxGFP vector was used as an isogenic control. PCR 
products were run on long 3% agarose gels to maximise resolution between bands with subtle differences in size. 
The presence of double bands and shifts in product size confirmed the successful sgRNA targeting of Cas9 to 
MRPL65 in this cell population. A number of clones ran with three bands (black arrows), suggesting that MRPL65 
is within a region of duplication on HEK293 Chromosome 5.
To acquire the precise karyotype of the wild-type HEK293 cells used for transfection, 
genomic DNA was once again extracted and sent for SNP genotyping. Copy number 
analysis confirmed that the 5p12 region in this cell line was also aneuploid, this time 
lying within a 50Mb region of triploidy. 
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5.3.10 PCR screens of second round transfected HEK293 clones
Following the confirmation of a triploid MRPL65 copy number, three suspected mutant 
HEK293 clones from the first PCR screen were selected for a second round of 
nucleofection. Each clone was transfected with a plasmid containing the same sgRNA 
sequence as its original transfection, to increase the likelihood of targeting only 
wildtype alleles. As above, transfected cells were sorted into single cell wells to obtain 
clonal populations. However, the recovery rate of these cells was very low and 
attempts to extract DNA from these populations were often unsuccessful due to very 
limited cell survival within each well. PCR screens were conducted where possible on 
surviving cells to identify clones with bands that differed in size to the pmaxGFP vector 
transfected control (Figure 5.18).
Figure 5.18 PCR screening of surviving second-round post-transfection HEK293 clonal populations. 
Attempts to amplify MRPL65 exon 1 using genomic DNA extracted from HEK293 clones following a second round 
of transfection with sgRNA positive PX458 plasmids was successful in very few clones. Empty lanes correspond 
to failed PCR reactions. All successful PCR reactions confirmed the presence of MRPL65 mutations through the 
presence of bands corresponding to multiple PCR products. 
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5.3.11 Investigation into steady-state MRPL65 in HEK293 clones
Of the clones that underwent PCR screening following a second round of transfection, 
only four grew to a confluency that allowed cell lysis for investigation into the steady-
state levels of MRPL65. No clone exhibited any significant loss of MRPL65 protein 
(Figure 5.19). These data suggest that, despite the introduction of mutations within 
the MRPL65 gene and repeated rounds of transfection with a CRISPR/Cas9 plasmid, 
the aneuploid nature of 5p12 prevented the generation of an MRPL65 knock-out cell 
line to model the variants identified in Family 1.
Figure 5.19 Western blot analysis of steady-state MRPL65 levels in four HEK293 CRISPR clones. Whole cell 
lysates were generated from the four clones that survived a second round of transfection with sgRNA positive 
PX458 plasmid, alongside a single pmaxGFP transfected clone as a control. SDS-PAGE and immunoblotting with 
MRPL65 antibody was carried out, alongside SDHA as a loading control. Data shown is representative of two 
independent repeats.
5.3.12 cDNA studies in Patient 2
Following the identification of a homozygous c.(601+5G>A) variant in a second 
paediatric patient, fibroblasts were obtained for functional investigation. RNA was 
extracted from the fibroblasts of Patient 2 for reverse transcription and the synthesis 
of cDNA, in order to investigate the splicing of MRPL65 transcripts in this patient using 
a primer pair targeting exons 1-4 (Figure 5.4) producing a product 915bp in size. A 
faint band was visible in the lane containing cDNA from Patient 2, that was very similar 
in size to the bands corresponding to MRPL65 product in controls (Figure 5.20). 
However, Sanger sequencing and Basic Local Alignment Search Tool analysis of 
sequence data revealed product to be non-specific and not MRPL65.
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Figure 5.20 MRPL65 cDNA studies in Patient 2. RNA extracted from the fibroblasts of Patient 2 was used for 
reverse transcription and second strand synthesis of cDNA, to investigate the potential impact of a homozygous 
c.(601+5C>A) variant on splicing of MRPL65 mRNA transcripts. Asterisks indicate product of expected size in 
control samples, arrow indicates a band of a similar size in the Patient 2 sample, possibly indicating MRPL65 cDNA 
product of a normal size.
A deeper investigation into potentially unstable MRPL65 transcripts was undertaken 
by treating growing cells with emetine, a specific inhibitor of nonsense mediated 
mRNA decay (NMD). A new primer set was designed to amplify a smaller 143bp region 
surrounding the boundary of exons 1 and 2. Using this primer pair, a larger amplimer 
between 400-500bp in length becomes visible in the cDNA of Patient 2, both with and 




Figure 5.21 MRPL65 cDNA studies with inhibition of nonsense mediated decay in Patient 2. Patient and 
control fibroblast cells were cultured in media containing 100ug/mL emetine for 10 hours prior to RNA extraction. 
RNA was extracted from untreated patient and control cells as a control. RNA was used for reverse transcription 
and second strand synthesis of cDNA. A primer pair amplifying a 143nt region encompassing the exon 1/ exon 2 
boundary was used for PCR and agarose gel electrophoresis. Asterisks indicate a band of increased size present 
only in patient samples.
5.3.13 Identification of cryptic MRPL65 splice donor site in Patient 2 
The larger MRPL65 cDNA band which was only present in samples from Patient 2 
was subjected to Sanger sequencing, leading to the identification of two unique 
sequence traces. The smaller of the traces corresponds to the expected product of 
this primer pair, containing the final 96 nucleotides of exon 1 and the first 47 
nucleotides of exon 2. However, the second underlying trace exhibits read-through 
from the end of exon 1 into intron 1 (Figure 5.22).
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Figure 5.22 Sequencing of larger MRPL65 product previously identified in Patient 2 cDNA sample. Sanger 
sequencing of cDNA generated from emetine treated fibroblasts of Patient 2 revealed two individual sequence 
traces. Trace 1 (red) is a product of normal splicing at the exon 1/ intron 1 and in intron 1/ exon 2 boundaries. This 
trace ends with the end of the reverse primer, lying 47 base pairs into exon 2. Trace 2 (blue) in the product of loss 
of processing at the exon 1/intron 1 boundary, resulting in intron retention and generating a longer transcript, 
corresponding to the larger band seen on the cDNA gel in (Figure 5.21).
Two free, online splice site predictor tools Alternative Splice Site Predictor (ASSP -
http://wangcomputing.com/assp/) (Wang and Marin, 2006) and Splice Site Prediction 
by Neural Network (https://www.fruitfly.org/seq_tools/splice.html) (Reese et al., 1997) 
were used for the analysis of wild-type and mutant MRPL65 genomic sequences . In 
the c.(601+5G>A) sequence, prediction of the regular splice donor site at the end of 
exon 1 was lost (Figure 5.23). Cross-referencing of predicted splice donor sites that 
aren’t typical donor sites with a second sequence trace containing intronic sequence 
was carried out in order to identify potential cryptic splice donor sites. A predicted 
donor site 268 nucleotides downstream of the exon 1/intron boundary (Figure 5.23) 
corresponds perfectly in size with the size of band seen on cDNA gels above the 400bp 
marker in Patient 2 (Figure 5.21) as retention of 268bp would result in a PCR product 
411bp in size. 
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Figure 5.23 Output from splice donor site predictor tool analysis of wildtype and mutant MRPL65. The 
analysis of MRPL65 sequence containing the c.(601+5G>A) variant demonstrates that this mutation is predicted 
to result in the loss of the typical splice donor site at the end of exon 1. Output from this prediction tool was searched 
for predicted splice donor sites not typically active, but that if active might result in retention of the length of intron 
seen via Sanger sequencing. A splice donor site was identified 268 nucleotides downstream of the typical splice 
site. Activation of this splice donor would result in a transcript identical in size to trace 2 in the sequencing data. 
Output obtained from (https://www.fruitfly.org/seq_tools/splice.html) (Reese et al., 1997).
I confirmed the activation of this predicted donor site through Sanger sequencing of 
the intron/exon boundaries, clearly demonstrating a trace corresponding to 268 
nucleotides of intronic sequence (Figure 5.24), corroborating its activation as a cryptic 
splice donor site in MRPL65 transcripts of Patient 2. 
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Figure 5.24 Exonic/intronic boundaries in transcript resulting from activation of a cryptic splice donor site. 
Dashed line on top panel marks boundary between exon 1 and intron 1 at which processing would normally occur 
to remove intronic sequence. Dashed line on bottom panel marks boundary at which a cryptic splice donor site 
results in the read-through of sequence belonging to intron 1 back into sequence of exon 2. 
5.3.14 Western blot analysis of protein levels in Patient 2 fibroblasts
Western blot analysis was carried out on fibroblast cell lysates of Patient 2, to 
investigate the impact of this homozygous c.(601+5G>A) splice variant on the steady-
state levels of MRPL65 and protein subunits of OXPHOS. 
Figure 5.25 Western blot analysis of steady state MRPL65 in fibroblasts of Patient 2. SDS-PAGE and 
immunoblotting of whole cell lysate from fibroblasts of Patient 2 alongside two paediatric control fibroblasts. 




The abundance of full-length MRPL65 protein appears to be unaffected in the 
fibroblasts of Patient 2 (Figure 5.25). There was also no observable OXPHOS defect 
at the steady-state level in the fibroblasts of Patient 2 (Figure 5.26).
Figure 5.26 Western blot analysis of OXPHOS proteins in fibroblasts of Patient 2. SDS-PAGE and 
immunoblotting of whole cell lysate from fibroblasts of Patient 2 alongside two paediatric control fibroblasts. An 
antibody cocktail containing NDUFB8, SDHB, CORE2, COXII and ATP5A was used to investigate OXPHOS 
complexes I-IV. VDAC1 was used as a loading control. Data shown is representative of three independent repeats.
5.3.15 Investigation of MRPL65 assembly within the LSU
Next, I used sucrose gradient centrifugation and immunoblotting to investigate the 
assembly of MRPL65 within the LSU. The ultracentrifugation of 700 ug of protein 
through sucrose gradients allowed the sedimentation of mitoribosomal subunits based 
on size. SDS-PAGE and western blotting of MRPL45 confirmed the presence of the 
LSU in lanes six and seven in both Patient 2 and control sample. However, in Patient 
2 MRPL65 signal appears to be limited to lanes three and four, containing protein 
complexes smaller than the mitoribosomal LSU (Figure 5.27). This could indicate that 
MRPL65 does not assemble successfully within the LSU of the mitoribosome. 
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Figure 5.27 Sucrose gradient ultracentrifugation and immunoblotting to investigate MRPL65 in 
mitoribosome assembly. 700 μg of total protein from the fibroblasts of patients 2 and a paediatric control was 
separated on a linear 10-30% sucrose gradient. Following ultracentrifugation, eleven fractions were taken to be 
run on SDS-PAGE gels and immunoblotted for MRPL45 and MRPL65. Fractions 6 and 7 (blue) contain proteins of 
the LSU, demonstrated through MRPL45 signal. Whole cell lysate used for loading controls. Data shown is 
representative of three independent repeats.
5.3.16 [35S] translation assay in growing fibroblasts
To assess the impact of a potential loss of MRPL65 from the assembled LSU, 
metabolic labelling assay using [35S] labelled methionine/cysteine was used to 
investigate de novo protein synthesis in Patient 2 fibroblasts. Incubation of growing 
patient and control fibroblasts with radiolabelled media for 1 hour was conducted in 
the presence of 100 μg/mL emetine to inhibit cytosolic translation. Phosphorimaging 
of the resulting signal revealed a generalised defect of mitochondrial translation in 
Patient 2. All visible bands, corresponding to newly-synthesised mtDNA encoded 
OXPHOS proteins, are decreased in signal when compared to signal in the control 
lane (Figure 5.28).  
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Figure 5.28 [35S] methionine/cysteine incorporation in growing MRPL65 patient fibroblasts as a measure 
of de novo mitochondrial protein synthesis. Signal detected from fixed and dehydrated SDS-PAGE gel using 
Typhoon Phosphorimager. Bands are visible for radiolabelled COXI, ND4, cyt b. ND2, ND1, COXIII, COXII and 
ATP6 in Patient 2 and control sample. Loading is demonstrated using the Coomassie Brilliant Blue (CBB) stain on 




5.4.1 Ploidy of cell lines used for CRISPR/Cas9 studies
While cancer derived cell lines such as U2OS and HEK293 are of immense value to 
biomedical research, they are characteristically genotypically unstable, and often have 
extremely abnormal karyotypes (Ozaki et al., 2003). As the ploidy of a target region 
increases, the likelihood of successful CRISPR/Cas9 editing of all target alleles 
decreases. Despite the successful introduction of indels using PX458 plasmids 
expressing sgRNAs 1, 3 and 4, no MRPL65 knockout clones were successfully 
generated (Figure 5.14, Figure 5.19). This is highly likely to be a result of the tetraploid 
and triploid nature Chromosomal region 5p12 in U2OS and HEK293 cells respectively 
(Figure 5.16), and highlights the importance of identifying the cell line most amenable 
to genome editing at a desired target site when still in the early stages of knockout 
study design. 
5.4.2 Resolving specific genotypes of heterozygous CRISPR clones
Due to the random and unpredictable nature of indels introduced upon NHEJ following 
the introduction of DSBs by Cas9, sequencing of clones with multiple indels can 
produce chromatograms with multiple frameshift traces (Figure 5.12). As a result, from 
sequence data alone it is difficult to ascertain the precise mutations that have been 
introduced. A long-standing method used classically in the resolution of this type of 
problem is the cloning of the mixture of alleles into bacterial vectors, followed by 
bacterial transformation and cloning. Sequencing multiple colonies would result in the 
eventual sequencing of each individual allele, from which a single trace would be 
obtained, thereby allowing the identification and genotyping of precise insertions or 
deletions. However, the advent of CRISPR/Cas9 genome editing has resulted in the 
development of various tools and techniques, such as CRISP-ID, to circumvent this 
classic approach. CRISP-ID is a tool that allows the detection of exact indel sizes and 
locations within a given target region, based on Sanger sequencing alone (Dehairs et 
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al., 2016). This tool can resolve multiple frameshift sequences up to a maximum of 
three traces. Retrospective attempts to analyse the Sanger sequence data of the 
mutant U2OS CRISPR clones generated within this study using the CRISP-ID online 
tool, resulted in the detection of four sequences, preventing trace ‘unmixing’ for these 
data. Despite being unable to resolve the precise sizes of indels within these tetraploid 
clones, receiving information regarding the number of individual alleles within a single 
clone would be of use in the early stages of CRISPR/Cas9 studies, particularly if using 
a cell line with a normal target gene copy number. 
5.4.3 Knock-out Vs knock-in models
Repeated attempts to generate a CRISPR/Cas9 MRPL65 knockout cell line have 
proven to be unsuccessful. However, the identification of a second family at a later 
stage of the functional workflow, through the online GeneMatcher tool 
(https://genematcher.org/), allowed for more detailed functional validation studies 
using patient fibroblasts. The fibroblasts of Patient 2 did not exhibit any decrease in 
steady-state MRPL65. While this finding was surprising, it further highlighted the 
limitations of knockout studies in the absence of patient cell lines. Had the MRPL65 
knockout studies been successful, they would be used to model a c.(601+5A>G) 
disease variant that does not result in the loss of MRPL65 expression (Figure 5.25).
In addition to CRISPR/Cas9 knock-out studies using NHEJ, a second DNA repair 
mechanism, error-free homology directed repair (HDR), can also be triggered by the 
introduction of DSBs. HDR can be utilised for CRISPR knock-in or precise gene-
editing through the delivery of homology-containing donor DNA templates alongside 
the CRISPR/Cas9 machinery (Ryu, Hur and Kim, 2019). This technique offers a much 
more precise way of modelling specific variants in cell-lines and whole organisms 
which, with more time, would have proven to be a very useful tool in the modelling of 
disease in these patients.
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5.4.4 Impact of intron retention on MRPL65 function
The cDNA studies in Patient 2 revealed the specific impact of a c.(601+5G>A) variant 
on splicing at the donor site of exon 1 in some MRPL65 transcripts. Some transcripts 
fail to splice at the constitutive donor site and a downstream cryptic donor site is 
activated, resulting in the retention of 268 nucleotides of intron 1 (Figure 5.22). This 
c.(601_602ins601+1_601+268) transcript results in a frameshift, and the introduction 
of a downstream STOP codon, with the nomenclature p.(Asp201Glyfs*68). These 
transcripts are therefore extremely unlikely to produce any stable MRPL65 protein. 
However, steady-state levels of MRPL65 appear to be normal in the fibroblasts of 
Patient 2 (Figure 5.25). It is therefore difficult to connect the c.(601+5G>A) splice 
mutation with the translation defect in fibroblast cells (Figure 5.28), and the clinical 
disease in Patient 2. The antibody used against MRPL65 has been validated through 
siRNA knock-down studies in U2OS cells (Figure 5.6) which should rule out the 
possibility of a non-specific band being mistaken for full-length MRPL65 in the 
fibroblasts of Patient 2. However, the siRNA knock-down should be repeated in Patient 
fibroblasts to confirm with certainty that the visible band represents MRPL65. It would 
also be interesting to combine siRNA treatment with a [35S] translation assay, to 
investigate whether MRPL65 knock-down exacerbates the existing translation defect 
in this cell-line.
Diagnostic RNA sequencing was ordered by the referring clinician of Patient 2. These 
studies were carried out by MNG Laboratories in the US using RNA extracted by 
lymphocytes and skin fibroblasts and determined that 24% and 19% of MRPL65 
transcripts remained unprocessed at the affected splice donor site respectively. As the 
ratio of processed:unprocessed transcripts appears to vary in the two cell types tested, 
it is possible that the proportion of unprocessed transcripts may be high enough to 
cause a decrease in steady-state MRPL65 protein in cell types that are clinically 
relevant to the Patient’s disease presentation.
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5.4.5 Identification of multiple families through ‘GeneMatcher’
Both patients investigated within this chapter are of Lebanese ethnic origin. The 
c.(601+5A>G) mutation is present in Patient 1 in a compound heterozygous state and 
in Patient 2 in a homozygous state. A very recent GeneMatcher ‘hit’ has identified a 
third family of Lebanese origin, containing three paediatric patients homozygous for 
the c.(601+5A>G) splice variant and presenting with significantly overlapping clinical 
features to Patients 1 and 2 including ataxia, developmental delay and nystagmus. So 
far, this splice variant appears to be ethnically isolated to patients of Lebanese descent 
and is therefore a potential founder mutation. However, we don’t yet have samples 





Chapter 6 : Final discussion
The research within this thesis has contributed new understanding of the mitochondrial 
pathophysiology and mechanisms associated with two mitochondrial proteins not 
previously linked to human disease, MRPL47 and MRPL65, thus expanding the list of 
nuclear genes implicated in mitochondrial presentations. Novel disease variants in two 
previously reported genes, GFM2 and TSFM, have also been validated. Throughout 
this thesis I have employed a number of different techniques to assess mitochondrial 
function using patient cell lines and tissues, as well as working with CRISPR/Cas9 and 
siRNA in U2OS and HEK293 cell lines, to aid in the validation of these variants. This 
demonstrates the value of further research-based functional studies in assigning 
pathogenicity to novel variants as part of the diagnostic algorithm used for 
mitochondrial disorders.
6.1 Diagnostic algorithm
The investigation and diagnosis of suspected mitochondrial disease requires a 
dynamic multidisciplinary approach. Due to the vast clinical heterogeneity of 
mitochondrial disease, a wide range of different clinical and biochemical investigations 
can indicate disease with a mitochondrial aetiology. Abnormalities identified on brain 
MRI, nerve conduction studies or electrocardiogram together with metabolic 
abnormalities such as increased lactate or the presence of urinary 3-methylglutaconic 
acid could be suggestive of a mitochondrial disorder. However, these presentations 
are not limited to diseases with underlying mitochondrial dysfunction and thus require 
further investigation (Thompson et al., 2019). Biochemical and histopathological 
techniques using patient muscle biopsies are used to identify defects in respiratory 
chain function or abnormalities in muscle morphology, both of which can also signify 
a mitochondrial defect (Taylor et al., 2004; Frazier et al., 2020).
Approaches to the diagnosis of mitochondrial disease are steadily adapting as the 
power of NGS technologies continues to grow. The identification of mitochondrial 
disease variants via this ‘genetics first’ approach potentially avoids the requirement for 
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skin or muscle biopsies when identified variants have been previously reported 
(Wortmann et al., 2017). Further large data-set methods such as proteomics, 
transcriptomics and metabolomics (‘multi-omics’) are also increasingly being 
incorporated into functional characterisation pathways (Stenton and Prokisch, 2020). 
However, as a result of NGS and ‘multi-omic’ implementation, the list of nuclear genes 
implicated in mitochondrial disease is ever-growing. Half of the 14 reported MRP 
mitochondrial disease genes have been reported within the past three years alone 
(Table 4.1). This rate of gene discovery drives the need for molecular characterisation 
studies in the investigation of novel variants. The availability of skin and/or tissue 
biopsies is extremely beneficial to functional studies that allow confirmation of 
pathogenicity. The studies conducted in the investigation of MRPL65 variants in 
Chapter 5 highlight the advantages of having access to patient biopsies rather than 
drawing conclusions on the molecular mechanisms of a particular variant based only 
on knock-down and knock-out experiments. In the absence of a patient cell line, 
sirRNA and CRISPR/Cas9 studies were carried out working under the assumption that 
the variants identified in MRPL65 would result in a loss of steady-state protein. 
However, subsequent patient samples harbouring one of the same variants 
demonstrated that this was not the case (Figure 5.25). Biopsies of tissues with clinical 
relevance to the specific disease presentation in each patient are of particular value, 
owing to the tissue specificity often observed in mitochondrial disorders, as can be 
seen in the investigation of novel TSFM variant. 
6.2 Tissue specificity in mitochondrial disease
Tissue specific patterns of mitochondrial dysfunction and subsequent clinical 
presentations are frequently observed in mitochondrial disorders of both mtDNA and 
nuclear genetic origins. While often reported, the mechanisms underlying tissue 
specificity in mitochondrial disease remain elusive in many cases. Clinical and 
functional tissue specific features can be seen in the cases presented throughout this 
thesis, however it was particularly striking in the TSFM patient presented in Chapter 
3. This patient presented with clinical features linked almost exclusively to cardiac 
dysfunction which was mirrored by the presence of a steady-state level OXPHOS 
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defect in cardiac tissue but not in fibroblasts (Figure 3.12). While mtEF-Ts levels were 
decreased in both cardiac tissue and fibroblasts, its interacting elongation factor mtEF-
Tu was only decreased in cardiac tissue as patient fibroblasts appeared to exhibit 
over-expression of mtEF-Tu protein (Figure 3.11). Increased abundance of mtEf-Tu 
might form a compensatory mechanism that prevents the loss of mtEF-Ts from 
severely impeding mitochondrial translation. As mtEF-Tu steady-state levels are not 
increased in the cardiac tissue of this patient, this may offer an explanation for the 
stark tissue specificity observed. 
Fifteen patients with mitochondrial disease arising as a result of variants in the TSFM 
gene have been reported to date (Emperador et al., 2017; Finsterer, 2019; Perli et al., 
2019; Scala et al., 2019; Traschutz et al., 2019; Smeitink et al., 2006a; Calvo et al., 
2012; Ahola et al., 2014; Vedrenne et al., 2012), including the patient presented here. 
Hypotrophic cardiomyopathy is common to almost all of these patients, but despite 
this overlap a number of TSFM cases also present with clinical features affecting other 
organs and systems, such as optic atrophy and ataxia. Interestingly, one of the three 
TSFM patients whose clinical features do not include cardiac involvement exhibits no 
decrease in of steady-state mtEF-Tu in myoblasts (Ahola et al., 2014), further 
supporting the theory that increased levels of mtEF-Tu might act as a protective 
compensatory mechanism in some tissues. 
6.3 Mitoribosome biogenesis and stability
Throughout Chapter 4 and Chapter 5 I have described the investigation of two 
mitoribosomal proteins, MRPL47 and MRPL65. The vast majority of reported 
mitochondrial disease variants in mitoribosomal subunits have been demonstrated to 
result in the destabilisation of the mitoribosome, leading to a defect of mitochondrial 
translation (Di Nottia et al., 2020). While it is known that the process of mitoribosome 
construction is extremely energy-demanding, the precise mechanisms of 
mitoribosome biogenesis remain relatively poorly understood. High-resolution crystal 
structures of the mammalian mitoribosome have been obtained through the use of 
sophisticated cryo-EM techniques, shedding new light on the structural nuances that 
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distinguish the mitoribosome from its bacterial and cytosolic counterparts (Amunts et 
al., 2015). Attention has now begun to shift to obtaining a deeper understanding of 
mitoribosome biogenesis and assembly (Bogenhagen et al., 2018).
Although a handful of mitoribosome assembly factors have been identified, there are 
likely more to be discovered and characterised. The process of bacterial ribosome 
assembly requires approximately 20 proteins (Shajani, Sykes and Williamson, 2011), 
while the number of identified cytoplasmic ribogenesis factors lies at ~200 (Klinge and 
Woolford, 2019). With a greater understanding of the proteins involved in 
mitoribosome assembly, it may be possible to elucidate the specific assembly 
pathways affected by mutations in MRP genes that result in the mitoribosome 
destabilisation observed in patients. This in turn could identify possible therapeutic 
targets within the mitoribosome assembly pathway that could be genetically or 
pharmacologically manipulated to stabilise the mitoribosome. To this end, cell-lines 
obtained from patients with pathogenic variants in MRP genes and an observable 
mitoribosome assembly defect are potentially a valuable resource for the identification 
and/or validation of new mitoribosome assembly factors. I have plans to further 
investigate the MRP defects presented here while collaborating with Dr. Joanna 
Rorbach at the Division of Molecular Metabolism, Karolinska Institute. This work will 
first focus on understanding the precise impact that the truncated MRPL47 has on 
mitoribosome assembly and function.
6.4 The investigation of splicing mutations 
The difficulties encountered in Chapter 5 when attempting to ascertain the precise 
impact on splicing of the c.601+5G>A variant highlights the importance of functional 
validation of variants found at intron/exon boundaries. The process of pre-mRNA 
transcript splicing is carried out by a large protein-RNA complex named the 
spliceosome (Zhang et al., 2019). In the majority of cases, the spliceosome recognises 
and binds cis splicing elements in the form of highly conserved GT and AG nucleotides 
at the 5’ (donor) and 3’ (acceptor) ends of each intron. As the splicing consensus 
sequences are short, there are many other similar sites found throughout an individual 
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gene known as pseudo or cryptic splice sites (Green, 1986). Binding of the 
spliceosome at the correct splice donor and accepter sites is aided by other cis splicing 
elements such as splicing branchpoints (Mercer et al., 2015), polypyrimidine tract 
sequences (Coolidge, Seely and Patton, 1997) and exonic splicing enhancers 
(Jobbins et al., 2018). Mutations that occur within cis splicing element sequences can 
result in the skipping of exons/exon fragments or the inclusion of intronic sequence. 
These changes to splicing may produce a transcript that remains in the same reading 
frame or cause a shift in the reading frame thus introducing a premature stop codon 
(Abramowicz and Gos, 2018).
The patients presented in Chapter 5 harboured a c.601+5A>G splicing mutation in the 
MRPL65 gene. The most common splicing mutations are found at the +1 and +2 
nucleotides of a splicing donor site, and usually lead to exon skipping (Krawczak et 
al., 2007). Splicing mutations that occur further from the intron/exon boundary, such 
as the +5 variant in the MRPL65 patients presented here, are less commonly identified 
in disease and the effects are harder to predict. If the affected splice site is weak, a 
+3/+4/+5/+6 mutation may result in the activation of a cryptic splice site and cause 
intronic fragment retention or exonic fragment removal (Abramowicz and Gos, 2018). 
A number of in silico tools have been developed to analyse and identify splice 
consensus sequences using a range of databases and statistical models. However, 
the results from such in silico tools must be treated as predictions only and cannot be 
used in isolation to assign pathogenicity to a novel splicing mutation (Spurdle et al., 
2008). 
6.5 Concluding remarks
The work presented within this thesis documents the validation of multiple pathogenic 
variants in mitochondrial disease cases, and is a product of the increasing rate of gene 
discovery in mitochondrial disease brought about by NGS implementation into 
diagnostic pathways. My research has allowed the assignment of pathogenicity to 
novel variants in four genes, GFM2, TSFM, MRPL47 and MRPL65, across eight 
families. Obtaining this information enables the provision of risk recurrence estimates 
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and reproductive advice to affected families. A genetic diagnosis can be achieved in a 
higher proportion of mitochondrial disease patients than ever before, with the functional 
characterisation of novel variants being an integral part of this field of diagnostic 
research. The further implementation of multi-omic pipelines in this genetics-first era 
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